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ABSTRACT 
Sodium (Na+) and water are closely linked in body fluid physiology by the concepts of 
osmosis and long-term balance. Our traditional understanding of fluid and electrolytes 
homeostasis has recently been challenged by suggestions of a systemic metabolic shift 
favouring water preservation when excess Na+ intake is excreted, and of skin as a depot for 
Na+ accumulation in multiple cardiovascular diseases and risk factors.  
In particular, a catabolic state would produce endogenous free water and facilitate its renal 
reabsorption independent of Na+, via urea generation and recycling: in the long term this 
could adversely impact cardiovascular risk, but has only been shown in preclinical settings. 
Similarly, the proposed water-independent nature of interstitial Na+ accumulation has the 
potential to induce local pathogenic changes to the surrounding structures, including the 
microvasculature, but lacks firm demonstration.  
The aims of this Thesis were therefore to investigate: 1) the impact of high Na+ intake on 
renal water-preserving mechanisms and metabolism in a real-life hypertensive population; 
2) the nature, distribution and clinical correlates of tissue Na+ accumulation; 3) 
microvascular function, including capillary-interstitium fluid exchange and lymphatic 
drainage, in relation to interstitial Na+ accumulation. 
I herein retrospectively analysed clinical and biochemical blood and 24h-urinary data from 
consecutive patients with essential hypertension, collected at the time of screening for 
secondary causes, and found that kidneys can indeed dissociate Na+ and water handling (as 
estimated by their fractional excretions) when exposed to high Na+ intake. However, this 
comes at the cost of higher glomerular filtration rate, increased tubular energy expenditure, 
and protein catabolism at metabolomics signatures. 
By conducting a chemical analysis of multiple tissues from rodent models of salt 
sensitivity/salt loading and of skin from patients with hypertension or heart failure with 
preserved ejection fraction (HFpEF), I showed that tissue Na+ excess upon high Na+ intake 
is a systemic, rather than skin-specific, water-paralleled phenomenon reflecting the 
expansion of the extracellular compartment, and subclinical oedema in most cases. 
Despite the lack of any hypertonic interstitial Na+ accumulation to osmotically drag water 
out of vessels and facilitate the typical “congestion”, I also identified structural and 
molecular alterations in the skin blood and lymphatic microvasculature of patients with 
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HFpEF, along with evidence of impaired lymphatic drainage of interstitial fluids upon 
pressure challenge. 
In summary, I confirmed the previous suggestions of a Na+-driven metabolic shift in a real-
life population of hypertensive patients and largely expanded on the novel concepts of 
tissue Na+ accumulation. In particular, I disproved its water-independence in both 
experimental models and human subjects and suggested systemic isotonic Na+ excess as an 
important and likely prevalent determinant in the pathogenesis of hypertension and other 
cardiovascular diseases. The biophysical and molecular impact of this subclinical or 
clinically overt oedema on organ function, as well as the mechanisms of function and 
dysfunction of lymphatic vessels in the control of interstitial fluid in cardiovascular 
disease, need further exploration.
  
  4 
TABLE OF CONTENTS 
ABSTRACT ............................................................................................................. 2 
LIST OF TABLES .................................................................................................... 9 
LIST OF FIGURES ................................................................................................ 10 
ACKNOWLEDGEMENTS ..................................................................................... 13 
AUTHOR’S DECLARATION ................................................................................. 15 
1 INTRODUCTION ............................................................................................ 16 
1.1 THE CLINICAL CONTEXT: HYPERTENSION AND HEART FAILURE ................................. 16 
1.1.1 Hypertension ..................................................................................................................... 16 
1.1.2 Heart failure ....................................................................................................................... 17 
1.1.3 A common ground .......................................................................................................... 18 
1.2 SALT IN CARDIOVASCULAR DISEASE – A “CLASSIC” ASSOCIATION ........................... 20 
1.2.1 Salt, high blood pressure and cardiovascular outcomes ............................. 20 
1.2.2 Salt-sensitivity of blood pressure ............................................................................ 21 
1.3 A NOVEL BLOOD PRESSURE-INDEPENDENT ASSOCIATION ......................................... 23 
1.4 NOVEL CONCEPTS ON SODIUM HOMEOSTASIS ............................................................... 25 
1.4.1 Disproof of a constant sodium balance ................................................................ 26 
1.4.2 Water-independent tissue sodium accumulation ............................................. 26 
1.5 THE LYMPHATIC SYSTEM ...................................................................................................... 28 
1.5.1 Lymphatic role in microvascular haemodynamics .......................................... 28 
1.5.2 Anatomy and function ................................................................................................... 30 
1.6 TRADITIONAL VS NOVEL VIEWS: OPEN QUESTIONS ....................................................... 31 
1.7 RESEARCH AIMS ...................................................................................................................... 33 
2 GENERAL METHODS ................................................................................... 34 
2.1 ASSESSMENT OF THE METABOLIC IMPACT OF HIGH SODIUM INTAKE ....................... 34 
2.2 ASSESSMENT OF TISSUE SODIUM ACCUMULATION ....................................................... 35 
2.2.1 Modelling (Chapter 4) ................................................................................................... 35 
2.2.2 Animal models (Chapter 5) ........................................................................................ 35 
2.2.3 Human subjects (Chapters 6-7) ............................................................................... 37 
2.2.4 Skin biopsy ......................................................................................................................... 39 
2.2.5 Chemical analysis of tissues ..................................................................................... 40 
 
 5 
2.3 ASSESSMENT OF VASCULAR AND MICROVASCULAR FUNCTION ................................ 42 
2.3.1 Ex-vivo study of arterial function on wire myography .................................... 42 
2.3.2 Non-invasive study of arterial function (humans) ............................................ 45 
2.3.3 In-vivo study of fluid microvascular dynamics (humans) ............................. 50 
3 METABOLIC IMPACT OF HIGH SODIUM INTAKE ...................................... 56 
3.1 BACKGROUND AND STUDY AIM ........................................................................................... 56 
3.2 STUDY-SPECIFIC METHODS ................................................................................................. 56 
3.2.1 Screening protocol and patient selection ............................................................ 56 
3.2.2 Biochemistry ...................................................................................................................... 59 
3.2.3 Renal function and energetics .................................................................................. 61 
3.2.4 Metabolomics .................................................................................................................... 63 
3.2.5 Statistics .............................................................................................................................. 63 
3.3 RESULTS .................................................................................................................................... 64 
3.3.1 Cohort characteristics ................................................................................................... 64 
3.3.2 Na+ and Water renal handling ................................................................................... 66 
3.3.3 Excess Na+ excretion is paralleled by glomerular hyperfiltration ............. 67 
3.3.4 High Na+ increases tubular reabsorption and renal energy expenditure ...... 68 
3.3.5 Sympathetic nervous system activation ............................................................... 69 
3.3.6 Re-setting of nitrogen balance and metabolic signatures ........................... 70 
3.3.7 Excess cortisol upon high Na+ intake .................................................................... 71 
3.4 DISCUSSION .............................................................................................................................. 72 
3.4.1 Main findings ..................................................................................................................... 72 
3.4.2 Limitations, conclusions and perspectives ......................................................... 75 
4 TISSUE SODIUM ACCUMULATION: MODELLING ..................................... 78 
4.1 INTRODUCTION AND RATIONALE ......................................................................................... 78 
4.2 METHODS: CALCULATIONS ................................................................................................... 80 
4.2.1 Expected total concentration of Na+ and K+ in a tissue ................................ 80 
4.2.2 Expected total concentration of Na+ and K+ in oedematous tissues ...... 81 
4.2.3 Changes in total tissue Na+, K+ and water due to oedema ......................... 82 
4.2.4 Biological assumptions ................................................................................................. 82 
4.3 RESULTS .................................................................................................................................... 82 
4.4 DISCUSSION AND IMPLICATIONS ......................................................................................... 84 
 
 6 
5 TISSUE SODIUM ACCUMULATION: PRECLINICAL DATA ....................... 86 
5.1 BACKGROUND AND STUDY AIMS ......................................................................................... 86 
5.2 METHODS .................................................................................................................................. 88 
5.2.1 Animal protocols .............................................................................................................. 88 
5.2.2 Harvesting and chemical analysis of rat tissues .............................................. 88 
5.2.3 Histology: extracellular matrix ................................................................................... 89 
5.2.4 Gene expression analysis .......................................................................................... 91 
5.2.5 Ex-vivo study of arterial function on wire myography .................................... 91 
5.2.6 Statistical analysis .......................................................................................................... 92 
5.3 RESULTS .................................................................................................................................... 93 
5.3.1 Salt-loading: experimental groups .......................................................................... 93 
5.3.2 Histochemical effects of salt-loading ..................................................................... 93 
5.3.3 Ageing model .................................................................................................................. 102 
5.3.4 Impact of salt on arterial function .......................................................................... 105 
5.4 DISCUSSION ............................................................................................................................ 109 
6 TISSUE SODIUM ACCUMULATION: HYPERTENSIVE PATIENTS .......... 114 
6.1 BACKGROUND AND STUDY AIMS ....................................................................................... 114 
6.2 STUDY-SPECIFIC METHODS ............................................................................................... 115 
6.2.1 Study protocols .............................................................................................................. 115 
6.2.2 Skin punch biopsy and chemical analysis ........................................................ 117 
6.2.3 Sodium intake questionnaire ................................................................................... 118 
6.2.4 Transepidermal water loss ....................................................................................... 119 
6.2.5 Pilocarpine-induced sweat test .............................................................................. 119 
6.2.6 Statistics ............................................................................................................................ 120 
6.3 RESULTS .................................................................................................................................. 120 
6.3.1 Histochemical analysis ............................................................................................... 122 
6.3.2 Clinical correlates in hypertensive patients ...................................................... 126 
6.3.3 Skin-specific mechanisms of Na+/water exchange ....................................... 128 
6.4 DISCUSSION ............................................................................................................................ 129 
7 INTERSTITIUM AND MICROVASCULAR FUNCTION ............................... 134 
7.1 BACKGROUND AND STUDY AIMS ....................................................................................... 134 
7.2 STUDY- SPECIFIC METHODS .............................................................................................. 135 
 
 7 
7.2.1 Protocol and subjects ................................................................................................. 135 
7.2.2 Blood pressure measurement ................................................................................. 136 
7.2.3 Echocardiography ......................................................................................................... 137 
7.2.4 Traditional non-invasive assessment of arterial function ........................... 137 
7.2.5 Plethysmography and microvascular fluid dynamics ................................... 138 
7.2.6 Surgical skin samples ................................................................................................. 139 
7.2.7 Ex vivo assessment of vascular function ........................................................... 140 
7.2.8 Skin histochemical analysis ..................................................................................... 140 
7.2.9 Skin microvascular immunofluorescence and image analysis ................ 140 
7.2.10 Skin gene expression analysis ............................................................................... 143 
7.2.11 Statistical analysis ........................................................................................................ 143 
7.3 RESULTS .................................................................................................................................. 144 
7.3.1 Subject characterstics ................................................................................................ 144 
7.3.2 Arterial function: ............................................................................................................. 146 
7.3.3 Skin salt ............................................................................................................................. 149 
7.3.4 Rarefaction of skin microvessels and gene expression ............................. 152 
7.3.5 Microvascular fluid dynamics .................................................................................. 153 
7.4 DISCUSSION ............................................................................................................................ 156 
7.4.1 Rarefaction of microvessels ..................................................................................... 156 
7.4.2 Interstitium, microvasculature and congestion in HFpEF .......................... 157 
7.4.3 The lymphatic system in HFpEF ............................................................................ 159 
7.4.4 Limitations ........................................................................................................................ 161 
7.5 CONCLUSIONS ....................................................................................................................... 161 
8 DISCUSSION ............................................................................................... 163 
8.1 THE ENERGETIC IMPLICATIONS OF SALT EXCESS ........................................................ 163 
8.2 THE NATURE OF SALT EXCESS .......................................................................................... 166 
8.2.1 An isotonic systemic phenomenon ....................................................................... 166 
8.2.2 A new speculative theoretical framework .......................................................... 167 
8.3 NEGLECTED REGULATORS OF INTERSTITIAL SALT EXCESS ...................................... 170 
8.4 CONCLUSIONS ....................................................................................................................... 173 
APPENDICES ..................................................................................................... 175 
APPENDIX 1 - S2ALT PROTOCOL ................................................................................................... 175 
APPENDIX 2 - S2ALT PARTICIPANT INFORMATION LEAFLET ................................................... 181 
 
 8 
APPENDIX 3 - S2ALT SALT INTAKE QUESTIONNAIRE ................................................................ 185 
APPENDIX 4 - HAPPIFY PROTOCOL ............................................................................................ 187 
APPENDIX 5 - HAPPIFY ADVERTISEMENT FOR HEALTHY VOLUNTEERS ............................ 200 
APPENDIX 6 - HAPPIFY PARTICIPANT INFORMATION LEAFLET ............................................ 201 
APPENDIX 7 – SYCAMORE: METABOLOMIC PEAKS, > IN HIGH-NA+ VS LOW-NA+. ....... 208 
APPENDIX 8 – SYCAMORE: METABOLOMIC PEAKS, > IN LOW-NA+ VS HIGH-NA+. ....... 212 
APPENDIX 9 – IMAGEJ MACRO FOR ALCIAN BLUE+ AREA QUANTIFICATION. ......................... 213 





  9 
LIST OF TABLES 
Chapter 3 
Table 3-1 Clinical and biochemical characteristics of patients by Na+ intake group 
Table 3-2 Renal function by Na+ intake group.  
 
Chapter 5 
Table 5-1 Rat SKIN histochemical analysis. 
Table 5-2 Rat LIVER histochemical analysis. 
Table 5-3 Rat LUNG histochemical analysis. 
Table 5-4 Rat SKELETAL MUSCLE histochemical analysis. 
Table 5-5 Rat LEFT VENTRICULAR MYOCARDIUM histochemical analysis. 
Table 5-6 Impact of in-vivo and ex-vivo Na+ excess on arterial function. 
 
Chapter 6 
Table 6-1 Characteristics of S2ALT patients. 
Table 6-2 Skin histochemical differences between hypertensive males and females. 
Table 6-3 Characteristics of young healthy volunteers.  
 
Chapter 7 
Table 7-1 HAPPIFY: group characteristics. 
Table 7-2 HAPPIFY: echocardiographic characteristics. 
Table 7-3 HAPPIFY: macrovascular function. 
Table 7-4 Characteristics of young healthy subjects, for contrast. 
Table 7-5 Skin chemical analysis, contrasted with young healthy subjects. 
Table 7-6 Microvascular dynamics. 
  
  10 
LIST OF FIGURES 
Chapter 1 
Figure 1-1 Natriuretic-ureotelic water-preserving mechanisms upon high salt intake. 
Figure 1-2 Starling-Landis equilibrium and the lymphatic system. 
Figure 1-3 Lymphangion contraction cycle. 
 
Chapter 2 
Figure 2-1 WKY and SHRSP phenotype. 
Figure 2-2 Skin biopsy protocol. 
Figure 2-3 Reproducibility of tissue chemical analysis. 
Figure 2-4 Wire myography ex-vivo experimental protocol to assess arterial function. 
Figure 2-5 Central Aortic waveform and key parameters of PWA. 
Figure 2-6 Flow-mediated dilatation. 
Figure 2-7 Representative FMD tracings. 
Figure 2-8 Application of a limb gauge and rapid inflation cuff. 
Figure 2-9 Plethysmography protocol for the assessment of microvascular filtration 
parameters and interstitial fluid accumulation. 
Figure 2-10 Extended protocol with deflation steps 
 
Chapter 3 
Figure 3-1 SYCAMORE study flowchart. 
Figure 3-2 Validation of the expanded dataset (Passing and Bablok regression). 
Figure 3-3 Renal Na+ and Water handling upon differential Na+ intake. 
Figure 3-4 Absolute Na+ excretion and reabsorption and energy cost. 
Figure 3-5 Metabolomics signature. 
Figure 3-6 Metabolic impact of high Na+ intake - summary figure. 
 
Chapter 4 
Figure 4-1 Histochemical impact of tissue architecture. 





Figure 5-1 Histological sulphated glycosaminoglycans myocardial quantification. 
Figure 5-2 Collagen and glycosaminoglycan deposition with ageing. 
Figure 5-3 Blood pressure in the experimental groups. 
Figure 5-4 Nature and distribution of tissue Na+ excess upon salt loading. 
Figure 5-5 Fat content in skin and liver. 
Figure 5-6 Regression lines for tissue Na+ and water content in different tissues. 
Figure 5-7 Predicted and experimental results. 
Figure 5-8 Tissue-specific TonEBP expression upon salt loading. 
Figure 5-9 Rat phenotypes in the ageing experiment. 
Figure 5-10 Myocardial Na+ excess and TonEBP expression in hypertensive ageing. 
Figure 5-11 Myocardial glycosaminoglycans in hypertensive ageing. 
Figure 5-12 Impact of in vivo Na+ excess on agonist-independent contractile function. 
Figure 5-13 Impact of in-vivo and ex-vivo Na+ excess on arterial function. 




Figure 6-1 Human skin samples and anatomical strategy of analysis. 
Figure 6-2 Na+ and K+ concentrations and water content by skin layer. 
Figure 6-3 Histochemical correlations. 
Figure 6-4 Histochemical sex-differences in the skin of young healthy volunteers and 
impact of fat. 
Figure 6-5 Histochemical parameters and ageing. 
Figure 6-6 Histochemical parameters and other relevant clinical correlates. 
Figure 6-7 Sweat Na+ concentration in relation to ESD Na+ concentration and age. 
Figure 6-8 Sweat and blood pressure. 
 
Chapter 7 
Figure 7-1 Immunofluorescence imaging analysis. 
Figure 7-2 Peripheral arterial function assessed in vivo. 
Figure 7-3 Peripheral arterial function assessed ex vivo. 
Figure 7-4 Chemical analysis of the skin. 
 
 12 
Figure 7-5 Skin microvascular anatomy. 
Figure 7-6 Skin microvascular gene expression. 
Figure 7-7 Microvascular fluid dynamics. 
Figure 7-8 Microvascular fluid dynamics and reduced lymphatic reserve in HFpEF. 
 
Chapter 8 
Figure 8-1 Secondary analysis of the DASH-Sodium trial. 
Figure 8-2 The “sieve” hypothesis. 
Figure 8-3 Human lymphnode with afferent and efferent lymphatic vessels. 
  
  13 
ACKNOWLEDGEMENTS 
I would like to express here the most profound gratitude to all those who contributed to the 
work in this thesis and to my professional and personal growth during my years in 
Glasgow. 
Firstly, thanks to my supervisors Prof. Christian Delles, Prof. Mark Petrie and Prof. Rhian 
Touyz for providing the richest, most comprehensive and multifaceted guidance I could 
ever expect. Thanks also to Prof. Mike Davis, who provided the warmest welcome and the 
most passionate supervision when I visited his lab in Columbia, Missouri.  
Thanks to the British Heart Foundation, for funding my studies, my salary and – most 
importantly - the BHF Centre of Research Excellence in Glasgow at the Institute of 
Cardiovascular and Medical Sciences (ICAMS), which truly represented a centre of 
continuous interdisciplinary interaction which enriched and lifted the bar of my idea of 
cardiovascular research.  
I am also indebted to all my study participants, who made my research possible, and to the 
“Bearsden and Milngavie” and “Glasgow West End” University of the Third Age for the 
active contribution to volunteers recruitment. 
In brief, but truly in depth, thanks also to: 
all the colleagues who provided any input to my research in ICAMS, including Prof J. 
Titze when he visited Glasgow and spent time to discuss my very first experimental 
results; 
Mrs Christine McAllister, Mrs Ammani Brown and the Clinical Research Facility team, as 
well as Sister Karen Campbell and the other Glasgow Blood Pressure Clinic nurses, for 
their support; 
Dr Augusto Montezano, Dr Rheure Alves-Lopes, Dr Karla Neves, Dr Francisco Rios, Dr 
Adam Harvey, Mrs Jackie Thomson, Mrs Laura Haddow, Mr John McAbney, Dr 
Aikaterini Anagnostopoulou, Dr Livia De Lucca Camargo, Mrs Wendy Beattie, Mrs Linda 
Hood, Ms Margaret Kinninmont, Mrs Carol Jenkins, Mr Andrew Carswell, Mr Arun Flynn 
as the Touyz lab core and/or ICAMS staff, for teaching and helping me;  
 
 14 
Mr Micheal Beglan, from the chemistry department, for providing the technical expertise 
and tools necessary to implement the chemical analysis of tissues. 
A special ‘lab’ thank you goes to Dr Sheon Mary Samji, a tireless, passionate and 
inspirational scientist, for guiding me step-by-step in understanding and performing all the 
basic science I was not used to.  
Much more, I’m grateful to her, to Dr Angela Lucas-Herald and to Ms Daniele Kerr for 
their true friendship over these years; my English still falls short in expressing all my 
gratitude.  
Similarly, thanks to Dr Eilidh McGinnigle, Dr Sharon Mackin and Dr Jennifer Lees for 
sharing the joys and frustrations of this journey. A big thank you goes also to Dr Katriona 
Brooksbank, for her help and advice with research applications, but also for taking care of 
us.  
Finally, thanks to Alessandra Pizziol, for standing the tests of time and distance, and for 
loving me. Similarly, thanks to my entire family and particularly to my parents, Lucia 
Campaci and Giancarlo Rossitto: I would like to dedicate this thesis to them. 
  
  15 
AUTHOR’S DECLARATION 
I declare that the studies in this thesis were the work of the author, Dr Giacomo Rossitto, 
under the supervision of Professors Christian Delles, Mark C. Petrie and Rhian M. Touyz, 
unless otherwise stated. 
I acknowledge support from: 
- Dr Giuseppe Maiolino, Silvia Lerco, Giulio Ceolotto, Alessio Pinato, Giorgia 
Antonelli (University of Padua, Padua, Italy) and Mrs Elaine Butler in completing the 
clinical and biochemical database informing the SYCAMORE study (Chapter 3), by 
reviewing charts, processing or conducting the biochemistry measurements on plasma 
and urine samples for my later analyses. 
- Dr Gavin Blackburn and Dr Ronan Daly (Glasgow Polyomics), in processing the 
samples I extracted for metabolomics and independently reviewing the analysis I 
performed on the results (Chapter 3). 
- Dr Adam Harvey and Dr Sheon Mary, in taking care of all the animal work prior to 
the harvesting and chemical analysis of tissues (Chapter 5). 
- Dr Sheon Mary, in conducting with me all the steps of the gene expression analyses 
(Chapter 5 and 7) 
- Ms Jun Chen, in contributing to the chemical analysis of tissues (Chapters 5) and to 
the conduct of the S2ALT study, including the skin biopsies, TEWL and sweat tests 
(Chapter 6), under my supervision in fulfilment of the requirements for a BSc degree. 
- Dr Karla Neves, Mrs Laura Haddow, Dr Rheure Alves-Lopes and Mr John McAbney 
in dissecting the resistance arteries from my subcutaneous gluteal biopsies or rat 
mesenteries and mounting them for myography (Chapters 5 and 7).  
No part of this work has previously been submitted in support of application for another 
degree or qualification by this or any other university. 
Dr Giacomo Rossitto,  
December 2020 
  
  16 
1 INTRODUCTION 
1.1 The clinical context: hypertension and heart failure 
The personal background to this thesis is dual: 1) a clinical and research experience in 
hypertension during my years of training in Internal Medicine, and 2) a vivid and long-pre-
existing interest in the hydraulic mechanisms of fluid balance. The latter dates back to my 
years as a medical student, when I studied the concepts of “forward” and “backward” 
pressures in the heart chambers and cardiovascular system in general, as well as the magic 
of Starling forces in the most peripheral vascular branches, and I learned to extrapolate all 
this from pure physiology to the most obvious clinical translation, i.e. “congestion” and 
heart failure (HF). 
1.1.1 Hypertension 
Hypertension, or high blood pressure (BP), is recognised as the biggest contributor to the 
global burden of cardiovascular disease (CVD) and related disability. Whilst the 
relationship between BP and cardiovascular events is continuous (Ettehad et al., 2016), the 
pragmatic use of thresholds to guide unequivocally beneficial treatments defines 
‘hypertension’ as office systolic BP (SBP) values ≥ 140 mmHg and/or diastolic BP (DBP) 
values ≥ 90 mmHg (Williams et al., 2018). Around 2015, the estimated rate of systolic BP 
(SBP) above 140 mmHg was > 20% of the global population (Forouzanfar et al., 2017), 30 
- 45% in adults and up to >60% in those aged >60 years (Chow et al., 2013), with 14% of 
all global deaths linked to SBP values above that threshold. Remarkably, all these rates 
were increasing compared to 1990 (Forouzanfar et al., 2017, Williams et al., 2018). In 
2016 a team of experts acknowledged that “despite extensive knowledge about ways to 
prevent as well as to treat hypertension, the global incidence and prevalence of 
hypertension and, more importantly, its cardiovascular complications are not reduced—
partly because of inadequacies in prevention, diagnosis, and control of the disorder in an 
ageing world” (Olsen et al., 2016). Based on the above, they listed ten key actions to 
globally improve the management of blood pressure, including “better identification of 
people at high risk to optimise treatment approaches”: needless to stress how this ties to 
the quest for better pathophysiological understanding, particularly in relation to an 
individual’s risk of cardiovascular events.  
Chapter 1 - Introduction 
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In the recent past, such risk was traditionally identified with ischaemic heart disease (4.9 
million SBP-related deaths per year), haemorrhagic stroke (2.0 million), and ischaemic 
stroke (1.5 million)(Forouzanfar et al., 2017). However, hypertension is independently 
associated also with other common and prognostically relevant complications, such as 
peripheral artery disease, end-stage renal disease, atrial fibrillation, cognitive decline and 
heart failure (HF). In fact, most longstanding hypertension ultimately leads to HF unless 
the sequence of events is interrupted by other outcomes and patients with HF very 
commonly have a history of hypertension (Messerli et al., 2017). When HF deaths and 
hospitalisations were properly assessed in hypertension trials, they comprised up to 50% of 
primary endpoints (Wright et al., 2015) and were significantly prevented by 
antihypertensive treatment (ALLHAT collaborative research group 2002, Rodeheffer, 
2011, Wright et al., 2015), even to a point of leading to early study termination in specific 
populations (64% reduction of events in the Hypertension in the Very Elderly Trial; 
Beckett et al., 2008). 
1.1.2 Heart failure 
Heart failure (HF) is defined as “a clinical syndrome characterized by typical symptoms 
(e.g. breathlessness, ankle swelling and fatigue) that may be accompanied by signs (e.g. 
elevated jugular venous pressure, pulmonary crackles and peripheral oedema) caused by a 
structural and/or functional cardiac abnormality, resulting in a reduced cardiac output 
and/or elevated intracardiac pressures at rest or during stress” (Ponikowski et al., 2016). 
These elevated intracardiac pressures and their backward transmission eventually lead to 
“congestion” and typical symptoms and/or signs above. Congestion, referred to as the 
“core of the syndrome, regardless of the cause” (Pfeffer et al., 2019), reflects a global 
disturbance in the regulation of body fluid balance and the accumulation of oedema. 
According to the most recent national and international audits, HF is common 
(nicor.org.uk), with a prevalence of approximately 1–2% of the adult population in 
developed countries rising to ≥10% among people >70 years of age (Curtis et al., 2008, 
Ponikowski et al., 2016), and represents a leading cause of morbidity and mortality: once a 
clinically determined diagnosis of HF is made, this confers a multifold higher risk for 
cardiovascular death as well as for subsequent repeat exacerbations of symptoms requiring 
hospitalizations for HF management. Mortality during a hospitalisation is approximately 
4%, and 10% within 1 month after discharge (Pfeffer et al., 2019).  
Chapter 1 - Introduction 
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For the purpose of classification, HF is defined according to the fraction of the left 
ventricular volume ejected per beat, i.e. the Ejection Fraction (EF), with EF ranging from 
normal (≥ 55%) or only mildly reduced (i.e. typically ≥50% in HF with preserved EF; 
HFpEF) to those with markedly reduced EF (i.e. typically < 40% in HF with reduced EF; 
HFrEF). The grey area in between has recently been named ‘HF with mid-range EF’; its 
biological nature and amenability to treatment, compared to the other two extremes, is still 
under investigation (Ponikowski et al., 2016).  
Beyond the arbitrary cut-offs of systolic function used for their definition, HFpEF and 
HFrEF are biologically different diseases (Lam et al., 2018): in contrast to the many 
therapeutic advances for HFrEF over the last decades, an effective treatment for HFpEF 
remains elusive. Owing to this gap and to the ageing of the population, which tends to 
closely cluster with HFpEF, the predicted raise in the prevalence of HF (Benjamin et al., 
2018) seems driven by patients where the left ventricular ejection fraction is not markedly 
abnormal. Similar to the general HF prevalence, the current increases in HF 
hospitalizations are mostly due to HFpEF (Chang et al., 2018), carrying a 1-year prognosis 
almost as poor as in patients with HFrEF (Campbell et al., 2012).  
The initial simplistic identification of HFpEF with diastolic HF – as opposed to the 
“systolic” HFrEF – evolved over the years in parallel with better appreciation and 
understanding of myocardial and peripheral abnormalities, as well as specific clinical 
fingerprints, typically associated with the syndrome. In particular, HFpEF patients are 
more frequently affected by multiple cardiovascular comorbidities and risk factors like 
hypertension (but also obesity, coronary artery disease, diabetes mellitus, atrial fibrillation 
and chronic kidney disease) compared to HFrEF (Pfeffer et al., 2019). This observation, 
along with new available data on myocardial structure, function, and signalling in HFpEF, 
led to the idea of a systemic microvascular disease rather than a purely cardiac 
phenomenon (Paulus and Tschope, 2013, Kitzman et al., 2015). 
1.1.3 A common ground 
Since the seminal Framingham Study, hypertension was identified as the most common 
risk factor for developing HF, with a hazard ratio of 2-fold in men and 3-fold in women 
after adjustment for age and other HF risk factors (Levy et al., 1996).  
Chapter 1 - Introduction 
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Most of the understanding from traditional pathophysiology identifies the mechanical 
stress on the myocardium as the initial trigger for the association (Messerli et al., 2017). In 
a time-dependent sequence of events, prolonged pressure overload induces concentric left 
ventricular hypertrophy (LVH), ventricular stiffening, diastolic dysfunction and, 
eventually, HFpEF (Borlaug, 2014). Indeed, more than 90% of HFpEF diagnoses are 
antedated by recognised or unrecognised hypertension. Whenever hypertension clusters 
with other conditions favouring also volume overload (e.g. obesity, chronic kidney disease, 
anaemia), eccentric hypertrophy with increase in both cardiac mass and chamber volume 
may be the prevailing phenotype. The result of longstanding pressure and volume overload 
is dilated end stage hypertensive cardiomyopathy, with both diastolic dysfunction and 
reduced ejection fraction. At this stage of LV dysfunction, patients who previously 
exhibited high blood pressure values may paradoxically present with “decapitated 
hypertension”, i.e. normal or even low BP values. Reversion of these vales by improving 
the global performance of the ventricles, for example with cardiac resynchronization 
therapy (Ather et al., 2011), clearly suggests that the underlying biological derangements 
are still in place regardless of BP readings.  
After the ‘microvascular paradigm for HFpEF’ was first put forward (Paulus and Tschope, 
2013), suggesting a systemic ‘inflammatory’ state affecting myocardial vascularisation as 
the underlying cause of the disease, a large amount of clinical and preclinical data 
accumulated in support of the paradigm. Surprisingly, these included animal models where 
vascular – and ultimately ventricular – dysfunction occurred and lead to a HFpEF 
phenotype in the absence of arterial stiffening or elevated BP values (Waddingham and 
Paulus, 2017).   
At variance or at least in parallel with the cause-and-consequence interpretations based on 
a mere pressure-overload perspective, I found the idea of a common pathophysiological 
ground between hypertension and HF - particularly HFpEF - of extreme speculative and 
potentially therapeutic interest. Emerging perspectives on the homeostasis of salt, 
traditionally coupled to water by the basic concepts of osmosis but approached as 
independent by these novel perspectives, gave me the stimulus to dig into this question. 
The research results discussed in this thesis eventually suggested that such ground is 
common non only to hypertension and HF, but also to many other conditions predisposing 
to HFpEF and herein suggested to be part of a ‘congestion-continuum’.   
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1.2 Salt in cardiovascular disease – a “classic” association 
1.2.1 Salt, high blood pressure and cardiovascular outcomes 
A large and diverse body of evidence supports a close association between salt (NaCl) and 
high BP. 
On a population basis, there is general agreement that a reduction in salt (or more 
appropriately sodium, Na+) intake translates into lower BP, as shown by both 
observational/epidemiological (Prior et al., 1968, Intersalt, 1988) and randomised 
controlled interventional (Sacks et al., 2011 and other studies, reviewed in He et al., 2020). 
Based on the predicted benefit that would follow a population-level decrease in BP, 3 
million deaths per year and 70 million disability-adjusted life-years were attributed to high 
salt intake (GBD 2017 diet collaborators 2019). In light of the global burden of 
hypertension (Murray and Lopez, 2013, Forouzanfar et al., 2017) and the relatively recent 
increase in Na+ intake due to processed food, many national and international bodies, 
including WHO (World Health Organization, 2012), recommended a reduction in the 
population’s salt consumption. To which extent, is a matter of ongoing debate.  
In fact, many cohort studies have investigated the relationship between salt intake and 
cardiovascular events and/or mortality (He et al., 2020) beyond the above prediction. 
However, differences in methodologies and inclusion criteria affected the conclusions to a 
point that a J or U-shaped association (i.e. both low and high salt intakes being associated 
with an increased risk) has been suggested by some authors (O'Donnell et al., 2014, Mente 
et al., 2018) and disputed by others (Cogswell et al., 2016, He et al., 2020). Therefore, a 
general consensus for the optimal range of salt intake is still far from reach (Messerli et al., 
2018, He et al., 2019, Mente et al., 2019, O'Donnell et al., 2020). 
Conclusions from both parts have their own strengths and inherent limitations. 
Unfortunately, long-term randomized trials on the effect of salt reduction on 
cardiovascular disease, which could possibly overcome at least some of these limitations, 
“are extremely scarce because they are difficult to carry out, owing to ethical concerns 
over subjecting participants to high salt intakes as well as to multiple methodological 
challenges, such as compliance with lower salt intake over many years in food 
environments where highly salted processed foods are widespread, cross-contamination 
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between study groups, and the large sample size that would be required to achieve 
sufficient statistical power” (He et al., 2020).  
All in all, a Cochrane review of the few studies with follow-up of at least six months 
reported an insufficient power to draw any firm conclusions and recommendations. 
Importantly, however, the estimates of the clinical benefits from dietary salt reduction 
were “larger than would be predicted from the small blood pressure reductions achieved” 
(Adler et al., 2014). These findings parallel previous suggestions of a link between salt-
induced blood BP changes and cardiovascular events (Morimoto et al., 1997) or death 
(Weinberger et al., 2001) that was intriguingly independent of BP. 
1.2.2 Salt-sensitivity of blood pressure 
From a pathophysiological point of view, the relationship between salt and BP finds its 
reasons in the seminal work by Guyton and colleagues. Since the ‘70s, they proposed a 
mechanistic link between Na+ overload and the development of overt hypertension, 
whereby an increase in blood pressure would be a compensatory mechanism (Guyton and 
Hall, 2011, Guyton et al., 1980, Hall et al., 1980, Hall, 2016). In simple terms, any 
impairment in the multiple and intricate body systems devoted to the homeostasis of Na+ 
(Guyton et al., 1972, Elijovich et al., 2016), primarily involving the kidneys, would lead to 
a resetting of the steady-state blood pressure to a higher level in order to facilitate adequate 
Na+ and water excretion by pressure-natriuresis.  
Over the years since the original conceptualization, Guyton’s gigantic cardiovascular 
physiology model of everything then known (Guyton et al., 1972) inevitably faced the 
advancement of knowledge, as well as criticism from those favoring a primary vascular - 
rather than renal - impairment in the response to a salt load as the drive for the increase in 
BP (Morris et al., 2016, Kurtz et al., 2016, Kurtz et al., 2018): these authors suggest that a 
subnormal vasodilatory response to increases in Na+ intake, in the absence of an 
abnormally large increase in renal retention of sodium, mediates the initiation of salt-
induced increases in blood pressure. 
A pragmatic synthesis of the opposite positions, offering a simple hydraulic but ultimately 
clinical point of view, indicates that derangements in either renal, or vascular, or even 
neural (Blaustein et al., 2012) regulations upon salt loading (or a variable mixture of these 
and possibly other factors) would result in a salt-sensitive phenotype. This concept of ‘salt-
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sensitivity of blood pressure’ reflects the marked heterogeneity of individuals in their BP 
response to salt loading (Weinberger et al., 1986). At variance with experimental animals, 
where the trait has been inbred since the pioneer approach by Dahl et al (Dahl et al., 1962), 
in humans it is normally distributed, as a result of combined genetic, environmental, 
physiologic (e.g. aging, gender, ethnicity) and clinical factors (Elijovich et al., 2016, 
Gensalt, 2007).  
When these factors are clustered or dissected, as in many of the aforementioned population 
studies, the extent of the BP fall upon salt intake reduction appears more pronounced in old 
or African-American groups, in individuals with low renin hypertension (Warnock, 1999), 
in persons with hypertension and those consuming diets containing > 5 g Na+/day (Mente 
et al., 2014), with large variations resulting from the uneven distribution of salt-sensitivity 
and its determinants (He et al., 2020, Elijovich et al., 2016). When the focus is rather on a 
single general hypertensive patient, the unpredictable therapeutic effect of a decrease in 
salt intake is unraveled only by cumbersome loading tests with arbitrary diagnostic cut-offs 
(Weinberger et al., 1993) and a practical salt-sensitivity definition suitable for everyday 
clinical practice remains elusive. 
Of note, the very same pathophysiological mechanisms underlying blood pressure salt-
sensitivity may contribute to the risk for cardiovascular disease independent of pressure 
effects (Safar et al., 2000) and the role for salt-dependent changes in BP as the sole causal 
determinant of salt-dependent cardiovascular disease (whichever the definition is) has not 
been proven (Kotchen et al., 2013). 
For the purpose of this thesis, the topic of salt in cardiovascular disease was not observed 
through the lens of what is ultimately a single, although universally accessible and 
adopted, biomarker, i.e. BP (Currie and Delles, 2016). Different questions, related to 
systemic and local sodium handling and its mechanistic implications for pathophysiology, 
rather emerged as the topics of interest. 
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1.3 A novel blood pressure-independent association 
Firstly, recently work by J. Titze and co-workers suggested a BP-independent link between 
high Na+ intake and a global shift in metabolism, driven by the ultimate need to preserve 
water upon this dietary habit.  
This conclusion came from a puzzling observation, made in the unique experimental 
setting of a human long-term Na+ balance study (Rakova et al., 2013): this unprecedented 
investigation took advantage of Russian spaceflight simulations. The small and tightly 
controlled setting of the flight program, comparable to an animal metabolic cage, allowed 
to circumvent the aforementioned compliance, cross-contamination and ultimately ethics 
issues related to the conduction of trials of salt intake modulation. The investigators 
modified the salt intake of 10 male cosmonauts, fixed at 12 g/day, 9 g/day or 6 g/day, each 
for 30-60 days, and collected 24 hr urine daily. Contrarily to previous human 
investigations, largely based on unphysiological short-term shifts from very low to high 
salt intakes, this design led to novel observations in relation to Na+ and water long-term 
homeostasis. In particular the authors reported: 
1) Large infradian changes in total-body Na+ without parallel changes in body weight 
(Rakova et al., 2013), as discussed in the next sections;  
2) A decrease, rather than the expected increase in water intake upon high-salt 
compared to low-salt diet (Rakova et al., 2017).  
Notably, the latter unanticipated finding did not prevent equal (or even increased, 
depending on data stratification) urinary volumes upon high-salt diet. To reconcile the 
mismatch, the authors advocated surplus endogenous free water generation from an 
exaggerated catabolic state and from enhanced renal accrual, which would make any extra 
exogenous water intake unnecessary.  
The hypothesis was tested in rodent models, where urea excess was identified as a key 
osmotic force to minimise free water loss (Kitada et al., 2017), via renal recycling and 
extrarenal generation from a salt-driven catabolic state (Figure 1-1). 
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Figure 1-1. Natriuretic-ureotelic water-preserving mechanisms upon high salt intake. 
Symbols: red = Na+, blue = water, green = urea. Upper panel: under low salt intake conditions, classic 
mechanisms (including the renin-angiotensin-aldosterone system) favour Na+ reabsorption from the urinary 
tubular lumen to the circulation to maintain electrolyte homeostasis. Lower panel: Rakova et (Rakova et al., 
2017) and Kitada et al (Kitada et al., 2017) suggest that upon high salt intake, renal specific and systemic 
mechanisms, are in place to prevent water depletion caused by passive osmotic diuresis. While Na+ 
reabsorbing mechanisms are downregulated, free water accrual is facilitated by higher reabsorptive gradients, 
generated by excess urea in the medulla via enhanced recycling and metabolic generation, i.e. protein 
catabolism. The catabolic reactions generate further endogenous water for maintenance of fluid homeostasis. 
Salt-driven glucocorticoid release is held to sustain the metabolic shifts and the catabolic state.   
In particular, an extremely high-salt dietary regimen (4% NaCl in the chow + 0.9% saline 
to drink) induced a substantial weight loss upon pair-feeding with the low-salt fed controls; 
likewise, with ad libitum feeding, food intake was markedly increased in high-salt + saline 
mice to maintain a body weight similar to controls. Further analyses in these mice revealed 
muscle mass loss and protein breakdown, as a source for urea generation, as well as a 
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In both their human and rodent studies, the authors observed an increase in 24h urine 
glucocorticoids excretion upon high-salt, opposite to the trends observed for aldosterone.  
While aldosterone data were in keeping with the traditional understanding of the renin-
angiotensin-aldosterone axis as a sodium retentive effector in relation to salt intake, 
spontaneous rhythmical glucocorticoid excretion was paralleled by increased urine volume 
without increase in water intake, thus implying generation and excretion of surplus 
endogenous water. Overall, a rhythmical and/or subclinical hypercortisolism was 
suggested to mediate the observed metabolic shifts and lean mass loss (Figure 1-1). 
With such reprioritisation of energetic and metabolic pathways, high salt intake could 
impact global cardiovascular health in a much broader and more complex fashion than 
currently appreciated. The shift of metabolic patterns observed in experimental settings 
upon high salt intake – representative of the current average Western diet - could 
significantly contribute to the highly prevalent and prognostically ominous clustering of 
diabetes, dyslipidaemia and obesity in the hypertensive population. Notably, a direct 
association between salt-intake and obesity independent of energy intake has recently been 
reported in the UK National Diet and Nutrition Survey (Ma et al., 2015).  
1.4 Novel concepts on sodium homeostasis  
Intake is just one (experimentally convenient but far from exhaustive) side of the coin for 
any homeostatic system. Classic physiology advocates the ultimate achievement of a 
balance between salt intake and excretion (Cannon, 1929), thus supporting the clinical 
practice of estimating Na+ intake from 24h Na+ urinary excretion.  
Independent experimental findings by Titze and others over the last 20 years, however, 
challenged the assumption. Heer et al first observed that short-term (1 week) experimental 
increases in Na+ consumption led to a positive Na+ balance (i.e. Na+ retention) without 
commensurate water retention or body weight changes in young healthy male subjects 
(Heer et al., 2000). As an explanation, they suggested the interstitial space as a site for 
potential sodium storage without an osmotic effect. Further work by Titze’s group 
substantially expanded on the topic of Na+ long-term homeostasis and tissue accumulation. 
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1.4.1 Disproof of a constant sodium balance 
In a preliminary observational (Titze et al., 2002) and the subsequent interventional 
spaceflight simulation studies (Rakova et al., 2013, Lerchl et al., 2015), they identified a 
marked variability in daily urinary Na+ excretion (uNaV) despite fixed intake, as well as 
some degree of dissociation between Na+ and water balance. In particular, they concluded 
that single 24-hour urine collections at intakes ranging from 6 to 12 g salt per day did not 
precisely reflect individual salt intake, with repeated measurements improving this 
performance (Lerchl et al., 2015): this has obvious implications for use of uNaV in clinical 
practice. Even by accounting for this variability, periodic changes in total body Na+ 
without parallel changes in body weight and extracellular water were detected and related 
to rhythmic hormonal control (Titze et al., 2002, Rakova et al., 2013).  
Notably, in the healthy subjects taking part in these studies, steady state between sodium 
intake and excretion was eventually achieved (Lerchl et al., 2015), although not within few 
days but rather weeks or months. No such demonstration exists in the ultra-long term 
(lifespan) and particularly for individuals with known cardiovascular or renal disease.   
1.4.2 Water-independent tissue sodium accumulation  
Whether the interstitial space could offer a depot for a long-term storage of Na+ (Heer et 
al., 2000), potentially preventing achievement of a steady state in individuals other than the 
young healthy cosmonauts involved in the spaceflight simulations, was experimentally 
investigated.  
Preclinical rodent models of normotension, salt-resistant and salt-sensitive hypertension, 
showing different degrees of Na+-associated fluid retention upon high Na+ intake, first 
suggested a role for water-independent Na+ storage in the pathogenesis of hypertension 
(Titze et al., 2002a). Subsequent experiments conducted by desiccation and dry ashing of 
whole rat carcasses or specific compartments (e.g. bones, quadriceps muscles and skin) 
pointed to skin as the specific depot for excess Na+ accumulation (Titze et al., 2003, Titze 
et al., 2005, Machnik et al., 2009, Wiig et al., 2013) and negatively charged 
glycosaminoglycans (GAGs) network was identified as the dynamically regulated substrate 
for putative interstitial skin Na+ binding (Titze et al., 2004). The apparent dissociation 
between Na+ and water tissue content, consistent with the results of the balance studies, led 
to the conceptualisation of a hypertonic phenomenon. 
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This was paralleled by two lines of complementary evidence: 1) the activation of 
pathogenic immune-inflammatory cells upon culture in supraphysiological concentrations 
of Na+ and 2) the in vivo visualisation of Na+ excess in the skin and skeletal muscle of 
patients with cardiovascular diseases or risk factors, by means of magnetic resonance 
imaging.   
1) Hypertonic extracellular Na+ was first found to boost the activation of 
inflammatory TH17 cells in vitro (Kleinewietfeld et al., 2013). Similar results were 
reported by independent investigators for macrophages (Jantsch et al., 2015, Zhang 
et al., 2015) and dendritic cells (Barbaro et al., 2017, Van Beusecum et al., 2019). 
All the above investigations assumed that the in vitro exposure of immune cells to a 
hypertonic milieu recapitulated the in vivo tissue conditions. 
2) Translation of the experimental findings from rodents to humans was made 
possible by 23Na magnetic resonance spectroscopy and high-magnetic field imaging 
(MRI). Spectroscopy quantification of Na+ in skeletal muscle and skin from rats 
and from patients undergoing limb amputation was first validated against direct 
chemical analysis of tissues (Kopp et al., 2012). By using dedicated phantoms 
loaded with different concentrations of NaCl as calibration solution, 3-7T MR 
imaging quantification was thereafter implemented. This allowed to identify excess 
skin and/or skeletal muscle Na+ content in patients with refractory hypertension or 
primary aldosteronism compared to normotensive controls (Kopp et al., 2012, 
Kopp et al., 2013) and in other clinical conditions such as acute heart failure 
(Hammon et al., 2015), systemic sclerosis (Kopp et al., 2017) and diabetes(Karg et 
al., 2018). Skin Na+ was also found to correlate better than total body 
overhydration or blood pressure with left ventricular mass in patients with chronic 
kidney disease(Schneider et al., 2017), thus stimulating the quest for interventions 
specifically targeting tissue Na+ to improve cardiovascular outcomes in this 
extremely-high-risk population. 
Overall, this new notion of local Na+ accumulation was acknowledged by independent 
reports as a paradigm shift (Elijovich et al., 2016, Mancia et al., 2017), closely linked to 
the enormous public health burden of ageing and cardiovascular disease. Other authors 
claimed that “dissociation of blood pressure from fluid volumes” could reflect 
“complexities of sodium handling not accounted for by Guyton’s hypothesis” (Coffman, 
2014). 
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1.5 The lymphatic system 
In further support of a hypertonic interstitial Na+ accumulation was the evidence of 
tonicity-responsive enhancer binding protein (TonEBP) activation in the skin resident 
mononuclear phagocytic cells of rodents upon salt loading (Machnik et al., 2009). 
Downstream signalling included VEGF-C secretion, VEGF receptor 3 (VEGFR3) 
activation and plastic expansion of the lymphatic vascular network to provide enhanced 
local Na+ excess clearance (Wiig et al., 2013). Whenever any intermediate effector of this 
signalling was blocked and the lymphatic expansion prevented, the resulting phenotype 
entailed hypertonic skin Na+ retention and salt-sensitive hypertension.  
After these first reports, enhanced cardiac lymphangiogenesis induced by VEGF-C was 
shown to reduce myocardial fibrosis and macrophage infiltration, decrease blood pressure 
and preserve myocardial function in a salt-sensitive rat model of hypertension, while 
VEGF-C blockade produced opposite effects (Yang et al., 2014). Similarly, an inducible 
genetic model of kidney-specific lymphangiogenesis proved resistant to the development 
of hypertension induced by high-salt diet (Lopez Gelston et al., 2018).  
Overall, these studies uncovered a novel role for lymphatic vessels in the control of local 
Na+ homeostasis and the pathogenesis of hypertension. In fact, the importance of this 
frequently neglected part of the circulation and microcirculation is currently undergoing a 
substantial reappraisal in the context of cardiovascular physiology as a whole (Mortimer 
and Rockson, 2014, Herring, 2018, Aspelund et al., 2016), as detailed below.  
1.5.1 Lymphatic role in microvascular haemodynamics 
At the level of microcirculation, where the exchange of metabolic substrates for tissues 
takes place, the interplay between plasma, the highly organized microvascular wall, the 
perivascular interstitial space and the primary force sustaining the circulation, i.e. blood 
pressure, generates filtration. This phenomenon is governed by the Starling-Landis 
principle, whereby the rate is proportional to the hydraulic pressure gradient between 
plasma and interstitium minus the corresponding oncotic gradient (Pp-Pi and ∏p - ∏i, 
favouring and opposing filtration, respectively (Herring & Paterson, 2018)).  
Contemporary evidence, based on direct measurements of the hydraulic and oncotic 
interstitial forces, disproved the commonly held idea of a sustained reabsorption of 
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interstitial fluid at the venous end of the capillary beds, where hydraulic forces drop 
(Figure 1.2): with few anatomical and/or disease exceptions (e.g. in intestinal mucosa or in 
post-haemorrhagic states), the net sum of forces along the entire length of well-perfused 
microvessels consistently favours filtration over absorption (Levick and Michel, 2010). 
Therefore, local fluid balance is achieved by other structures and mechanisms, namely the 
lymphatic vessels, which constantly drain the ultrafiltrate and filtered plasma protein and 
transport it back as lymph to the central venous blood. A substantial volume of lymph is 
generated and transported every day (4-8 L), even in the face of a vanishing small filtration 
fraction in most tissues (i.e. the fraction of plasma water that escapes during one transit 
through the capillary, ~0.1%-0.3%). 
 
Figure 1-2. Starling-Landis equilibrium and the lymphatic system.  
Panel A) traditional arteriovenocentric model assuming interstitial forces negligible and, therefore, 
reabsorption of fluids at the venous end of the microvascular bed. Panel B) reappraisal of the above by 
including direct measurement of hydrostatic (P) and oncotic (∏) pressures; calculated values (grey arrows) 
and actual filtration (black arrows), as vascular glycocalyx modulates ∏i across the capillary bed. Fluid 
filtered as a constantly positive sum of forces is drained by the lymphatic system to central venous blood via 
lymphatic capillaries, afferent collecting vessels, lymphnodes, efferent collecting vessels and ducts. PA, PV 
and Pi = arterial, venular and interstitial hydrostatic pressures, respectively; ∏P and ∏I = plasma and 
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1.5.2 Anatomy and function 
Lymphatic vessels are unidirectionally and hierarchically organized into series of blind-
ended lymphatic capillaries, pre-collecting vessels and collecting vessels that, via chains of 
lymph nodes, ultimately drain into to the blood circulation via the thoracic or right 
lymphatic duct and the subclavian veins (Figure 1.2 B). 
Lymphatic capillaries (diameter 20-70 µm) are composed of a single layer of lymphatic 
endothelial cells (LECs) with an incomplete basement membrane and characteristic 
“buttonlike” junctions, opened and closed by intraluminal and external pressures and 
suitable for the controlled entry of solutes, macromolecules and cells. The larger collecting 
vessels (70-500 µm) are less permeable, are covered by periendothelial lymphatic muscle 
cells and are organized into a series of coordinated functional units, each called 
“lymphangion”, separated by intraluminal one-way valves and capable of spontaneous 
pumping activity. In addition to the extrinsic forces resulting from intermittent 
compression of the lymphatics by tissue movements, like skeletal muscle contractions, 
intestinal peristalsis, movement of the skin or pulsation of adjacent arteries, this 
autonomous contractile activity generates intrinsic propulsion forces for progression of 
lymph through the lymphatic system.  
Lymphatic muscle shares biochemical and functional aspects with both vascular and 
cardiac muscle. It is characterised by a pacemaker-generated action potential within each 
lymphangion and by a sequence of systolic (contractile) and diastolic (filling) phases 
which bear striking similarities with the mechanics of the cardiac pump; in particular, 
contractility is sensitive to preload, afterload and neuro-hormonal regulation (Figure 1-3). 
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Figure 1-3. Lymphangion contraction cycle.  
Panel A) scheme of the systolic-diastolic phases of lymphangion contraction, with representative pressure 
and diameter traces. Panel B) opening and closing of a lymphatic valve corresponding to the different phases 
of the contraction cycle (end-diastole for the downstream lymphangion, left; mid-systole of the upstream 
lymphangion, right. Panel C) contractile activity of a mouse flank lymphatic collector, isolated and mounted 
on a myograph system by the author of this thesis in the lab of Michael Davis (University of Missouri, 
Columbia, MO) and pressurised with identical input and output pressures – modulated as per blue tracing 
(range 0.5-8 cm H2O). Please note the difference in systolic frequency and amplitude at different pressures; 
each spike corresponds to a systolic deflection, as per panel A (bottom). 
Intriguingly, not only the lymphatic vascular density but also the ultimate result of this 
contractile activity, i.e. lymph flow, was increased in rats with evidence of skin Na+ 
accumulation after salt exposure (Karlsen et al., 2018). 
1.6 Traditional vs novel views: open questions 
As discussed in previous sections, all these novel perspectives on Na+ homeostasis and its 
impact on hypertension and cardiovascular disease at large, even independent of BP 
values, emerged as possible paradigm shifts. However, at the time my PhD studies were 
conceived and conducted, the concepts of a sodium-driven shift in metabolism and of 
water-independent accumulation in tissues had not faced the challenge of either 
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On the one hand, the proposed catabolic mechanisms of water preservation upon high Na+ 
intake lacked demonstration in humans who were not in a dietary- and environmentally-
controlled experimental setting (addressed in Chapter 3). 
On the other hand, the suggestion of a water-independent hypertonic accumulation of Na+ 
in tissues and its extremely high prevalence in many cardiovascular diseases and risk 
factors (based on chemical analysis in rodent models and 23Na-MRI in humans, by 
syllogism) disputed, at least in the ultra-long term, the dogma of an even intake-excretion 
balance. While doing so, however, it raised critically important questions regarding: 
1) differential local Na+ handling beyond the kidney in different sexes, ages, organs 
and clinically relevant conditions; in other words: “when and where – or in whom - 
does it happen?” (addressed in Chapters 4-7) 
2) differential functional impact of such hypertonic interstitium on the surrounding 
cells and structures other than hypertonic Na+-activated immune cells, such as 
vessels. In other words: “is it - and if so, how is it - biologically and clinically 
relevant, particularly to vascular function?” (addressed in Chapters 5 and 7) 
Such key questions, addressed in this thesis by direct tissue chemical analysis and 
assessment of vascular function in multiple experimental settings and conditions, 
confronted some discrepancies in the original observations.  
First, the novel phenomenon of hypertonic tissue Na+ accumulation was initially described 
as skin specific (Titze et al., 2003, Titze et al., 2005) but 23Na-MRI in humans identified 
also skeletal muscle and, more recently, myocardium (Christa et al., 2019) as a site of 
excess Na+ signal, thus questioning the original specificity.  
Second, it seemed difficult to unequivocally reconcile a dual osmotically-active and -
inactive nature of interstitial Na+, driving TonEBP-mediated signalling while 
simultaneously eluding parallel and commensurate water accrual. Therefore, I 
hypothesised that a hypertonic Na+ accumulation in the interstitium could facilitate 
capillary fluid extravasation and oedema, and identified patients with HF, where oedema is 
a typical feature, as a suitable population where to test such contention. In particular, the 
high prevalence and public health relevance, the established microvascular dysfunction, 
the overt body fluid/Na+ homeostasis disturbance and the typical clustering with conditions 
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known to exhibit excess tissue Na+ at 23Na-MRI (e.g. hypertension, diabetes and CKD) 
made HFpEF the ideal and clinically relevant disease for my research aims. 
Additionally, based on the anatomical and functional lymphatic expansion under 
conditions of Na+ excess in preclinical models, I included lymphatics in the morphological 
and functional assessment of the microvasculature in HFpEF (Chapter 7), under the 
hypothesis of a bidirectional link between microvascular dysfunction and Na+ 
accumulation. 
1.7 Research aims 
In summary, under the overarching aim of investigating novel aspects of sodium 
homeostasis in cardiovascular disease, this thesis focuses on both systemic and “local” 
mechanisms. 
Specific aims were to investigate: 
1) the impact of high Na+ intake on renal water-preserving mechanisms and 
metabolomics signatures, as well as their association with cortisol as the putative 
intermediate effector of the proposed BP-independent metabolic shift, in a real-life 
hypertensive population.  
2) the phenomenon of tissue Na+ accumulation in terms of: 
• isotonic (water-paralleled) or hypertonic (water-independent) nature, by 
theoretical modelling (Chapter 4) and experimental assessment in rodent 
models of salt sensitivity/salt loading (Chapter 5), in patients with 
hypertension (Chapter 6) and patients with HFpEF (Chapter 7); 
• tissue/organ distribution in relevant rodent models (Chapter 5); 
• clinical correlates in a hypertensive population (Chapter 6). 
3) microvascular function, in relation to interstitial Na+ accumulation. This was 
assessed: 
• ex vivo in rodent models (Chapter 5);  
• ex vivo and in-vivo in patients with HFpEF (Chapter 7), including measures 
of capillary-interstitium fluid exchange and lymphatic drainage. 
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2 GENERAL METHODS 
This chapter is arranged as per proposed experimental aims and closely recapitulates the 
sequence of the chapters and sections in the thesis. The general approach and methods to 
address aims are presented here; additional details, particularly those specific to individual 
studies, are provided in the dedicated chapters. 
2.1 Assessment of the metabolic impact of high sodium intake  
To investigate: 1) the renal water-preserving mechanisms primarily proposed to induce a 
metabolic shift upon high Na+ intake, 2) the metabolomics signatures and 3) their 
association with cortisol, I took advantage of a large and carefully characterised real-life 
hypertensive population, as part of the SYCAMORE study: Sodium intake and subclinical 
hYper-Cortisolism: Association and MetabOlic signature. 
The study analysed clinical and biochemical data from consecutive consenting patients 
referred to the tertiary Hypertension Center of the University of Padua, who underwent 
biochemical screening for secondary causes of hypertension between 2012 and 2017.  
The screening protocol included blood sampling and 24h urine collection on usual diet and 
avoidance or washout from medications affecting the renin-angiotensin-aldosterone 
system. Patients with a conclusive diagnosis of essential (primary) hypertension were 
stratified according to classes of Na+ intake (Low ≤2.3g/d; Medium 2.3-5g/d; High >5g/d) 
defined based on urinary 24h Na+ excretion at the time of the screening.  
Blood and 24h urine data were used to calculate creatinine clearance, as a surrogate for 
glomerular filtration rate (GFR), fractional excretions of Na+ and water, as measures of 
their tubular handling, and tubular energy expenditure, as estimated by measured Na+ 
reabsorption and Na+/ATP stoichiometry. Non-targeted liquid chromatography–mass 
spectrometry (LC-MS) metabolomics was conducted on plasma samples from an 
unselected subcohort. 
Univariate and multivariate comparisons of renal measures of Na+/water handling, cortisol 
and plasma metabolomics signatures were performed across Na+ groups.  
Please see Chapter 3 for further details.  
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2.2 Assessment of tissue sodium accumulation 
Investigation of the nature of tissue Na+ accumulation, previously indicated as hypertonic 
by other investigators, was approached by theoretical modelling (chapter 4) and by 
experimental assessment in tissue samples from suitable rodent models (Chapter 5) or skin 
from human subjects (chapters 6 and 7). The latter entailed healthy volunteers, as controls, 
and patients affected by conditions where the phenomenon of tissue Na+ excess had been 
already reported (i.e. hypertension; chapter 6) or was likely to occur based on the typical 
clustering of comorbidities similarly associated with tissue Na+ accumulation (i.e. HFpEF; 
chapter 7). 
In addition to theoretical speculations and actual conduct/interpretation of tissue chemical 
analyses, other relevant focuses were on: 1) the distribution of the phenomenon in organs 
other than skin, investigated in rodent models; 2) clinical correlates of skin Na+ 
accumulation in hypertensive patients, as well as local mechanisms of regulation as 
putative direct determinants.  
2.2.1 Modelling (Chapter 4) 
A simple mathematical model to predict the chemical composition of different tissues, 
which accounted for the complexity deriving from heterogeneously represented 
intracellular and extracellular fractions whenever a whole-tissue analysis is performed, was 
developed. The key underlying assumption was that Na+ and K+ are, by approximately 1.5 
orders of magnitude, the most abundant cations of the extracellular and intracellular space, 
respectively 
Specific calculations, based on physiological values of Na+ and K+ concentrations in the 
intracellular and extracellular fluids, are extensively reported in Chapter 4. 
2.2.2 Animal models (Chapter 5) 
For the purpose of this thesis, Wistar-Kyoto (WKY) and stroke-prone spontaneously 
hypertensive (SHRSP) rats from colonies inbred at the University of Glasgow since 1991 
were used as rodent models of salt-resistance and salt-sensitivity, respectively.  
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SHRSP rats are a long established (Okamoto et al., 1974), sub-strain of SHR, with 
remarkable salt-sensitivity (Griffin et al., 2001) driven, at least in part, by a secondary 
aldosteronism evident since 18 weeks of age (Kim et al., 1992). Established blood 
pressure, body weight and RAAS phenotypes of WKY and SHRSP male rats are presented 
in Figure 2-1. 
 
Figure 2-1: WKY and SHRSP phenotype. 
BW = body weight; BP = blood pressure; PRA = plasma renin activity; PAC = plasma aldosterone 
concentration. Adapted and redrawn from Kim et al, Hypertension 1992; 20:280-291. 
In two independent sets of experiments, I investigated the effect of salt-loading and ageing 
on Na+ accumulation in different tissues. Experimental details on protocols and assessment 
of additional outcome measures related to Na+ accumulation (e.g. extracellular matrix 
remodelling, gene expression or tissue fat content analyses) are provided in Chapter 5.  
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2.2.3 Human subjects (Chapters 6-7) 
Na+ accumulation was investigated in skin samples from healthy volunteers, hypertensive 
patients and patients with HFpEF. Common to all these groups is the collection of a small 
skin punch biopsy, primarily but not solely used for the chemical analysis of the tissue.  
2.2.3.1 Young healthy volunteers 
A preliminary pilot study, designed to optimize of the collection and ex-vivo analysis of 
small human skin samples from self-defined healthy volunteers (SKILLS: SKin biopsy for 
Interstitium and Lymphatic vesseLS assessment), was approved by the University of 
Glasgow, MVLS College Ethics Committee (ref. 200160109) and conducted between May 
2017 and April 2018. Due to the technical nature of the study, the sole exclusion criterion 
was history of potential coagulation disorders for safety reasons.  
The SKILLS study allowed optimisation of the surgical procedures (2.2.4), tissue 
processing and chemical analysis (2.2.5), but also histology or immunohistochemical-
fluorescence staining and RNA/protein isolation (please see chapters 6-7), of small human 
skin samples from minimally invasive punch biopsies. This was necessary to avoid 
jeopardizing the participation of patients or volunteers to subsequent clinical studies 
because of the biopsy requirement, as well as to maximize the yield of the small samples. 
Eighteen subjects were involved in the study, out of a ≤ 20 initial estimate at the time of 
ethics application.  Both ice spray and lidocaine-based topical cream were tested for local 
anaesthesia, in order to avoid any major impact on the chemical content of the sampled 
skin; upon experimental confirmation of no detectable Na+ or K+ content at flame 
photometry analysis (please see 2.2.5.3), the latter was confirmed as the preferred option. 
Both the gluteal upper quadrant and the arm were tested as suitable sites. Overall, the 
biopsies were well tolerated, and no adverse events were observed. 
A subsequent cross-sectional study on healthy volunteers (SOWAS: SOdium and WAter 
Skin Balance) recruited among MVLS students was approved by the University of 
Glasgow, MVLS College Ethics Committee (ref. 200170153) and conducted between July 
and December 2018. One of the study aims, relevant to this section, was to provide sex-
specific skin chemical reference values from a young healthy population. Exclusion 
criteria entailed: lack of consent, office BP > 140/90 mmHg; obesity; previous diagnosis of 
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diabetes, thyroid, renal or coagulation disease; extremely low (<100 mmol/die) or high 
(>216 mmol/die) sodium excretion on 24h urine collection, as assessed on site by 
colorimetric strips (Salinity View, Health Mate®) at the time of the study visit. For female 
participants, the date of the main visit was arranged in the early follicular phase of their 
menstrual cycle, just after period termination; in 4 cases, due to personal logistics or 
continuous progesterone treatment (skin implants or vaginal coil) the main visit coincided 
with a luteal or luteal-like phase. Please see also section 6.2.1.2. 
2.2.3.2 Hypertensive patients  
The S2ALT (Skin Sodium Accumulation and water baLance in hyperTension) study was 
designed to explore the nature (iso- or hyper-tonicity) and clinical correlates of skin Na+ 
accumulation in a hypertensive population, also in relation to the mechanisms and degree 
of surface Na+/water exchange.  
In brief, adult, consenting non-pregnant patients were recruited from the Blood Pressure 
clinic, Queen Elizabeth University Hospital, Glasgow between March and July 2019 and 
underwent a skin punch biopsy on the day of their scheduled clinic appointment (9:00 AM 
to 4:30 PM). The complete study protocol and material (Appendices 1-3), as well as 
assessment of correlates and additional outcome measures, including transepidermal water 
loss and sweat analysis, are further discussed in Chapter 6.  
2.2.3.3 Patients with HFpEF vs healthy controls of similar age and sex  
Based on the initial hypothesis of a prevalent and pathologically-relevant hypertonic skin 
Na+ accumulation in the syndrome, I designed and conducted the HAPPIFY (Heart fAilure 
with Preserved ejection fraction: Plethysmography for Interstitial Function and skin 
biopsY) study. Subjects with stable HFpEF (identified from outpatient HF clinics in 
Glasgow) and volunteers of similar age and sex, with no history or evidence at the time of 
the eligibility visit of cardiovascular or renal disease, hypertension or diabetes, were 
recruited in the study between August 2017 and December 2018. 
In addition to the skin biopsies (2.2.4), participants underwent extensive vascular 
functional phenotyping, both in-vivo and ex-vivo (please see below, section 2.3.1 and 
2.3.2), and plethysmographic assessment of microvascular dynamics and interstitial fluid 
accumulation in-vivo, reflecting the balance between capillary extravasation and lymphatic 
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drainage (please see below section 2.3.3). The complete study protocol material 
(Appendices 4-6), details on the histological and molecular analyses of skin samples and 
the approach to (micro)vascular functional assessment are further discussed in Chapter 7.  
2.2.4 Skin biopsy  
Approximately 40 minutes before the planned biopsy, lidocaine-based topical anaesthetic 
cream (LMX4) was applied: a) on the outer upper arm, approximately halfway between the 
elbow and shoulder, for S2ALT study or b) on a gluteal external upper quadrant for 
SOWAS and HAPPIFY study. After cleaning the skin with cotton gauze pads and Na+/K+ -
free 70% alcohol wipes, skin punch biopsies were performed on the anaesthetised site with 
a disposable instrument (3-4 mm blade diameter; Kai Medical). The excised skin sample 
was cut on the bench into two hemicylinders, each including both epidermis and dermis: 
one was fixed in PFA 2% for 8-10h at room temperature, washed in PBS and stored in 
70% ethanol at 4°C until paraffin inclusion for subsequent histological analyses; the 
second was immediately put into a pre-cooled Eppendorf tube, frozen in dry ice and stored 
at -80°C until tissue chemical analysis (Figure 2-2). For S2ALT study, due to time and 
logistics constraints, no bench processing was feasible and the whole sample was 
immediately frozen in dry ice. For SOWAS, both hemicylinders were frozen and one 
additional biopsy was collected for whole tissue culture (please see chapter 6). 
 
Figure 2-2. Skin biopsy protocol.  
Part of this figure was modified from  https://en.m.wikipedia.org/wiki/File:Skin_Punch_Biopsy.png, by 
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2.2.5 Chemical analysis of tissues 
A chemical analysis of tissues, focused on Na+ but also on K+ and water (complementary 
to Na+ assessment and results interpretation, as per Lowry and Hastings, 1942 and Lowry 
et al., 1942), was conducted in all the rat tissue and human skin samples by using a 
consistent approach.   
2.2.5.1 Gravimetric analysis of tissue water content 
From frozen rat tissue samples, aliquots representative of full parenchyma were cut and 
their wet weights (WW) measured on a 4 decimal (0.0001 g) electronic scale (samples 
WW range = 15-60 micrograms). 
Frozen human skin samples from punch biopsies were macroscopically transversally cut 
into a superficial layer, including the epidermis and the immediately adjacent superficial 
dermis (ESD), and deeper dermis (DD). At variance with rat tissues, a 5 decimal (0.00001 
g) scale (Ohaus, DV214CD) was used for weight measurements due to the small size of 
the samples. 
To prevent evaporation of tissue water, all the process of cutting was performed in a cold 
room and tissues were transported in Eppendorf tubes (Sarstedt) in dry ice. Samples were 
desiccated at 65°C in a ThermoMixer (Eppendorf), for > 40 hours, to a stable dry weight 
(DW). Water content was estimated as (WW-DW)/DW and expressed as mg 
water/mgDW, or as water percentage (W% = (WW-DW) x100/WW). 
2.2.5.2 Tissue digestion 
Dried samples were digested at 65°C in 20-40 µl of 70% HNO3 (Fisher) for 3 h and, after 
1:10 v/v dilution in deionised water (MilliQ), for 2 additional hours. Digestion blank 
controls (i.e. HNO3 and MilliQ only) were prepared and analysed with the digested 
samples to confirm the lack of Na+/K+ contaminations. Digested samples and blanks were 
centrifuged for 1 min at 16.000 g and stored at room temperature; solubilised supernatants 
were used for Na+ and K+ quantification. Acid-insoluble residues from rat skin and liver 
samples were used for total fat quantification (please see chapter 5). 
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2.2.5.3 Flame photometry analysis of Na+/K+ content  
After unsuccessful attempts with NMR, limited at least in part by the size of the rat tissue 
samples and the digestion protocol, a flame photometer (Sherwood scientific, model 410C) 
approach was optimised for Na+ and K+ quantification in the samples.  
Na+ and K+ calibration standards of 0-5 ppm (mg/l) were prepared from 1000 ppm 
solutions (Fisher Chemical) using HNO3- and milliQ- carefully washed glassware. Before 
photometric measurements, digested samples were further diluted to fall within the range 
of 0 - 5 ppm. MilliQ was used as the diluent for both standards and samples after Na+/K+ 
contamination of HNO3 was excluded on blanks. Na+ and K+ concentrations in the digested 
sample solutions were calculated against the five-points regression line obtained from the 
calibration standards. At the calibration used, reported CV% for reproducibility is < 2% 
(i.e. < 0.005 mmol/l for both Na and K in the measured sample); in our hands CV% was 
1.5 intra-sample and 3% inter-sample (from the same original tissue). Concordance 
correlation coefficient for replicated (technical) measurements was 0.98; random duplicate 
samples from the same stored tissues showed similarly good reproducibility (Figure 2-3 
below). 
 
Figure 2-3. Reproducibility of tissue chemical analysis. 
Panel A: replication of the flame photometer chemical analysis on the same HNO3-digested samples 
(technical replicates; batch of female rat skin samples reanalyzed at time 2, months after time 1) shows 
excellent reproducibility (r = 0.98 [95%CI: 0.96 to 0.99]; p<0.0001). The shift from the identity line (in red; 
slope of the regression line = 0.91 [0.87-0.95]; p < 0.001 vs 1.0) is likely due to unavoidable minimal 
differences in the progressive dilutions of calibration standards at the two different times. Panels B-C: 
reproducibility of results from the same tissue of the same animal; random duplicate samples from different 
tissues are shown for water content (gravimetric approach; panel B) and Na+ content (flame photometry; 
panel C); red= identity line. 
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All samples from the same type of tissue were analysed in a batch on the same day to 
minimise technical variability; therefore, few samples irreversibly affected by 
experimental issues (e.g. accidentally dropped sample, contamination, volume shortage) 
had to be excluded. During measurements, blank (diluent) and calibration standards were 
checked after every block of approximately 8 samples to control for drift. Na+ and K+ 
concentrations in the analysed solutions were used to back-calculate their total content in 
the digested samples and normalised by DW for Na+ and K+ tissue content (mmol/gDW), 
or by tissue water for Na+ and K+ tissue concentration (mmol/l).  
The flame photometry analysis was conducted blind to group allocation of samples. 
2.3 Assessment of vascular and microvascular function  
The putative impact of tissue Na+ accumulation on vascular function was investigated in 
the aforementioned salt-loaded rodents (Chapter 5) and in patients with HFpEF, compared 
to controls of similar age and sex, in the HAPPIFY study (Chapter 7).  
In rodents, the assessment of arterial function was based on ex-vivo preparations of 
mesenteric arteries, by using the wire myograph technique and by testing the vascular 
effects of dietary (in-vivo) animal exposure to high-sodium and those of ex-vivo exposure 
of vessels to supraphysiologic concentrations of Na+ in the experimental bath.  
In HAPPIFY, ex-vivo assessment of subcutaneous resistance arteries was part of a 
comprehensive vascular phenotyping, including also in-vivo approaches, of patients with 
HFpEF. The primary study hypothesis was that a hypertonic interstitium would facilitate 
capillary fluid extravasation and accumulation of oedema. To test the above, I used a 
plethysmographic protocol which allowed the simultaneous evaluation of microvascular 
filtration and lymphatic drainage of extravasated fluid. 
2.3.1 Ex-vivo study of arterial function on wire myography 
Wire myography is the study of vascular muscular (and, by upstream signalling 
modulation, endothelial) function, applied for the purposes of this thesis to small resistance 
arteries. In particular, it measures capacity of the vascular wall to constrict or relax in 
response to different stimuli. At variance with isobaric preparations (pressure myography), 
where changes in vascular diameter in response to changes in intraluminal pressure are 
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measured, wire myography relies on the isometric set up of a vessel pre-stretched by two 
wires inserted through the lumen and on high-sensitivity force transducers measuring the 
changes in wall tension exerted on those wires. This tension is modulated by adding 
agonists or antagonists to the bath where the vessel is mounted, in order to induce vascular 
contraction (i.e. increased tension) or relaxation (i.e. decreased tension), respectively. 
For this thesis, third-branch mesenteric arteries from rats (Chapter 5) and small 
subcutaneous arteries from HAPPIFY participants consenting also to the ‘subcutaneous fat 
biopsy sub-study’ (Chapter 7) were dissected. Their function was assessed on the same day 
for rat and on the following day, after overnight incubation at 4°C in physiological saline 
solution [PSS; 119.0 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4.7H2O, 24.9 mM NaHCO3, 
1.2 mM KH2PO4, 2.5 mM CaCl2 and 11.1 mM glucose], for human vessels. 1.5-2 mm 
vascular ring segments were mounted on isometric wire myographs (Danish Myo 
Technology [DMT] Denmark) filled with 5ml of fresh PSS and continuously gassed with a 
mixture of 95% O2 and 5% CO2 while being maintained at a constant temperature of 
37±0.5°C.  
Following 30 minutes of equilibration, baseline tension was normalised as per DMT 
recommendations (www.dmt.dk/uploads/6/5/6/8/65689239/dmt_normalization_guide.pdf); 
this process consists of pre-stretching a vessel to an internal diameter that produces a 
physiologic resting transmural pressure before any experimental stimulus is applied to the 
vessel. This step standardises conditions across different vessels to guarantee reproducible 
and comparable results.  Upon normalisation, the internal diameter was estimated as 
recommended. Vessels with an internal diameter ³ 500 µm, traditionally identified as the 
maximum size of resistance arteries (Mulvany and Aalkjaer, 1990, Heagerty et al., 1993), 
were excluded from further analysis.  
After normalization, the viability of arterial segments was assessed by the addition of KCl 
(62.5mmol/L), repeated after 10 minutes of washout. The contractile response of vessels to 
the thromboxane agonist U46619 was tested with concentration-response curves (10-10 - 
3x10-6 M). Endothelium-dependent and -independent relaxation was assessed by a dose-
response to acetylcholine (Ach; 10-10 - 3×10-5 M) or the nitric oxide (NO)-donor sodium 
nitroprusside (SNP; 10-10 - 10-5 M), respectively, following pre-constriction with U46619 
dose that produced 75% of the maximal contractile response.  
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Additional vascular segments from control (non-salt loaded) normotensive and 
hypertensive rats were incubated for 5 hours in PSS or in NaCl-supplemented-PSS (+15 
mM NaCl, hypertonic, HT) to test the impact of environmental hypertonicity on vascular 
function. Duration and tonicity of the incubations were based on previously reported tissue 
changes with high-salt diet (D(treated – control) in Machnik et al.,2009 and Wiig et al., 
2013) and effects of hypertonic culture conditions on rat vascular smooth muscle cells 
(VSMCs) hypertrophy (Gu et al., 1998).  
After the incubation and one additional KCl stimulation, concentration-response curves for 
U46619 and SNP were conducted as described above (Figure 2-4).  
 
Figure 2-4. Wire myography ex-vivo experimental protocol to assess arterial function. 
Top: standard protocol, used for both human and rat vessels. After normalisation, viability and agonist-
independent contractility was assessed by repeated 62.5 M KCl stimulations. The magnitude of the agonist-
independent contractile response to the second KCl stimulation was used as reference for the agonist-induced 
response. Cumulative concentration response curves (CCRC) to U46619, Acetylcholine (Ach) and sodium 
nitroprusside (SNP) were conducted to assess contractility, endothelium-dependent relaxation and 
endothelium-independent relaxation, respectively. CCRCs were conducted after 30 minutes of washout from 
the previous agonist/antagonist. Bottom: for rat vessels only, a similar sequence of CCRCs was conducted 
after vessels incubation in a hypertonic solution (+15 mM NaCl, vs 144 mmol Na+ in standard PSS) to test 
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Vessels with no or trivial post-incubation response to KCl or U46619 pre-constriction were 
considered non-viable and their curves were excluded from the analysis.  
Unfortunately, I was not able to conduct a similar incubation protocol in vessels from 
HAPPIFY participants due to the smaller number of viable subcutaneous arterial segments 
available for functional testing than originally expected. 
2.3.2 Non-invasive study of arterial function (humans) 
All HAPPIFY participants underwent non-invasive assessment or arterial function. In 
particular: Pressure Waveform Analysis (PWA) and assessment of carotid-femoral Pulse 
Wave Velocity (PWV) were used to estimate arterial stiffness; brachial Flow-Mediated 
Dilatation (bFMD) was used to estimate post-ischemic hyperaemic responses and 
endothelium dependent vasodilatation of large arteries. 
2.3.2.1 Pressure Waveform Analysis 
Arterial pressure is used in everyday clinical practice as a surrogate of arterial function. 
Many traditional cardiovascular risk factors, similar to the process of ageing, induce and 
perpetuate biological changes at the cellular level (namely chronic inflammation, oxidative 
stress, endothelial dysfunction and cell senescence, among others) which underpin 
structural changes in the vascular wall. The ultimate functional result of such changes is 
stiffening. This primarily affects aorta and elastic arteries and typically determines 
increased systolic and pulse pressure. A self-perpetuating vicious cycle ensues: the left 
ventricle (LV) pumping into a stiffened aorta suffers an increased afterload; the diastolic 
component of the aortic pulse, resulting from the sum of the forward with the backward 
reflected pressure wave arising from arterial branching points, undergoes anticipation to 
the systolic phase due to faster wave transmission in stiffened arteries and induces 
augmented central systolic pressure (Nichols and O'Rourke, 2011) which further increases 
LV stress and oxygen demand; with the loss of “cushion” properties from elastic vessels, 
pulsatile pressure is inappropriately transmitted into the distal microvasculature of target 
organs, thus maintaining and worsening endothelial damage and the biological 
dysfunctional changes listed above (Currie and Nilsson, 2019). 
The prominent pathogenic role of central blood pressure and wave form can be 
investigated by non-invasive methods, which provide estimates of central parameters from 
Chapter 2 – General Methods 
 46 
peripherally assessed pulses, by applying general transfer functions previously validated 
against invasive measures.  
In the HAPPIFY study, I used a SphygmoCor XCEL (AtCor Medical) to perform this 
Pulse Wave Analysis (PWA) (Laurent et al., 2006). Briefly, multiple sequential artery 
pressure waveforms are acquired from a dedicated brachial cuff and averaged into an 
ensemble, used by the software to derive and synthesize the central aortic pressure 
waveform. Key derived parameters, summarised in Figure 2-5, are: systolic and diastolic 
central blood pressure values, resulting from the predicted sum of forward and backward 
waves; central pulse pressure (PP); augmentation pressure (AP), i.e. the difference between 
the systolic inflection point (denoting the initial upstroke of the reflected pressure wave) 
and the systolic peak; augmentation index (AIx), as the proportional ratio between AP and 
PP, traditionally normalised to a heart rate of 75 bpm (AIx@75) to correct for the 
confounding effect of chronotropy. More sophisticated discussion on the technique is 
beyond the scope of this thesis; in general, the stiffer the peripheral arteries, the faster the 
reflected wave returns towards the heart, merges with the forward wave and hence 
increases AP and AIx.  
 
Figure 2-5. Central Aortic waveform and key parameters of PWA.  
This figure is from https://commons.wikimedia.org/wiki/File:Augmentation-index.PNG, by Icternol, licensed 
under the Creative Commons Attribution-Share Alike 4.0 International license. 
In HAPPIFY, AP and AIx@75 were measured as surrogates of arterial stiffness. Specific 
protocol details, including timing and conditions of testing, are provided in Chapter 7. 
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2.3.2.2 Pulse Wave Velocity 
A more direct approach to measure arterial stiffness relies on the actual measurement of 
the pulse wave transit time over a certain vascular segment, i.e. velocity (PWV).  In 
particular, the technique used in HAPPIFY, with the SphygmoCor XCEL (AtCor Medical) 
device, measures the speed of the pulse as it travels between the heart, carotid and femoral 
vessels (cfPWV): reduced vascular compliance and wall stiffening result in shorter pulse 
wave transit time and higher PWV (Laurent et al., 2006, Van Bortel et al., 2012). By 
reflecting the speed of pressure waves propagation (both forward and backward), increased 
PWV as a result of stiffening is a direct determinant of AP and AIx. PWV is universally 
accepted simple and robust measure of arterial stiffness, with independent predictive value 
for cardiovascular mortality and events across a variety of populations and conditions (The 
reference values for arterial stiffness' collaboration 2010, Townsend et al., 2015, Currie 
and Nilsson, 2019).  
Specific protocol details for the application of cfPWV, including timing and conditions of 
testing, are provided in Chapter 7. 
2.3.2.3 Brachial Flow-Mediated Dilatation 
In addition to the process of stiffening, which predominantly (but not solely) involves the 
medial and adventitial layers of the vascular wall, the endothelium is another central 
determinant of vascular function. It is typically responsible for the release of nitric oxide 
(NO) and other vasodilatory substances. Flow-mediated dilation (FMD) is a widely used 
non-invasive tool for examining peripheral artery endothelium-dependent dilation 
(Thijssen et al., 2019). At variance with invasive approaches, which rely on the infusion of 
a variety of vasoactive substances in specific vascular territories, FMD relies on a phase of 
induced reactive hyperaemia as the stimulus for shear stress on the endothelial layer of 
large arteries, resulting in vasodilatation. 
The technique measures the change in vessel diameter from baseline to the peak observed 
during the hyperaemic phase as indicative of endothelial function; simultaneous 
acquisition of blood flow velocity signals allows also quantification of the shear stress 
generated by the procedure (Figure 2-6).  
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Figure 2-6. Flow-mediated dilatation.  
Schematic presentation of vessel diameter and shear stress responses before and after a 5-min ischaemic 
stimulus. Adapted and simplified from Thijssen DHJ et al, Eur Heart J 2019; 40, 2534–2547. 
Substantial methodological variation in performing FMD is present in the literature 
(Thijssen et al., 2019). However, the most widely adopted and guidelines-based approach 
is based on brachial artery imaging with high-resolution ultrasound, before and after distal 
(forearm or hand) ischaemia is induced through interruption of arterial flow using a blood 
pressure cuff inflated to supra-systolic pressure for 5 min. Cuff release results in dilation of 
the distal microvasculature via multiple mechanisms (Pyke and Tschakovsky, 2005), 
reactive hyperaemia is induced and arterial vasodilation follows. 
In HAPPIFY, brachial FMD measurements and analysis were performed according to 
guidelines (Thijssen et al., 2011), using with a semi-automated device and a proprietary 
software (UNEX EF, Japan; https://unex.co.jp/ENG/unexef.htm).  
The device is equipped with an automated edge-detection software and a vessel tracking 
system which facilitates and continuously micro-correct probe positioning for steady 
images at the beginning and during the test. The H-shaped probe, generating one long-axis 
and two short-axis B-mode images, operates at ultrasound wave frequency of 8MHz. 
Blood velocity is simultaneously measured by the same probe, with an automatically 
adapted flow sampling rate (7.1kHz, 5.9kHz, 5.0kHz, 4.0 kHz) and a sample volume 
adjusted to the internal vessel diameter. Intensity weighted mean velocity assuming a 
circular cross-section of the vessel and its time-average during the cardiac cycle are 
automatically calculated. Due to the dependence of velocity assessment on the angle of 
Doppler insonation and its fixed value in the UNEX EF device (75°), preventing absolute 
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comparisons with different machines, averaged blood velocity (V) and the derived flow (V 
× π (vessel diameter/2)2 × 60) and shear rate (8 × V/diameter) changes are analysed as 
relative to baseline. 
After BP measurement and 10 additional minutes of quiet supine rest, an occlusion cuff 
was placed around the right forearm, the ultrasound probe 5-10 cm proximal to the elbow 
and ECG leads on the wrists. Following measurement of the rest diameter (intima-intima) 
and blood velocity for at least 30 s, the cuff was inflated 50mmHg above systolic BP to 
induce forearm ischaemia for 5 minutes. One minute before cuff release the tracking 
system automatically tracked the artery and adjusted the probe position to correct for small 
involuntary arm displacements; after deflation the vessel diameter was measured for 2 
minutes, for a total of 3 minutes of ECG-triggered images.  
All the images and automated outputs were manually reviewed and analysed with UNEX 
software off-line at the end of the study (Dobbie et al., 2020); the best position for edge-to-
edge diameter measurement was identified on the vessel and dynamically tracked by the 
automatic software throughout the course of the exam. FMD was calculated as [(Max 
Diameter – Rest Diameter)/Rest Diameter] × 100. 
 
Figure 2-7. Representative FMD tracings. 
Left: patient with preserved FMD (11%) in response to reactive hyperaemia. Right: patient with almost null 
vasodilatory response (0.8%), despite good hyperaemic response (12 x baseline flow values). In the graphs at 
the bottom: light blue = results of live diameter tracking during the performance of the exam; red = off-line 
manual review of rest and post-ischaemic diameters; purple = flow velocity signals, assessed by pulsed 
Doppler. 
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There is extensive literature on the rationale, technical aspects and clinical/research value 
and application of FMD; further discussion of this enormous amount of information is 
beyond the scope of this thesis. Literature relevant to this thesis and additional protocol 
details for HAPPIFY patients are discussed in the appropriate sections of Chapter 7. 
2.3.3 In-vivo study of fluid microvascular dynamics (humans) 
The exchange of fluids and solutes between the arteriovenous capillary beds and the 
interstitium is governed by the net result of forces summarised in the Starling equation 
(Herring & Paterson, 2018):  
Jv = Kf ([Pp-Pi] – σ [∏p - ∏i])         
where: 
- Jv is the rate (volume filtered per unit time) of fluid moving from the vascular 
lumen to the interstitium (extravasation) 
- ∏p and ∏i are plasma and interstitial osmotic pressures generated by proteins in the 
respective compartments; notably, albumin contributes to more than two thirds of 
the osmotic pressure exerted by proteins (i.e. oncotic; (Herring & Paterson, 2018));  
- σ is the osmotic reflection coefficient and quantifies “imperfect” semipermeability 
of the endothelium to proteins (or, in other words, slight leakiness, so that the 
potential osmotic pressure of proteins is not exerted fully but reduced by factor σ). 
- Kf is the constant of filtration (or microvascular filtration coefficient), i.e. the 
proportionality factor between Jv and the net result of the forces above; it is index 
of microvascular permeability to water and equals the sum of the capillary area (A) 
x wall permeability per unit surface area (Lp) in a given volume of tissue.  
Transcapillary fluid movement in an individual capillary was first measured by E. Landis 
in 1926, hence the “Starling-Landis” name to the principle (Krogh et al., 1932, Michel, 
1980). When interstitial fluid accumulation is measured in vivo, however, the simultaneous 
drainage fluids guaranteed by the other arm of microcirculation (i.e. lymphatic vessels) 
contributes to net volumes, as already discussed in Chapter 1 (section 1.5.1). In particular, 
the rate of lymphatic drainage opposes the rate of microvascular filtration.  
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Changes in at least some of the above parameters were non-invasively investigated using 
an established plethysmography protocol (Gamble et al., 1993), which allowed also the 
evaluation of local arterial blood flow (Φ) and peripheral venous pressure (PV), both 
relevant for the interpretation of microvascular dynamics data. The general rationale and 
conduct of the plethysmography protocol are presented here. Additional practical details, 
functional to the overall HAPPIFY study protocol, are provided in Chapter 7.  
Strain gauge plethysmography (EC6, Hokanson), a versatile measuring device which can 
accurately determine volume changes in limbs and digits, was applied to the upper and 
lower limbs (forearm and calf, respectively) of HAPPIFY participants. Indium-Gallium 
strain gauges are designed so that the active portion of the gauge is the same as the 
circumference of the limb or digit being measured; this allows the plethysmograph to relate 
resistance changes induced by stretch/distention to relative volume changes, expressed as 
% (i.e. ml/100ml of tissue). The plethysmograph was connected to a PowerLab data 
acquisition device (ADInstruments) and measured limb volume changes were recorded and 
later analysed by LabChart software (ADInstruments). 
Patients were positioned almost supine, except for an approximately 10° tilt of the back, 
with their forearm and calf maintained at the height of the right atrium by in-house made 
supports. Inflatable cuffs for venous occlusion were placed on the limbs, proximal to the 
strain gauges as shown in Figure 2-8. 
 
Figure 2-8. Application of a limb gauge and rapid inflation cuff. 
Lower limb set-up, with dedicated supports (left) and detail of the gauge, with a double loop of indium-
gallium filled rubber that hooks over the end of the gauge. The gauge is gently taped in place, so that small 
movements of the cable do not perturb measurements, and the two sides of the loop run in parallel around the 
limb in close contact with the skin (Hokanson material, EC6 plethysmograph manual). 
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After an adequate resting interval and limb volume tracing stabilization, PV was 
determined by gradually increasing the occlusion pressure in the cuff until any limb 
volume change was detected (Christ et al., 1997, Stewart, 2003).  
Limb Φ can be determined by the application of cuff pressures (Pcuff) great enough to 
occlude venous outflow, but not impede arterial inflow, and by measurement of the initial 
rate of swelling during the first few seconds, before vasoconstrictor axon reflex 
mechanisms kick in (Henriksen, 1977)). Occlusion pressures of 40 mmHg or more for ≤ 10 
seconds are adequate (Wilkinson and Webb, 2001, Gamble et al., 1998). HAPPIFY Φ 
measurements were performed in at least quintuplicate after consecutive cycles of sudden 
venous occlusion to 45 mmHg (E20 Rapid Cuff Inflator, Hokanson) for 7 s of every 28 
seconds. The first 1.5 seconds were excluded from calculation of the slope (rate of volume 
change) in LabChart due to limb motion artifacts induced by sudden cuff inflation.   
For the assessment of microvascular filtration parameters and interstitial fluid 
accumulation, we used a protocol with small (8-mmHg) cumulative pressure steps, lasting 
3.5 minutes each and starting at the first multiple exceeding PV up to a maximum of 56 
mmHg or less, if diastolic BP was lower. With such protocol, use of Pcuff values as great as 
arterial diastolic blood pressure was previously validated (Gamble et al., 1993) and shown 
not to invoke the local vasoconstrictor mechanism also known as “veno-arteriolar reflex” 
(Henriksen, 1977). Once applied to the cuffs, pressure is transmitted to the veins and 
capillaries and, when exceeding PV, it induces a volume change due to venous distension 
until equalisation; at lower steps, after a curvilinear initial phase lasting approximately 1 
minute, it reaches a plateau (Figure 2-9, A). However, above a certain equilibrium pressure 
up to which any fluid filtering across the microvascular interface due to Starling-Landis 
transcapillary forces is being removed at an equivalent rate by lymphatic drainage 
(Stewart, 2003, Michel, 1989, Bauer et al., 2004) the limb volume continues to increase 
linearly over time after completion of the venous filling (Figure 2-9, B). This equilibrium 
pressure, above which lymphatics cannot compensate for filtration and the interstitium 
enlarges at a rate proportionate to Pcuff (Stewart, 2003) is called isovolumetric pressure (Pi).  
At high Pcuff steps, the time needed to and the proportion of limb volume change due to 
further venous distention decreases, with an increase in net fluid extravasation 
accumulating in the interstitium. The time courses (slopes) of this fluid accumulation at 
each pressure step was calculated off-line (LabChart) as the averaged first derivative from 
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portions of tracing devoid of motion artifacts (Gamble et al., 1993), excluding the initial 
curvilinear phase of venous filling (fixed for all at: 90s at 8 mmHg, 80s at 16, 70s at 24, 
60s at 32, 50s at 40, 40s at 48 and 30s at 56).  
These slopes were plotted against Pcuff to determine the relationship between interstitial 
fluid accumulation and experimental increases in hydraulic pressure. Least-square fitting 
(Prism, GraphPad) of at least 3 valid pressure points was used to identify these linear 
associations for each limb/participant, in order to determine the slope (microvascular 
filtration coefficient, Kf) and the intercept with the pressure axis (i.e. Pi; Figure 2-9, C). 
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Figure 2-9. Plethysmography protocol for the assessment of microvascular filtration parameters and interstitial fluid accumulation. 
Panel A: Black lines showing increasingly steep changes in limb volume during the cumulative 8-mmHg pressure steps protocol are superimposed to a representative limb 
plethysmographic tracing (red). Panel B: inset from panel A, showing the intravascular (venous filling) and the interstitial component of limb volume changes after an 
increase in the cuff pressure (Pcuff), opposing venous drainage and backward increasing the hydraulic pressure at a capillary level. In our in vivo set up, net interstitial 
accumulation equals the difference between microvascular filtration (governed by Starling-Landis forces between capillary plasma [p] and interstitium [i]) and lymphatic 
drainage (JL). Panel C: interstitial fluid accumulation rates plotted against occluding (hydraulic) pressures. PV = peripheral venous pressure; Pi = isovolumetric pressure, 
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In single capillary studies, the pressure that needs to be exceeded to induce net fluid 
filtration is equivalent to the value σ∏ (Michel, 1980). In-vivo, however, Pi is 
predominantly modulated by lymphatics, which provide fluid drainage equivalent to 
the rate of fluid extravasation up to this critical pressure point.  
One may guess why, with our venous occlusion protocol, lymphatic drainage is not 
similarly impeded by increasingly high Pcuff. In fact, pumping pressures of lymphatic 
vessels composed of multiple contractile lymphangions in series have been reported to 
overcome pressures as high as 60 mmHg (Mohanakumar et al., 2019), 85 mmHg 
(Belgrado et al., 2016) or even above 120 mmHg (Belgrado JP, personal 
communication).  
In addition, lymphatics offer plastic responses to increased demand for drainage (i.e. 
modulation of contractility by preload and afterload; please see section 1.5.2). A 
“mirror image” plethysmography protocol, in which after a standard cumulative Pcuff 
sequence the pressures were decreased in the same order and over the same time 
course, demonstrated that the net accumulation of interstitial fluid at each successive 
pressure reduction was less than that observed during the corresponding pressure 
increase (Bauer et al., 2004). In other words, Pi was shifted to the right without changes 
in Kf, thus suggesting inducible potential in lymphatic drainage (Figure 2-10). 
Unfortunately, such extended protocol was not routinely feasible in our HAPPIFY 
cohort, due to poor tolerance of most participants over extended time, resulting in 
frequent motion artifacts and poor quality of the tracing. 
 
Figure 2-10. Extended protocol with deflation steps 
After interstitial fluid accumulation upon inflation, slopes of %∆ limb volume at each Pcuff steps during 
deflation were lower compared to the corresponding pressure increase (left panel). This corresponds to a 
right shift of the regression line in the right panel, with similar Kf and higher Pi, indicating increased 
lymphatic drainage. Adapted from Bauer A, Clin Sci, 106, 627-33.
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3 METABOLIC IMPACT OF HIGH SODIUM INTAKE  
3.1 Background and study aim 
As discussed in Chapter 1, an independent link between high Na+ intake and a shift in 
metabolism has recently been suggested, whereby a catabolic state induced by Na+ 
would ultimately serve preservation of body water (Rakova et al., 2017, Kitada et al., 
2017). A previously unrecognised, subclinical hypercortisolism associated with high 
Na+ intake was proposed to drive this catabolic state. 
These mechanisms, which may have obvious implications for a cardiovascular risk 
independent of or disproportionate to the classic association between Na+ and blood 
pressure, lacked demonstration in humans out of a dietary- and environmentally-
controlled experimental setting. 
Therefore, the aim of the SYCAMORE (Sodium intake and subclinical hYper-
Cortisolism: Association and MetabOlic signature) study was to investigate the impact 
of high Na+ intake on renal water preserving mechanisms, plasma metabolomics 
signatures and their association with cortisol in a real-life population of patients 
undergoing systematic biochemical screening for secondary causes of hypertension. 
3.2 Study-specific methods 
3.2.1 Screening protocol and patient selection 
The study retrospectively analysed clinical and biochemical data from consecutive 
patients, referred to the tertiary Hypertension Center of the University of Padua 
between 2012 and December 2017, who provided written informed consent for data 
and samples use as part of a local biobank for diagnosis of adrenal disease 
(Prot.1925P/2009), later implemented for the ongoing multi-centre ENSAT-HT study 
(http://www.ensat-ht.eu/; Padua ethics approval protocol 3998/AO/16), in which both 
institutions (University of Padua, University of Glasgow) participate.  
The biochemical screening entailed assessment of plasma electrolytes, aldosterone, 
renin and cortisol and 24h urinary Na+ and K+ excretion; additional biochemical data, 
including renal function, albuminuria, 24h creatinine excretion, 24h urinary 
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catecholamines/metanephrines and urinary free cortisol were measured as indicated by 
guidelines (Mancia et al., 2013, Funder et al., 2016, Nieman et al., 2008, Lenders et al., 
2014) and/or at the discretion of the requesting physician. Patients were not instructed 
to change their usual dietary habits before the screening. They were asked to complete 
a 24h urine collection, reporting start and stop times: collections were used for both 
clinical and study purposes when sampling time was ³ 22 hours and volume ³ 500 ml, 
with no significant loss during collection reported. On the morning of completion, 
blood sampling was performed after one hour in semi-supine position, between 8 and 
10 am. A sample from the 24h urine container and an additional blood sample in EDTA 
were collected depending on availability of the technician in charge on the day; the 
EDTA sample was centrifuged at room temperature for separation of plasma and frozen 
with the urine for long term storage in the local biobank. If requested, an additional 
sample from the 24h urine container was acidified with HCl and used for the 
measurement of urinary norepinephrine, epinephrine, normetanephrine, and 
metanephrine excretion. Attended office blood pressure values were determined at the 
time of the screening from 2 or 3 consecutive brachial blood pressure readings with an 
automated calibrated sphygmomanometer, as per guidelines (Mancia et al., 2013). 
Diabetes status was defined by diagnosis by a clinician or use of a diabetes medication; 
chronic kidney disease was defined by an estimated glomerular filtration rate <60 
mL/min/1.73 m² with CKD-EPI formula (Levey et al., 2009).  
The biochemical screening was systematically performed while off antihypertensive 
treatment or, if patients were already treated, after appropriate washout from 
confounding agents and switch to calcium channels blockers and/or doxazosin, as per 
guidelines (Funder et al., 2016); in patients on a mineralocorticoid receptor antagonist 
(spironolactone, canrenone or potassium canreonate), or on agents affecting the renin-
angiotensin-aldosterone system (diuretics, beta-blockers, angiotensin-converting 
enzyme inhibitors and angiotensin II type 1 receptor antagonists) at least six-weeks or 
two-weeks wash-out period was required, respectively. To minimise the confounding 
effect of medications, individuals who could not tolerate this change or for whom it 
was judged unsafe/impractical in the opinion of the physician in charge were excluded 
from this analysis. Similarly, individuals with reported/biochemical evidence of 
intramuscular or intravenous steroid use or abuse and those with a final diagnosis of 
secondary hypertension after appropriate work-up (biochemistry, anatomical/functional 
imaging, adrenal/renal vein sampling) and follow-up at the time of data-lock (1st 
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January 2019) were excluded. Upon database scrutiny, diagnoses of essential 
hypertension were confirmed with the physicians in charge. 
Patients with a conclusive diagnosis of essential hypertension were grouped according 
to classes of Na+ intake. Intake estimates were based on 24h urine excretion, which has 
limitations when applied to a single subject (Lerchl et al., 2015) but is only minimally 
affected by within-individual day-to-day variability when applied to groups with 
sufficient numbers of participants included (Cogswell et al., 2018). Intakes were 
defined as low ≤2.3g/d (100 mmol/d); medium 2.3-5g/d; high >5g/d (216 mmol/d; 
Figure 3-1), according to commonly used cut-offs (Institute of Medicine, 2005, 
Institute of Medicine Committee on Strategies to Reduce Sodium, 2010). 
Additionally, sub-cohorts of patients from the low and the high Na+ intake groups and 
available EDTA-plasma samples stored in Padua biobank from the time of screening 
were compared for plasma metabolomics signatures (Figure 3-1).   
 
Figure 3-1. SYCAMORE study flowchart 
Flowchart identifying the final study cohort, the distribution into classes of Na+ intake according to 24h-
uNa+ excretion and the subcohort of patients for non-targeted metabolomics comparison (vide infra). 
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3.2.2 Biochemistry 
Serum and urinary electrolytes, plasma renin, aldosterone and cortisol, as well as 
additional routine biochemistry as appropriate and detailed above, were all measured at 
the time of the secondary hypertension screening in an International Standard 
Organisation (ISO) 15189 accredited clinical laboratory (University of Padua).  
Serum and urinary electrolytes were measured using ion‑selective electrodes (ISE 
indirect Na-K-Cl Cobas, Roche Diagnostics GmbH, Mannheim). Renin was measured 
as plasma renin activity (PRA) until April 2015 and direct renin concentration 
thereafter (DRC). PRA was measured using a competitive radioimmunoassay kit (RIA, 
Beckman Coulter kit) based on in vitro generation of Ang I per hour, as reported (Rossi 
et al., 2016). DRC was measured by chemiluminescence (LIAISON® Direct Renin kit, 
DiaSorin, Saluggia, Italy); the normal range of DRC values in a multi-ethnic cohort of 
healthy normotensive subjects was 2.8-39.9 mIU·L-1 (5th-95th percentile) in the supine 
position (DiaSorin, Instruction for use). Renin data for the two cohorts are reported 
separately in the manuscript and/or the supplemental material. Plasma aldosterone 
concentration (PAC) was measured by a chemiluminescence competitive immunoassay 
(LIAISON®, Aldosterone kit, DiaSorin, Saluggia, Italy). Aldosterone-to-renin ratio 
(ARR) criteria for primary aldosteronism and further diagnostic work-up were 
previously reported (Maiolino et al., 2017). 
Plasma cortisol concentration (PCC) was measured by a chemiluminescence 
competitive immunoassay (Immulite 2000 cortisol, Siemens Healthcare Diagnostics 
Products Ltd., Gwynedd, UK). Urinary 24h free cortisol (UFC) was measured by a 
home-made LC-MS/MS, validated according to ISO15189:2012. The analytical 
measurement range was 5-6325 nmol/L, with a lower limit of quantification of 5 
nmol/L. Imprecision was less than 10% for both intra- and inter- assay coefficients of 
variation (Antonelli et al., 2014). Cases with cortisol values below the lower 
quantification limits (5,5 nmol/l for PCC and 5 nmol/l for UFC) or with 24h UFC > 
197 nmol/d, which suggest exogenous steroid use/abuse and diagnostic for Cushing 
syndrome with 100% specificity and sensitivity (Ceccato et al., 2014), respectively, 
were excluded from the analysis.  
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Urinary catecholamines and metanephrines were measured by HPLC with 
electrochemical detection with a CE-IVD kit (Chromsystems®, Chromsystems 
Instruments & Chemicals GmbH, Gräfelfing, Germany).  
Plasma and 24h urinary urea and creatinine were not routinely determined in all 
screened patients; the available biochemical dataset was expanded by analysing in 
Glasgow urine samples stored in the Padua biobank since the time of the screening. In 
particular: a) urea in plasma and urine was measured by a kinetic test with urease and 
glutamate dehydrogenase (UREAL Cobas, Roche Diagnostics GmbH, Mannheim); b) 
creatinine in plasma and urine was measured by an enzymatic method (CREP Cobas, 
Roche Diagnostics GmbH, Mannheim). Results available from the time of the 
screening served for comparison and validation of the entire de novo measured batches, 
according to the Passing & Bablok method (Passing and Bablok, 1983). Briefly, this is 
a linear regression procedure with no special assumptions regarding the distribution of 
the samples, estimating systematic, proportional and random differences and 
controlling for linear model validity (Cusum test).  
Representative results for plasma and urinary creatinine for the validation of the plasma 
and urine batches, respectively, are reported in Figure 3-2; no urinary values for urea 
were available from the time of the screening. Estimated regression equations were 
used for correction of results. 
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Figure 3-2. Validation of the expanded dataset (Passing and Bablok regression) 
Panel A, plasma creatinine; Spearman rank ρ=0.722 (95% CI: 0.677 to 0.761), p<0.0001. Panel B, 
urinary creatinine; Spearman rank ρ=0.962 (95% CI: 0.936 to 0.977), p<0.0001. For both panels: left, 
scatter diagram and regression line; Y axis = measurements at the time of screening; X axis = new 
measurements on stocked samples; red solid line = regression line with confidence interval (red dashed 
lines), black dotted line = identity line. Right, residual plot for goodness of fit, showing a linear 
relationship with no artificial pattern; red dots = outliers (Passing-Bablok regression is a non-parametric 
procedure, not influenced by the presence of one or relative few outliers). 
3.2.3 Renal function and energetics 
Urine samples collected over the 24h immediately before plasma standardised sampling 
were used for estimation of glomerular and tubular function, according to standard 
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GFR was also estimated according to CKD-EPI formula (eGFR),(Levey et al., 2009) for 
comparison with values routinely used in clinical practice.  
Tubular handling of Na+, K+ and water were assessed by their respective fractional 
excretions (FE), i.e. the ratio between the excreted and the filtered amount. In 
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later multiplied by 100 to express them as percentages; p and u prefixes indicate plasma 
and urinary concentrations, respectively. Fractional excretion of water is the volume of 







similarly multiplied by 100 for data presentation as percentages. 
GFR estimation by creatinine clearance (ml/min) and FENa allowed calculation of the 
absolute amount (mmol/d) of filtered [GFR x pNa x 24h x 60 min], reabsorbed [1 – 
(filtered x FENa)] and excreted Na+ [filtered x FENa]. Based on known stoichiometry of 
renal transepithelial Na+ transport to ATP (4.6 Na+/ATP) and assuming 7.3 kcal/mol 
for the free energy equivalent of ATP (Klahr et al., 2011), I calculated the estimated 
energy expenditure for the tubular reabsorptive activity [(reabsorbed Na+/d x 7.3 
kcal/mol ATP)/4.6 Na+/ATP; kcal/d]. 
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3.2.4 Metabolomics 
Samples were extracted with HPLC grade chloroform/methanol/water (1:3:1 v/v; 
Merck, Sigma-Aldrich). A pooled sample was prepared by combining an aliquot from 
each individual sample into a single sample and they were then stored at −80 °C until 
analysis by liquid chromatography – mass spectrometry (LC-MS). Detailed methods 
for the LC-MS analysis of the extracted samples, performed for the author of this thesis 
by others (Glasgow Polyomics), are reported elsewhere (Rossitto et al., 2020); 
importantly, before experimental sample analysis 3 mixes of authentic standards were 
analysed and later used to confirm the identity of metabolites where applicable based 
upon accurate mass and retention time. After the experimental sample analysis, 
fragmentation data was collected in both positive and negative ionisation mode for the 
pooled sample; this data was again used to confirm the identities of metabolites where 
applicable. The raw mass spectrometry data was converted and processed using 
dedicated software and eventually through PiMP (http://polyomics.mvls.gla.ac.uk/; 
Gloaguen et al., 2017), accessed by the author of this thesis. 
3.2.5 Statistics 
Categorical variables are presented as absolute numbers and percentages and compared 
by χ² test. Quantitative variables were tested for normal distribution in the whole cohort 
and in individual groups by graphical plot and Kolmogorov–Smirnov test; they are 
presented as mean ± SD, or median and interquartile range in case of a skewed 
distribution. Parametric and nonparametric statistics were used for normally and non-
normally distributed variables, respectively. In particular, one-way analysis of variance 
(ANOVA) or Kruskal-Wallis test was used to compare anthropometric, clinical, and 
biochemical data across study groups, with Tukey or Dunn’s as post-hoc tests, as 
appropriate; crude correlations were ascertained by Pearson or Spearman tests.  
Multivariable-adjusted comparisons (ANCOVA) and linear regression models included 
significant covariates identified at comparison of Na-intake groups, i.e. age, sex, BMI, 
aldosterone and systolic blood pressure, upon appropriate transformation to attain 
normal distribution. Little’s Missing Completely At Random (MCAR) test was used 
beforehand to test the assumption that variables were missing completely at random, 
including the above covariates and urinary Na+ excretion in the analysis; no imputation 
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methods were adopted and missing data were excluded, with valid numbers for each 
analysis reported in the manuscript.  
Slopes of the regression lines for fractional excretions, assessing tubular Na+ and water 
handling, were compared between high and low Na+ intake groups using the extra-sum-
of-squares F test, with automatic outliers exclusion (conservative Q for ROUT 
approach set at 0.5%) and normality of residuals confirmed with Kolmogorov–Smirnov 
test. 
For metabolomics, the intensity of peaks with a matching database formula (Wishart et 
al., 2018) was log transformed and t-test comparisons were conducted between high 
and low Na+ intake groups, using a moderated linear model. The p-values for the 
targeted and non-targeted analysis were corrected to control the false discovery rate 
(Storey et al., 2019, Benjamini et al., 2006).  
The α level was set at 0.05 and all statistical tests were 2-tailed. SPSS (version 25, 
IBM) and Prism (version 8.02, GraphPad Software) were used for the analysis. 
3.3 Results 
3.3.1 Cohort characteristics 
Out of 1464 patients, 592 in whom washout of confounding medications was not 
possible and 106 who received a final diagnosis of secondary hypertension were 
excluded. The final study cohort therefore included data from 766 patients, almost 
exclusively of Caucasian ethnicity (Figure 3-1).  
Their clinical and biochemical general characteristics by Na+ intake groups are reported 
in Table 3-1. Of note, pre-defined 24 u-Na+ cut-off values for group allocation (low ≤ 
100 mmol/d; medium 100-216 mmol/d, high >216 mmol/d) closely approximated the 
extreme quintiles of the distribution (102 and 219 mmol/day for 20th and 80th 
percentile, respectively). 
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Table 3-1. Clinical and biochemical characteristics of patients by Na+ intake group 







Age (years)  766 47 ± 13 47 ± 13 47 ± 13 44 ± 13 *† 0.015 
Sex (M; n/%) 766 428 / 55.9% 49 / 33.6% 248 / 53.4%* 132 / 84.1%*† <0.001 









SBP (mmHg) 647 150 ± 18 153 ± 20 149 ± 18 149 ± 15  0.165 
DBP (mmHg) 647 93 ± 10 93 ± 10 93 ± 10 94 ± 11 0.801 
Medications (n/%):       
     none  766 138 / 18.0% 27 / 18.5% 89 / 19.2% 22 / 14.0% 0.356 
     dhp CCB  766 444 / 58.0% 82 / 56.2% 261 / 56.3% 102 / 65% 0.158 
     non-dhp CCB  766 160 / 20.9% 30 / 20.5% 103 / 22.2% 27 / 17.2% 0.427 
     α-blockers  766 173 / 22.6% 24 / 16.4% 102 / 22.0%* 47 / 29.9% *† 0.016 
Diabetes (n/%) 630 24 / 3.8% 4 / 3.3% 15 / 4.0% 5 / 3.6% 0.927 
CKD (n/%) 645 24 / 3.7% 4 / 3.3% 18 / 4.7% 2 / 1.4% 0.222 
p-Na+ (mmol/l) 675 141 ± 2 141 ± 2 141 ± 2 141 ± 2 0.650 
p-K+ (mmol/l) 703 4.0 ± 0.4 4.0 ± 0.4 4.1 ± 0.4 4.0 ± 0.4 0.070 






































































Qualitative data presented as n (%) and compared by χ2 test. Quantitative data presented as mean ± SD 
or median (interquartile range) and compared by ANOVA or Kruskall-Wallis test, respectively, as 
appropriate. nvalid = number of patients with available information. BMI = Body Mass Index; SBP and 
DBP = systolic and diastolic blood pressure, respectively; dhp = dihydropyridine; CCB = calcium 
channel blockers; CKD = chronic kidney disease; p- = plasma; 24h-u- = 24 h urine; PAC  = plasma 
aldosterone concentration; PRA plasma renin activity; DRC = direct renin concentration; ARR = 
aldosterone-to-renin ratio. Post-hoc Tukey or Dunn’s tests, as appropriate: * p < 0.05 vs Low-Na+; † p < 
0.05 vs Medium-Na+. 
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Patients on high Na+ intake were generally younger, had a higher BMI and similar BP 
values, although more frequently required doxazosin on top of a first-line calcium 
channel blocker, compared with other Na+ groups. Prevalence of diabetes and/or CKD 
(KDIGO stage ≥ 3) in the cohort was low (<4% for both) and did not differ across 
study groups.  
While plasma Na+ and K+ did not differ, plasma aldosterone was higher with low Na+ 
intake (p=0.040). Renin showed a similar trend, which reached statistical significance 
upon correction for age and sex, significant predictors at multivariate regression 
analysis (not shown).  Overall, the aldosterone-to-renin ratio did not differ across study 
groups. In the 24h urine, higher Na+ excretion was paralleled by a higher K+ excretion 
and total urinary volume (p<0.001 for both). 
3.3.2 Na+ and Water renal handling 
The association between the fractional excretions (FE) of Na+ (available in n=282) and 
water (n=303), as expression of the traditional osmotic natriuresis mechanism 
challenged by the findings form the long-term balance space-flight simulation study 
(Rakova et al., 2017), was first investigated. The Little’s MCAR test excluded a 
systematic bias deriving from selection of the cases with available FE data (sig.=0.185 
for FENa and sig.=0.163 for FEwater).  
In the context of an expected positive correlation (Spearman ρ=0.402, p<0.001), the 
slope of the regression line was steeper at low compared to high salt intake (p=0.005; 
Figure 3-3, panel A). In fact, the FE of Na+ increased with increasing Na+ intake 
(p<0.001 across groups; post-hoc low vs. high: 0.39% [0.30-0.47] vs. 0.81% [0.73-
0.98], p<0.001) while FE of water decreased (p=0.016 across groups; post-hoc low vs. 
high: 1.13% [0.73-1.72] vs. 0.89% [0.69-1.12], p=0.015; Figure 1, panel B). No such 
difference was observed for K+ FE (p=0.892). 
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Figure 3-3. Renal Na and Water handling upon differential Na+ intake. 
Panel A) the positive association between Water and Na+ fractional excretions reflects he osmotic effect 
of Na+, driving a parallel excretion of accompanying water; however, the slope of this association is 
steeper at low (white dots; n=61) compared to high (red dots; n=63) Na+ intake (1.62 [95%CI: 1.14-2.09] 
vs 0.81 [95%CI: 0.56-1.06], respectively; p=0.005, extra-sum-of-squares F test; X indicate 
automatically-excluded outliers [ROUT approach, Q=0.5%] from High and Low Na+ intake groups). 
Panel B) with increasing Na+ intake, Na+ FE increases while water FE decreases (Kruskall-Wallis test: 
p<0.001 and p=0.017, respectively; Dunn’s post-hoc test results on top of bars); no significant difference 
across groups was noted for K+. Data are shown as median and IQR; * p<0.05, ** p<0.01; **** 
p<0.0001. 
3.3.3 Excess Na+ excretion is paralleled by glomerular hyperfiltration 
In keeping with evidence of a higher excretion of creatinine in the 24 h, BSA-corrected 
(and uncorrected) creatinine clearance was greater in high than in medium- and low-
Na+ intake (p<0.001 across groups; n=249; Little’s MCAR test Sig.=0.221; Table 3-2). 
In the High Na+ group 36.7% of the patients met the definition of “glomerular 
hyperfiltration” according to a commonly used cut-off (135 ml/min/1.73m2) (Tonneijck 
et al., 2017, Reboldi et al., 2018), compared to 16.4 and 8.2% in the Medium and Low 
Na+ intake group, respectively (χ2, p<0.001). Similar trends were confirmed with use of 
CKD-EPI formula, although with lower estimates of eGFR and of glomerular 
hyperfiltration prevalence, accordingly (Table 3-2). 
An independent association between 24h urinary Na+ excretion and creatinine 
clearance was confirmed at multivariate regression analysis, after correction for age, 
sex, systolic blood pressure, BMI, and aldosterone (p<0.001). In a regression model 
including also 24h urinary K+, as an independent surrogate marker for global food 
intake based on the above demonstration of a constant tubule handling, both variables 
remained significant predictors (p=0.003 and p<0.001, respectively). 
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Table 3-2. Renal function by Na+ intake group  
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Qualitative data presented as n (%). Quantitative data presented as median (interquartile range). p- = 
plasma; u- = urine. GFR = Glomerular filtration rate. Cl = clearance; BSA = body surface area; HF = 
hyperfiltration. padj = analysis of variance adjusted for age, sex, systolic blood pressure, BMI and 
aldosterone. Post-hoc tests:* p < 0.05 vs Low-Na+; † p < 0.05 vs Medium-Na+ . padj = sig. corrected for 
age, sex, systolic blood pressure, BMI, and aldosterone. 
3.3.4 High Na+ intake increases tubular reabsorption and renal energy 
expenditure 
Although the FE of Na+ was higher with high Na+ intake, the total amount of Na+ 
filtered by the glomerulus and reabsorbed by the tubules per day was far larger 
compared to medium and low Na+ intake (p<0.001, regardless of adjustment for the 
above covariates, including stratification by sex; Figure 3-4). The estimated energy cost 
for this excess reabsorptive tubular activity is shown in Figure 3-4, panel B (Δ high vs. 
low Na+ intake groups=18 [12-24] kcal/day; p<0.001). 
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Figure 3-4. Absolute Na+ excretion and reabsorption and energy cost.  
Panel A) The total excreted Na+ (shaded bars) is a trivial proportion of the reabsorbed amount; the latter 
is much higher upon high Na+ intake and resulted in 18 kcal of estimated excess energy expenditure per 
day (Panel B). Data are shown as median and IQR; ntot=282, nlow Na=61, nhigh Na=63. Kruskall-Wallis and 
Dunn’s post-hoc tests: ** p<0.01; *** p<0.001. 
3.3.5 Sympathetic nervous system activation 
Renal sympathetic nervous system activity (RSNA) plays a key role in renal 
haemodynamics and tubular Na+ reabsorption (Kopp, 2011). 24h urinary excretion of 
catecholamines and their more stable catabolites metanephrines were used in 
SYCAMORE as an indirect measure of RSNA (n = 372 and 628 patients, respectively).  
Urinary norepinephrine and normetanephrine, but not epinephrine or metanephrines 
that are predominantly produced by the adrenals, increased with higher Na+ intake (p < 
0.001 and p = 0.014, respectively). The significant association with 24h-uNa+ excretion 
persisted at multivariate analysis for norepinephrine (p = 0.027), but not for the less 
RSNA-specific normetanephrine (p = 0.393), after correction for age, sex, systolic 
blood pressure, BMI and aldosterone, and for use of calcium channel or α-receptor 
blockers, included in the model as known confounders (Eisenhofer et al., 2003). These 
findings support the evidence of a highly reabsorptive state in Na+ loaded tubules. 
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3.3.6 Re-setting of nitrogen balance and metabolic signatures 
While 24h-urine excretion data suggested a higher daily loss of both creatinine and 
urea with high Na+ intake (p≤0.001 for both), plasma values increased or did not differ, 
respectively (Table 3-2). No difference in the FE of urea was observed across groups 
(p=0.724). Overall, this suggested a global re-setting of the nitrogen balance.  
Analysis of non-targeted metabolomics showed that the majority of metabolites 
significantly increased in the High Na+ (n=35) compared to Low Na+ group (n=32) 
entailed intermediates or end products of protein catabolism (i.e. dipeptides, single 
amino acids or their derivatives) or urea cycle (N-Acetyl-L-glutamate 5-semialdehyde: 
fold change (FC)=1.52, pcorr=0.02; Figure 3-5, panel A). In particular, plasma levels of 
detectable amino acids (including the branched-chain leucine, isoleucine, and valine 
and with the exception of few conditionally-essential or non-essential aminoacids) were 
increased with High Na+ intake (Figure 3-5, panel B).  
 
Figure 3-5. Metabolomics signature. 
Panel A) Volcano plot shows the metabolomics comparison between High and Low (reference) Na+ 
intake. Y axis: uncorrected p values; curved lines: multiple comparisons-corrected significance 
(pcorr<0.05). Red dots: intermediates/end products of the urea cycle or protein catabolism; empty dots: 
other identified metabolites. Panel B) comparative profile of plasma aminoacids LC/MS signals (mean, 
95%CI); for visualisation, the x scale was made homogeneous by Z-score transformation, based on mean 
and SD from the low Na+ group, as a reference. Background: white = essential aminoacids; light grey = 
conditionally essential, dark grey = dispensable aminoacids. Bars: dashed for branched-chain 
aminoacids; red for significance (pcorr < 0.05). Peaks for asparagine, Cysteine, Glutamine and Methionine 
could not be unequivocally identified. 
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Other significantly increased metabolites identified by the non-targeted approach 
included products of triglycerides and fatty acid metabolism (diacylglycerols and acyl-
glycines), acyl-carnitines and some industrial food/tobacco-related compounds (Figure 
3 panel A). A complete list of significantly different metabolites is provided as 
Appendices 7-8. 
While no obvious shift in carbohydrate metabolism was observed at metabolomics 
analysis, higher Na+ intake was associated with higher plasma glucose (n=171; High 
Na+: 4.9 [4.6-5.4] mmol/l, Medium Na+: 4.7 [4.3-5.0] mmol/l, Low Na+: 4.5 [4.2-5.0] 
mmol/l; p=0.004) and insulin (n=47; High Na+: 7.46 [4.75-11.80] µU/ml, Medium Na+: 
5.81 [3.79-9.24] µU/ml, Low Na+: 4.89 [3.72-8.04] µU/ml; p=0.001); however, these 
associations did not persist at multivariable analysis, where BMI stood out as the 
strongest common independent predictor (r=0.38, p=0.002 and r=0.48, p<0.001 
respectively).  
3.3.7 Excess cortisol upon high Na+ intake 
Cortisol excess had been previously suggested to be the primary drive for muscle 
catabolism upon High Na+ intake (Kitada et al., 2017). In SYCAMORE, 24h urinary 
free cortisol (UFC) did increase across groups of Na+ intake (n=137, Little’s MCAR 
test Sig.=0.161; Low Na+: 63 [36-72] nmol, Medium Na+: 60 [47-86] nmol, High Na+: 
86 [75-139] nmol; p<0.001) and the positive association of UFC with 24h-uNa+ 
excretion persisted at multivariable analysis after correction for age, sex, systolic blood 
pressure, BMI, and aldosterone (p=0.017), and also for creatinine clearance (p=0.035). 
However, the latter stood out as the strongest independent predictor (p<0.001). 
Morning plasma-cortisol showed an opposite trend (n=658; Low Na+: 246 [203-309] 
nmol/l, Medium Na+: 238 [194-294] nmol/l, High Na+: 217 [171-294] nmol/l; 
p=0.047); no independent association with 24h-uNa+ was observed (p=0.284 at 
multivariate regression). 
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3.4 Discussion 
3.4.1 Main findings 
The idea that that high Na+ intake could induce mechanisms of water preservation and 
adversely affect metabolic signatures was first proposed by Titze et al, based on the 
diet-controlled experimental settings of a rodent study and a long-term simulated space 
flight of 10 healthy subjects (Kitada et al., 2017, Rakova et al., 2017). I herein 
retrospectively examined this hypothesis in a large real-life population of hypertensive 
patients.  
SYCAMORE results, obtained under normal dietary conditions and urinary salt 
excretions comparable to those reported in other populations (Cogswell et al., 2016), 
showed that the higher excretion of Na+ was indeed coupled with a higher excretion of 
water, in keeping with the classic concept of osmotic natriuresis. However, opposite 
trends relative to their filtered amount were identified: while the fractional excretion 
increased for Na+ upon high Na+ intake, it decreased for water. This was paralleled by a 
plasma metabolomic signature consistent with protein catabolism and with the results 
obtained by Titze et al. in rodent models. Such findings indicate that kidneys can 
effectively dissociate Na+ and water handling upon high Na+ intake. The associated 
catabolic state, likely participating in this water preservation mechanism, could 
independently affect body composition and, ultimately, the risk of cardiovascular 
disease. 
Previous clinical studies identified differential body water handling, assessed as body 
weight change and diuretic response upon salt load and depletion, between salt-
sensitive and salt-resistant (insensitive) subjects (Laffer et al., 2016). In this study, 
albeit lacking a formal assessment of salt sensitivity, I rather focused on the renal-
specific differential regulation of Na+/water excretion and its correlates, independently 
of blood pressure. Such fine regulation appears to rely upon a larger amount of 
processed urine and a higher GFR. A recent meta-analysis identified this association 
also in interventional trials (Nomura et al., 2017), but was limited in its conclusions by 
the heterogeneity in study designs, populations and approaches to estimation of GFR. 
The SYCAMORE study made use of a standardised screening approach and a rigorous 
protocol, including washout of confounding medications and 24h urine collections for 
the assessment of both Na+ and creatinine excretion, as well as non-targeted 
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metabolomics. In its large sample size, a considerable proportion of patients had 
glomerular hyperfiltration upon high Na+ intake: although estimates differ depending 
on the method used for GFR assessment (Levey et al., 2009), this proportion was 
consistently higher compared to both medium and low Na+ groups. Glomerular 
hyperfiltration, traditionally linked to obesity and diabetes (Tonneijck et al., 2017), is a 
recognised marker of early kidney damage, precedes microalbuminuria and/or decline 
in renal function and predicts cardiovascular events (Reboldi et al., 2018). The 
SYCAMORE study suggests that Na+ intake, independent of blood pressure values and 
of a surrogate for total food consumption, is a key determinant in the pathogenesis of 
glomerular hyperfiltration in hypertension, thus confirming previous suggestions from 
a smaller study (Mallamaci et al., 1996).  
While higher filtration carries the ultimate advantage of more precise distal regulation 
of solutes (Guyton and Hall, 2011), not only has it negative long-term prognostic 
implications but also comes at the cost of a much higher tubular activity at more 
proximal segments (Figure 3-4). The increase in Na+ reabsorption in response to the 
increased filtered Na+ load is known as glomerulo-tubular balance and is primarily 
active via Na+/K+ ATPase, with ancillary passive mechanisms facilitated by changes in 
tubular, interstitial and capillary physical forces. The extra Na+/K+ ATPase activity 
implicates a higher oxygen and energy consumption (Hansell et al., 2013). Pruijm et al. 
found that one week of high-Na+ diet reduced renal medullary oxygenation in both 
normotensive and hypertensive subjects by using blood oxygen level-dependent 
(BOLD) MRI (Pruijm et al., 2010), thus pointing to a higher oxygen extraction by 
tubular cells - in keeping with my contentions. 
The estimate of the excess energy cost upon high vs low Na+ intake in SYCAMORE 
was 18 kcal. This is a rough (potentially over- or under-) estimate, based on a 
stoichiometry value that averages different tubular segments with different activity and 
that was validated in ‘standard’ conditions (Klahr et al., 2011). Albeit imprecise, it 
offers an order of magnitude that corresponds approximately to 4.5 g of protein or 2 g 
of fat per day. These values should be considered in a lifespan or population 
perspective. Of note, with the due haemo- and tubule-dynamic corrections required 
between species, the magnitude of this energy cost well justifies the weight loss 
observed in high Na+-fed mice when their total caloric food intake was paired with low 
Na+-fed controls (Kitada et al., 2017). In that animal model, the catabolic state 
primarily oriented toward protein degradation and muscle loss served to generate both 
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endogenous water and osmotically-active urea. Overall, these mechanisms allowed 
water preservation against Na+ excess and a potentially volume-depleting osmotic 
diuresis (Kitada et al., 2017). A similar re-setting in nitrogen balance was observed in 
SYCAMORE: along with evidence of massive excretions of urea and creatinine upon 
high Na+ intake, we identified a catabolic signature at non-targeted metabolomics, 
mostly entailing intermediates or end products of the urea cycle or protein catabolism. 
In particular, plasma levels of all the identifiable essential aminoacids were increased, 
thus ruling out endogenous generation or the sole renal recycling process as sources for 
their excess.  
Finally, SYCAMORE explored whether a subclinical hypercortisolism were the 
intermediate determinant of the above catabolic state, as suggested by Titze et al. based 
on the increase in 24h urinary glucocorticoid excretion upon High Na+ diet (Rakova et 
al., 2017, Kitada et al., 2017). Although the limitations of a single morning plasma 
cortisol should not be ignored, plasma cortisol concentration did not increase – and 
rather decreased – with high Na+ intake. UFC excretion indeed increased and was 
independently associated with Na+ excretion; however, it had GFR as its far strongest 
predictor and its increase was clinically trivial, inconsistent with a condition of 
hypercortisolism, particularly when GFR-adjusted. The findings appear more in 
keeping with human physiological studies assessing the renal clearance of plasma 
cortisol, almost exclusively dependent on GFR (Schedl et al., 1959) or measuring UFC 
excretion in other glomerular hyperfiltration-associated conditions, like obesity (Rask 
et al., 2001) or simple water load (Fenske, 2006). In fact, only subtle increases in 
adrenal cortisol secretion in response to Na+ loading, possibly due to the cross 
stimulation of the hypothalamic-pituitary-adrenal axis by the water-preserving 
vasopressin (Tanoue et al., 2004), were observed by Ehrlich et al. despite marked 
changes in urinary excretion (Ehrlich, 1966). As discussed above, I propose that 
glomerular hyperfiltration and the consequent glomerulo-tubular balance per se would 
suffice to induce extra energy requirements and the development of a catabolic state.  
It is interesting to note that the authors of the first observations recently reported that 
the changes in cardiovascular energy expenditure and catabolism in rats fed high salt 
are dependent on renal sympathetic nerve activity (Morisawa et al., 2020), thus 
providing further ground to my conclusion in humans. 
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3.4.2 Limitations, conclusions and perspectives 
Some relevant study limitations should be acknowledged. 
Firstly, the analysis made use of use of a single 24-hour urine collection, which may 
not accurately estimate an individual’s usual long-term daily sodium intake, because of 
the previously reported day-to-day variability of Na+ excretion (Lerchl et al., 2015). 
However, estimates of intake by 24-hour urine collections in properly sized groups are 
not significantly affected by random variability across individuals (Cogswell et al., 
2018), particularly when they are not instructed to artificially change their dietary 
habits. In fact, even the fiercest proponents of multiple collections to estimate an 
individual’s Na+ intake observed that, despite the variability: “average urinary 
excretion of Na+ provided the expected valid estimate of mean salt intake” (Lerchl et 
al., 2015). 
In other words, the higher the number (n) of collections averaged, the higher the 
precision of the estimate; but accuracy, i.e. closeness to a true value, is unaffected 
(provided n is not trivial). Additionally, use of the same 24 urine samples for the 
assessment of all renal handling parameters in SYCAMORE provided an intra-patient 
control, with all fluctuations going in the same biological direction and, overall, 
levelling off in large numbers. 
Secondly, there were some missing data that potentially reduced the power of some 
analyses, e.g. for UFC. However, absence of evidence of systematic bias and strong 
statistical significance for most of our results makes type II error or any considerable 
impact of missing data on the overall conclusions unlikely. 
Thirdly, the ethnicity of our study participants was almost exclusively Caucasian; this 
obviously warrants validation in other ethnic groups. 
The most important limitation, worth appropriate discussion, is that the retrospective 
cross-sectional nature of the study is unsuitable to prove causality. Notably, however, 
mechanistic evidence of a metabolic shift had already been provided in preclinical 
models (Kitada et al., 2017); SYCAMORE, at variance, offers the advantage of a real-
life perspective, without fixed or restricted caloric and/or water intake. The study 
design indeed prevents discrimination as to how the renal energy cost (predominantly 
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but not exclusively in the form of protein) was paid and, although the association 
between Na+ intake and renal haemodynamics/energetics was independent of K+ 
excretion, a crude surrogate for total food intake, this could well reflect catabolism of 
either endogenous (muscle mass) or exogenous (dietary excess) sources. Based on the 
higher BMI and a larger urea clearance in the high Na+ group, one can speculate that 
both options could be exploited to different degrees in different individuals, according 
to multiple determinants. These would include cultural and socio-economical aspects, 
favouring or limiting food access. Overall, the importance of an altered caloric balance 
is such that the excess exploitation of exogenous protein sources would ultimately 
result in excess fat deposition, regardless of food relative composition (Bray et al., 
2012), and eventually obesity (Ma et al., 2015). Therefore, excess food consumption 
and lean mass loss, alternative or complementary sources for the catabolic state 
observed in our study, are both likely to favour a long-term adverse insulin-resistant 
metabolic phenotype, universally associated to worse cardiovascular outcomes (Figure 
3-6).  
Notably, the sodium-specific water-preserving mechanisms presented in Figure 3-6 and 
their detrimental effects on cardiorenal prognosis are actionable: specific dietary 
strategies and/or novel pharmacological approaches like SGLT-2 inhibition, reducing 
both glomerular hyperfiltration and the energy-demanding tubular Na+ reabsorption, 
could favourably impact the consequences of excess Na+ intake and the global risk 
profile of hypertensive patients.  
In order to address the above hypotheses in the design of future research, due 
consideration to the aforementioned methodological aspects should be paid.  
In particular, the per-protocol controlled caloric intake in the 10 healthy male 
cosmonauts could account for the reduced excretion and increased recycling of urea 
observed in the original study (Rakova et al., 2017) but not in our real-life cohort. 
Similarly, it could account for the discrepancy of those preclinical data with a recent 
secondary analysis of the DASH (Dietary Approaches to Stop Hypertension)-Sodium 
trial (Sacks et al., 2001), which found increased thirst upon high Na+ diet when caloric 
intake was not fixed (Juraschek et al., 2020). Such finding is possibly in keeping with 
reduced need for recycling of endogenous sources and reduced endogenous water 
preservation or generation, accordingly. 
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Figure 3-6. Metabolic impact of high Na+ intake - summary figure. 
High salt intake is traditionally linked to cardiovascular risk via its effect on blood pressure (BP, in 
grey). Preclinical studies recently described a metabolic shift toward catabolism upon high sodium (Na+) 
diet, ultimately favouring body water preservation and possibly impacting cardiovascular risk, 
irrespective of BP. In a large cohort of hypertensive patients, kidneys preserve water and excrete sodium 
excess upon high salt intake; this was associated with glomerular hyperfiltration, higher tubular 
workload and a plasma metabolomic signature suggestive of protein catabolism. Muscle loss and/or 
excess food consumption, paralleled by adverse renal haemodynamics in a putative vicious circle, could 
represent a novel BP-independent link between salt intake and cardiovascular disease. 
For this figure I used the file https://commons.wikimedia.org/wiki/File:Physiology_of_Nephron.png by 
Madhero88, licensed under the Creative Commons Attribution 3.0 Unported license. 
Additional findings and conclusions from that study, apparently opposing Titze’s 
original results, are of great interest and by-extension embrace many the topics 
discussed in this thesis, to a point that I requested access to DASH-Sodium data 
(available to researchers from the National Heart, Lung, and Blood Institute BioLINCC 
repository) for a complementary independent secondary analysis (University of 
Glasgow MVLS College Ethics Committee approval, 6th March 2020). An excursus on 
the findings of both analyses is provided in Chapter 8, as part of the conclusive thesis 
discussion.
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4 TISSUE SODIUM ACCUMULATION: MODELLING  
4.1 Introduction and rationale 
In the last decade the traditionally nephrocentric view of Na+ homeostasis expanded to 
include the concept of tissue Na+ (Titze and Luft, 2017). The negatively-charged 
glycosaminoglycans and a TonEBP/NFAT5-VEGFc-mediated expansion of the 
lymphatic network were suggested to serve as a depot and draining system for Na+ 
accumulation in the interstitium, respectively (Machnik et al., 2009, Wiig et al., 2013, 
Karlsen et al., 2018). The proposed water-independent nature of this phenomenon 
(Titze et al., 2002a, Titze et al., 2003, Titze et al., 2005) marked its novelty (Elijovich 
et al., 2016) and its potential implications in the pathogenesis of hypertension and 
cardiovascular disease at large, as independent studies reported a boosted activation of 
pathogenic immune-inflammatory cells upon culture in supraphysiological 
concentrations of Na + (Kleinewietfeld et al., 2013, Jantsch et al., 2015, Zhang et al., 
2015, Barbaro et al., 2017, Van Beusecum et al., 2019). The translational value of this 
evidence relies on the presence of Na+-hypertonic microenvironments in tissues. 
Importantly, the assessment of interstitial Na+ accumulation has thus far relied on 
whole tissue measurements. In their seminal body composition study (Titze et al., 
2005) and those which followed, Titze et al used a gravimetric approach (wet weight – 
dry weight) to measure the water weight of the skin, the carcasses and the muscles; the 
dried samples were then extensively ashed and dissolved in HNO3 for electrolyte 
measurement with a flame or atomic absorption. Such protocol gives a Na+ final 
readout which reflects the Na+ in the whole tissue “homogenate”. Therefore, all the 
available estimates of Na+ hypertonicity should more precisely refer to the tissue, rather 
than the extracellular compartment, i.e. interstitium. Unfortunately, more sophisticated 
approaches to separate the intracellular from extracellular fractions, for example by 
means of Nuclear Magnetic Resonance, are cumbersome and intrinsically limited by a 
similar relaxation time of Na+ in both compartments (Foy and Burstein, 1990); even 
use of chemical shift reagents is often unfeasible, at least in-vivo, because of their 
toxicity (Wimperis, 2011). Finally, new proposed methods in the field of MR imaging 
(Madelin et al., 2014) are limited by assumptions on aspects like constancy of 
extracellular Na+ concentration, which are the actual topic of investigation of this 
thesis.  
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Whole tissue data still retain informative value, if properly interpreted. In this regard, 
over the course of my PhD studies, it became clear that any estimate of Na+ based on a 
destructive measurement in the whole-tissue is exquisitely sensitive to the relative 
proportions of extracellular to intracellular volumes (where Na+ and K+ are the most 
abundant cations, respectively). By sampling a volume of tissue and averaging the 
signal from the whole volume, regardless of the intracellular or extracellular source, 
23Na MRI voxels can be seen as similarly “destructive” (Figure 4-1).  
 
Figure 4-1. Histochemical impact of tissue architecture. 
Intracellular compartments are rich in K+ (yellow), while extracellular compartments in Na+ (red); in 
both, the sum of K+ and Na+ concentrations ([K+] and [Na+], respectively) is similar. When intracellular 
and extracellular compartments are mixed, i.e. a whole tissue chemical analysis is performed, total [Na+] 
is higher in any tissue with physiologically less intracellular volume or undergoing loss of cellularity or 
oedema accumulation compared to a reference tissue. The concept applies to 23Na MRI (bottom), where 
the average signal from a voxel is presented as a shade of colour, typically grey in the commonly used 
radiological black-white lookup table. ECV = extracellular volume; ICV = intracellular volume. 
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I only later learned that others, almost 80 years ago, conducted chemical studies on rat 
tissues in relation to ageing, with a similar so-called “histochemical deductive” 
approach and interpretation (Lowry and Hastings, 1942, Lowry et al., 1942, Lowry et 
al., 1946). 
Based on the above appreciation, I first developed a simple model for prediction of 
total Na+ and K+ composition of any tissue, as a function of the extracellular volume 
fraction (ECV%). This model later served as reference for a throughout reevaluation of 
the nature and tissue/organ distribution of the previously reported hypertonic Na+ 
excess, in preclinical and clinical settings (Chapters 5 and 6, respectively).  
4.2 Methods: calculations 
For the purpose of the model calculations, the following abbreviations were used:  
[Na+]i, [Na+]e and [Na+]T = intracellular (IC), extracellular (EC) and total Na+ 
concentration (mmo/l), respectively; [K+]i, [K+]e and [K+]T = IC, EC and total Na+ 
concentration (mmo/l), respectively; Vi, Ve, VT = volume of IC, EC and total (EC + IC) 
water solution in tissue; ECV% = extracellular volume fraction (%) = 100 ∙ Ve/VT. 
4.2.1 Expected total concentration of Na+ and K+ in a tissue 
For any tissue, considered as a sum of two different water solutions (EC and IC):  
Na+ total moles = Na+ extracellular moles + Na+ intracellular moles.    
Therefore:  [Na+]T ∙ VT = [Na+]e ∙ Ve + [Na+]i ∙ Vi     
or   [Na+]T  = [Na+]e ∙ Ve/VT + [Na+]i ∙ Vi/VT    
   = [Na+]e ∙ ECV%/100 + [Na+]i ∙ (1-ECV%)/100   
Assuming a convenient reference volume of tissue containing 1 L of total (EC + IC) 
water solution, absolute Na+ tissue content (moles) numerically coincides (≈) with 
[Na+]T.  
Similarly, for potassium: [K+]T = [K+]e ∙ ECV%/100 + [K+]i ∙ (1-ECV%)/100. For a 
similar reference volume of tissue as above, absolute K+ tissue content (moles) ≈ [K+]T 
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The last two equations were used to generate the model for expected total concentration 
of Na+ and K+ for any tissue. 
4.2.2 Expected total concentration of Na+ and K+ in oedematous tissues 
The effect of a “Guytonian”, isotonic, water-paralleled extra amount of Na+ on the 
system was simulated by adding fixed and biologically plausible moieties (1%, 2.5% 
and 5%) of a solution equal in composition to the extracellular; this corresponds to 
oedema (OE% = percentage of oedema added to the tissue). The above OE% 
percentages were defined as v/v in relation to the “baseline” volume of the water 
solution in the tissue, which equals 1 L in the aforementioned convenient reference 
tissue. 
As per first equation above, absolute Na+ content in the oedematous tissue (OT) is: 
Na+ total moles OT  = (Na+ EC moles + Na+ IC moles)T + Na+ moles in oedema 
   = (Na+ total moles)T + Na+ moles in oedema  
For the reference tissue, it numerically corresponds to  
≈ [Na+]e ∙ ECV%/100 + [Na+]i ∙ (1-ECV%)/100 + [Na+]e ∙ OE%/100 
Total Na+ concentration in the oedematous tissue is: 
[Na+]OT= Na+ total moles OT / total Volume      
 = Na+ total moles OT / (Volume T + Volume oedema)    
 = Na+ total moles OT / (1L + 1L ∙ OE%/100)     
 ≈ {[Na+]e ∙ ECV%/100 + [Na+]i ∙ (1-ECV%)/100 + [Na+]e ∙ OE%/100}/(1L + 1L ∙ OE%/100) 
Similarly, for potassium: 
K+ total moles OT  ≈ [K+]e ∙ ECV%/100 + [K+]i ∙ (1-ECV%)/100 + [K+]e ∙ OE%/100  
[K+]OT  ≈ {[K+]e ∙ ECV%/100 + [K+]i ∙ (1-ECV%)/100 + [K+]e ∙ OE%/100} / (1L + 1L ∙ OE%/100) 
[Na+]OT and [K+]OT equations were used to generate the model for expected total 
concentration of Na+ and K+ in an oedematous tissue, after addition of oedema.  
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4.2.3 Changes in total tissue Na+, K+ and water due to oedema 
Percentage changes (Δ%) for absolute Na+ content and concentration were defined as: 
Δ% absolute Na+ content = (Na+ total moles OT - Na+ total moles T) ∙ 100 / Na+ total moles 
TΔ% Na+ concentration = ([Na+]OT – [Na+]T) ∙ 100 / [Na+]T 
Percentage changes (Δ%) for absolute K+ content and concentration were similarly 
calculated. Percentage changes (Δ%) for water content was assumed as equal to OE%, 
which in fact corresponds to the v/v Δ% of the solution, rather than solvent. This 
approximation would at most over-estimate the Δ% for water compared to Δ% for Na+ 
and K+. 
4.2.4 Biological assumptions 
The herein presented Figure 4-2 was generated assuming [Na+]e = 144 mmol/l and 
[K+]e = 4.64 mmol/l (as reported in a relevant experimental setting, for comparability 
(Titze et al., 2005); normal values for humans: 135-145 and 3.5-5.5 mmol/l, 
respectively (Herring & Paterson, 2018). [Na+]i and [K+]i were assumed as 10 and 140 
mmol/l, respectively, as classically reported (Herring & Paterson, 2018). 
4.3 Results 
As one would predict based on Figure 4-1, the model revealed that the higher the 
ECV% (i.e. the proportion of the Na+-rich extracellular solution), the higher the total 
concentration of Na+ in the “final solution” from whole tissue (Figure 4-2, panel A, 
open circles). Vice versa, the parallel decrease in K+ concentration, previously 
described by others as a “loss” (Titze et al., 2005, Bhave and Neilson, 2011) can be 
simply explained by a proportionally less represented intracellular K+-rich 
compartment (panel A, open squares), without any need for ionic exchange or “loss” 
mechanisms. 
When the above model was challenged by simulating the effect of adding a fixed and 
biologically plausible amount of oedema (please see methods above), the curves shifted 
up for Na+ and down for K+, as expected from the equivalent of a global increase in 
ECV% (Figure 4-2, panel A, representative closed symbols for 5% oedema). 
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However, the model also revealed that the proportional increase (Δ%) in tissue Na+ 
concentration secondary to oedema is higher than the increase in water in tissues where 
the ECV% is low, such as skeletal muscle and myocardium which have an ECV% of 
16-20% and 25-30%, respectively (Bhave and Neilson, 2011; panel B; black lines). 
This phenomenon is even more pronounced and holds true across all the spectrum of 
possible ECV% when absolute Na+ content, rather than concentration, is taken into 
account (panel B; red lines).  
Percentage changes (Δ%) for absolute K+ content and concentration, calculated as for 
Na+, were not plotted because scarcely informative: they showed a stable decrease, 
numerically close to –OE%, non-significantly affected by ECV% (data not shown). 
 
Figure 4-2. Histochemical modelling.  
Panel A: Model for expected total concentration of Na+ (open circles) and K+ (open squares) in a tissue, 
before and after addition of 5% of oedema (closed squares and circles, respectively), as a function of the 
extracellular volume fraction (ECV%). Values for representative tissues with different ECV% are shown 
in boxes. Panel B: Percentage change of tissue Na+ concentration (black) or absolute content (red) after 
addition of 1% (dotted line), 2.5% (dashed line) or 5% (continuous line) oedema to the tissue, as a 
function of the extracellular volume fraction (ECV%).   
  
A B
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4.4 Discussion and implications  
The mechanisms accounting for “excess Na+ storage” had already been addressed in a 
conceptual manner by Bhave and Neilson (Bhave and Neilson, 2011). They suggested 
that cell rich tissues like muscle would exchange K+ or other intracellular osmolytes 
with the extracellular phase in situations with ion surplus, whereas relatively acellular 
connective tissues with minimal intracellular osmolytes at their disposal, like skin, may 
use osmotic active storage with interstitial glycosaminoglycans. 
What the herein presented model adds to this “hypothetical framework” (Bhave and 
Neilson, 2011) is the additional mechanism for ‘apparent’ hypertonic excess Na+ 
storage, consistent with the aforementioned histochemical deductive considerations 
(Lowry et al., 1942, Lowry and Hastings, 1942, Lowry et al., 1946). The model 
provides confirmation and quantitation of how much relative differences and/or 
changes in the proportion of IC and EC compartments in a tissue, for example due to an 
isotonic phenomenon like oedema, can affect total tissue Na+ and K+ concentrations per 
se. While many metabolic studies neglected a careful K+ balance investigation, as 
pointed out by Bhave and Neilson, and chronic total-body potassium ‘loss’ can indeed 
occur in conditions such as primary aldosteronism, Figures 4-1 and 4-2 show how a 
decrease in whole-tissue K+ concentration in cell-rich tissues (and a parallel increase in 
[Na+]) can become apparent whenever the relative volumetric proportion of 
intracellular and extracellular compartments is affected, without the need for 
‘exchange’ or any long-term metabolic re-setting. 
This histochemical concept applies to chemical analysis of digested tissues, but also to 
any other technique that does not allow accurate spatial differentiation between 
intracellular and extracellular compartments. As alluded above, this is the case for MRI 
voxels in clinical practice: apart from some approaches currently limited to research 
(Gerhalter et al., 2017, Petracca et al., 2016), 23Na-MRI only offers “total” 23Na signal 
thus far.  
Importantly, the analysis of Na+ can be much (up to 3.5-4 times) more sensitive than 
water itself to detect isotonic accumulation, i.e. oedema, particularly in highly cellular 
tissues. Therefore, it is not acceptable to claim solely for a “more pronounced Na+- 
than water- accumulation” (Nikpey et al., 2017) to support its water-free, hypertonic 
nature. This is key for MRI, in particular: by recording signals from single atoms in 
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voxels, it provides measurements closer to absolute (i.e. red lines in Figure 4-2) rather 
than concentrations changes. In fact, when differences or changes in human skin or 
muscle water content were carefully examined in parallel to those reported for tissue 
Na+, despite sometimes lacking statistical significance due to the sensitivity issue 
described above, they could often be found (Schneider et al., 2017, Karg et al., 2018). 
Recent evidence of higher sensitivity of 23Na-based analysis over standard 1H T2 MRI 
approaches to monitor acute ischaemic extracellular compartment changes within 
skeletal muscle in humans (Gerhalter et al., 2017) further supports the contention of 
differential sensitivity rather than distinct biology.  
Overall, the results of the model prompted a throughout reappraisal of the nature and 
tissue/organ distribution of the previously reported hypertonic Na+ excess in a new 
body composition study (Chapter 5). 
 
  86 
5 TISSUE SODIUM ACCUMULATION: PRECLINICAL DATA 
5.1 Background and study aims 
Over the last decade, our understanding of Na+ homeostasis has been reshaped by the 
suggestion of skin as a depot for “osmotically inactive”-Na+ accumulation.  
Based on evidence from 7-days Na+ balance studies in humans (Heer et al., 2000), 
failing to show the expected total body water storage upon salt-loading, Titze et al first 
conducted similar studies in rodent models of normotension, salt-resistant and salt-
sensitive hypertension and observed differences in total body Na+, Na+-associated 
volume and BP increases across groups (Titze et al., 2002). Additional rodent studies, 
in which different body compartments were separated, led to the suggestion of a skin-
specific and water-independent tissue Na+ accumulation (Titze et al., 2003, Titze et al., 
2005). The depot for this local hypertonic Na+ accumulation was identified in the 
plastic and negatively charged glycosaminoglycans (GAGs) network in the 
extracellular matrix (Titze et al., 2004). A local self-regulatory system, driven by 
activation of the osmo-sensor TonEBP/NFAT5 and VEGFc/VEGFR3-mediated 
signalling to induce expansion/functional stimulation of the lymphatic network and 
provide interstitial Na+ clearance, was later described (Machnik et al., 2009, Wiig et al., 
2013, Karlsen et al., 2018). Disruption of the system led to skin Na+ accumulation and 
salt-sensitive hypertension in the animals.  
In humans, evidence of skin Na+ excess has been found in many cardiovascular 
diseases or associated risk factors (i.e. older age and hypertension, in Kopp et al., 2012 
and Kopp et al., 2013; diabetes, in Karg et al., 2018; chronic kidney disease, in 
Schneider et al., 2017; acute heart failure, in Hammon et al., 2015), as well as in 
sclerodermic (Kopp et al., 2017) or infected skin (Jantsch et al., 2015), by means of 
23Na-MRI. However, in most of these studies skeletal muscle (and more recently also 
myocardium in patients with primary aldosteronism, a prototypic example of salt-
sensitive hypertension; Christa et al., 2019) similarly showed high Na+ signal, thus 
questioning the skin-specificity of the phenomenon. 
Moreover, the results of the theoretical model discussed in chapter 4 casted some 
doubts on the proposed water-independent nature of this tissue Na+ accumulation, 
which has experimentally-demonstrated potential to induce local pathogenic changes  
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(Kleinewietfeld et al., 2013, Jantsch et al., 2015, Zhang et al., 2015, Barbaro et al., 
2017, Van Beusecum et al., 2019) but lacks demonstration in tissues.  
On these premises, I sought to test the existence of a hypertonic, water-independent 
tissue Na+ accumulation in preclinical models of arterial hypertension by probative and 
disprobative approaches (i.e., by verifying and by assuming its occurrence, 
respectively). 
In particular, I conducted a new body composition study in rats similar to those used by 
Titze et al in their original experiments. Wistar-Kyoto (WKY) and stroke-prone 
spontaneously hypertensive (SHRSP) rats, inbred at the University of Glasgow since 
1991, conveniently represented the extremes of a spectrum which goes from 
normotension to salt-sensitive hypertension. In different sets of experiments, animals 
were “challenged” by salt-loading or by physiological ageing, which carries intrinsic 
predisposition to or worsening of salt-sensitivity (Elijovich et al., 2016). Taking into 
account the histochemical implications of the architectural heterogeneity of tissues 
discussed in chapter 4, I adapted Titze’s approach of tissue harvesting and processing 
to obtain robust information on multiple different organs. Additional histochemical 
considerations presented below and the previously developed theoretical model 
(chapter 4) guided the interpretation of chemical data.  
The disprobative approach, independent of the chemical results above, aimed to 
investigate the impact of extracellular Na+ excess on the function of resistance arteries, 
based on the salt-sensitive hypertensive phenotype induced by experimental blockade 
of the TonEBP-VEGFc-lymphangiogenic signaling (Machnik et al., 2009, Wiig et al., 
2013). If the resulting excess tissue Na+ were independent of water (i.e., volume), the 
expectation is that it would impact on the other determinant of hypertension, i.e. 
peripheral resistance. To test this hypothesis, the effects of in-vivo (HS) and ex-vivo 
Na+ excess on arteries were compared. 
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5.2 Methods 
5.2.1 Animal protocols 
All protocols were performed in accordance with the United Kingdom Animals 
Scientific Procedures Act 1986 (Project Licence 70/9021 held by Delyth Graham) and 
ARRIVE Guidelines and approved by the institutional ethics review committee 
(University Animal Welfare and Ethics Review Board, University of Glasgow, UK). 
Rats were housed under controlled environmental temperatures (21±3 °C) and lighting 
(12-hour light-dark cycles). In a first set of experiments testing the effects of salt-
loading, male and female SHRSP and WKY were maintained on standard rat diet (rat 
and mouse no. 1 maintenance diet; Special Diet Services, Grangemouth, United 
Kingdom) and provided tap water ad libitum until 11 weeks of age. At 12 weeks, rats 
(littermates) were randomized to 1% NaCl (High Salt, HS) or normal drinking water 
(Normal Salt, NS) for three weeks (n=8 males/group and n=10 females/group, except 
n=9 female WKY NS). Systolic blood pressure was measured at 11 weeks of age 
(baseline) and then monitored weekly by tail-cuff plethysmography, in an operator-
blind fashion whenever possible.  
In a second set of experiments testing the effects of ageing, male SHRSP and WKY 
were maintained on standard diet and normal tap water ad libitum until 20 and 52 
weeks of age (WKY 20w n=10; WKY 52w = 9; SHRSP 20w = 6; SHRSP 52w = 9). 
5.2.2 Harvesting and chemical analysis of rat tissues 
At the end of the 3 weeks of experimental treatment (main experiment) or at the 
appropriate age (additional experiment) rats were euthanized by exsanguination under 
general terminal isoflurane anaesthesia. Myocardium (left ventricle), lungs, liver and 
samples from shaved abdominal skin and skeletal muscle from the thigh, freed of fascia 
and tendon, were dissected and snap-frozen in liquid nitrogen. The dissection time was 
kept to a minimum to prevent evaporation of moisture. Any excess blood was removed 
by gently blotting the tissues on tissue paper; prior to blotting, the heart was cut into 
transverse sections. An aliquot from each tissue was cut on the surgical table and stored 
into tubes pre-filled with RNA-later (Qiagen Group). All tissues were stored at -80°C 
until use. 
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The protocol for water and Na+/K+ tissue content analysis has been already extensively 
discussed in Chapter 2 and is only briefly recollected here. Tissue aliquots 
representative of full parenchyma were cut from frozen rat tissue samples and weighted 
to determine Wet Weight (WW); sample cutting and handling was performed in a cold 
room to prevent evaporation of tissue water. After complete desiccation of samples at 
65°C to a stable dry weight (DW), water content was estimated as (WW-DW)/DW, or 
as percentage (WW-DW) ∙ 100/WW. 
Dried samples underwent complete digestion in HNO3 and the resulting solutions were 
used for Na+ and K+ quantification by flame photometry (Sherwood Scientific, model 
410C), with calibration standards as reference. All samples from the same type of 
tissue were analysed in a batch. Na+ and K+ concentrations in the analysed solutions 
were used to back-calculate their total content in the digested samples and normalised 
by DW for Na+ and K+ tissue content (mmol/gDW), or by tissue water for Na+ and K+ 
tissue concentration (mmol/l). The flame photometry analysis was conducted blind to 
group allocation of samples. 
Acid-insoluble residues from rat skin and liver samples were used for total fat 
quantification. After careful removal of the solubilised material (used for Na+/K+ 
quantification, as described above), 200 ul of a chloroform/methanol, 2:1 v/v mixture 
were added to the insoluble residues (protocol adapted from Lowry and Hastings, 1942 
and Folch et al., 1957). This protocol was unfeasible with all rat tissue samples other 
than skin or liver because of scarcity or total absence of the insoluble residue. After 
overnight incubation at room temperature under agitation, solubilised extracts were 
transferred to pre-weighed glass tube inserts (Agilent Technologies) and solvents 
evaporated at 55°C to constant weight through repeated SpeedVac cycles. Total fat 
content in tissues was normalised by the original WW (%WW).   
5.2.3 Histology: extracellular matrix 
Sulphated glycosaminoglycans (sGAG) myocardial content was estimated by Alcian 
Blue staining of available paraffin-embedded transverse mid-ventricular 5 µm sections 
from the 20 or 52 weeks old WKY and SHRSP male rats (n = 4-5/group). After 
deparaffinization (Histoclear) and progressive rehydration to distilled water, slides 
were incubated in Alcian Blue solution (1% Alcian Blue 8GX, Sigma, in 3% acetic 
acid; pH2.5) for 20 minutes, washed in running tap water for 5 minutes, rinsed in 
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distilled water and counterstained in Nuclear Fast Red solution (Vector), washed again 
in running tap water for 1 minute and mounted following dehydration. Random, non-
consecutive pictures were taken at 40x from mid-myocardium (n ³ 25/animal) and 
subepicardium (n ³ 12/animal; immediately below the epicardial layer) with an 
Olympus BX41 microscope and dedicated image capture software. sGAG were 
quantified as %AlcianBlue+ stained area after standardised thresholding across pictures, 
with an in-house developed macro (Appendix 9) for ImageJ (Figure 5-1).  
 
Figure 5-1. Histological sulphated glycosaminoglycans myocardial quantification 
Representative subepicardial picture stained with Alcian Blue (sGAG) and Nuclear Fast red, subject to 
automated thresholding and quantification in inverted-colour image. Right: distribution of sGAG density 
(as % Alcian Blue+ stained area) in multiple subepidermal random, non-consecutive pictures from the 
same rat.  
Paraffin-sections adjacent to some of those stained with Alcian Blue were stained with 
Picrosirius Red (1 h) after deparaffinization and rehydration as above for the purposes 
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ß Figure 5-2. Collagen and glycosaminoglycan deposition with ageing. 
Representative pictures of left ventricular remodelling in SHRSP old (52-week-old) compared to WKY 
young (20-week-old) male rats. Although a robust head-to-head comparison was not performed, collagen 
(stained with picrosirius red on the left) and sGAG (stained with Alcian Blue, pH 2.5, with nuclear fast 
red as counterstain, at higher magnification; Alcian Blue+ thresholding shown on the right) appeared to 
distribute similarly. * = right ventricular-left ventricular junctions. 
5.2.4 Gene expression analysis 
Total RNA was extracted from frozen rat tissues using QIAzol lysis reagent and 
RNAesy mini-column kit (Qiagen) according to the manufacturer’s instructions. For 
qRT-PCR, cDNA was generated from total RNA using the High-Capacity cDNA 
Reverse Transcription Kits (Applied Biosystems).  
Taqman fast advanced master mix with specific Taqman gene expression assay probes 
for TonEBP (Rn01762487_m1), GAPDH (Rn01462661 g1), beta-actin (Rn00667869 
m1) were used. The expression levels in tissues were normalised to either GAPDH (for 
myocardium) or beta actin (for other tissues; the housekeeping gene was selected upon 
evidence of Ct consistency across groups). 
5.2.5 Ex-vivo study of arterial function on wire myography  
Rationale and methodology used for the study of arterial function has already been 
extensively discussed in Ch2. Briefly, when rats were euthanized at the end of the 
experimental treatment with HS or NS, mesenteries were dissected and third-branch 
mesenteric arteries carefully isolated. Vascular ring segments were mounted on 
isometric wire myographs (Danish Myo Technology, Denmark) in physiological saline 
solution (PSS).  
After normalization, the viability of arterial segments was assessed by contraction to 
KCl (62.5mmol/L), repeated after 10 minutes of washout. The contractile response to 
the thromboxane agonist U46619 (10-10 - 3x10-6 M). was first tested. Endothelium-
dependent and -independent relaxation was assessed with acetylcholine (Ach; 10-10 - 
3×10-5 M) or sodium nitroprusside (SNP; 10-10 - 10-5 M), respectively, following pre-
constriction with U46619 dose that produced 75% of the maximal contractile response.  
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Results was compared between strains (WKY vs SHRSP) and, by strain, between NS 
and HS-treated animals to assess the impact of in-vivo salt-loading on vascular 
function.  
Additional vascular segments from control (NS) WKY and SHRSP rats were incubated 
for 5 hours in PSS or in NaCl-supplemented-PSS (+15 mM NaCl, hypertonic, HT) after 
the successful viability test with KCl to assess the impact of environmental 
hypertonicity on vascular function. Concentration-response curves for U46619 and 
Ach/SNP after 5 h incubations were the same as described above. 
5.2.6 Statistical analysis 
Statistical analysis was performed using Prism (GraphPad Software) and SPSS (IBM). 
Categorical variables are presented as absolute numbers and percentages and compared 
by χ2 test. The effect of two factors (e.g. strain and salt load) on different quantitative 
response variables in the experimental groups was tested by two-way ANOVA. For 
predefined comparisons (e.g. the effect of HS vs NS), Fisher least-significant-
difference test was used for normally distributed variables (presented as mean±SD or, 
graphically, as mean [95%CI]) and Mann-Whitney test for non-normally distributed 
variables (presented as median [interquartile range] or, graphically, as median 
[95%CI]). For post-hoc comparisons (e.g. between strains or sexes), labelled as such in 
the relative figures/tables, Holm-Sidak test was used. Data tested against a specified 
value were analysed by one-sample t-test.  
Prior to any comparison, outliers were identified by ROUT method (Q = 1%) and 
excluded from analysis but reported on the relative figures.  
Regression curves were derived by least-square method and compared by Extra sum-
of-squares F test; for vascular function analysis, maximal contraction/relaxation and 
(Log)EC50/IC50 were independently compared. Correlations were ascertained by 
Pearson test, upon appropriate transformation of skewed variables to attain normal 
distribution.  
The α level was set at 0.05 and all statistical tests were 2-tailed (*p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001). 
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5.3 Results 
5.3.1 Salt-loading: experimental groups 
Male and female stroke-prone spontaneously hypertensive (SHRSP) and control 
Wistar-Kyoto (WKY) rats (12-week-old) were treated with 1% NaCl in drinking water 
(high salt, HS) or normal tap water (normal salt, NS) for 3 weeks. In males, baseline 
blood pressure (BP) was higher, irrespective of strain differences, and salt-sensitivity of 
BP was confined to SHRSP (Figure 5-3). 
 
Figure 5-3. Blood pressure in the experimental groups. 
Panel A: baseline systolic blood pressure (SBP) values before the experimental interventions, by sex and 
strain; data are presented as box-and-whisker plot (Tukey). Panel B: SBP response to experimental 
intervention by sex and strain. Data are presented as mean ± 95%CI and individual dots; X = 
automatically excluded outlier (ROUT, Q = 1%). For all panels, 2-way ANOVA results at bottom and 
post-hoc tests on top; # p < 0.05 for two-tailed one-sample t-test vs 0 mmHg (no change vs baseline; 
Female WKY_HS: p<0.001, Female SHRSP-HS: p=0.0147; Male SHRSP-HS: p<0.001). 
5.3.2 Histochemical effects of salt-loading 
Skin Na+ content (mmol/g of dry weight) was increased in SHRSP-HS (+20.7%), as 
expected; however, similar increases in tissue Na+ were observed also in liver 
(+10.3%), lungs (+14.8%) and skeletal muscle (+23.6%), but not in myocardium 
(Figure 4-4 and Tables 4-1 to 4-5). Apart from skeletal muscle, they were consistently 
paralleled by increases in tissue water (skin: +14.1%; liver: +4.8%; lungs: +9.0%) with 
similar trends observed for Na+ concentrations (i.e. normalized for water content, 
[Na+], mmol/L). These changes upon HS were not observed in WKY rats (Figure 5-4).  
























































Strain: p=0.459Interaction: p=0.207; Sex p<0.0001; Strain: p<0.0001
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Figure 5-4. Nature and distribution of tissue Na+ excess upon salt loading. 
Bars: empty = WKY, dashed = SHRSP, red = High Salt (HS) treatment; all bars show mean ± 95%CI; 
significant differences at predefined comparisons are shown by brackets, on top. Tissue Na+ content 
increased in all tissues in SHRSP-HS, but in myocardium; with the exception of skeletal muscle, it was 
consistently paralleled by water accrual. Total Na+ + K+ concentration in tissues fell in physiological 
ranges (light blue) and was unaffected by salt loading in either strain, ruling out hypertonic 
accumulations. 
A sub-analysis for males and females showed very similar patterns (Tables 5-1 to 5-5; 
for all tables, data presented as mean ± SD; NS = normal salt, tap water; HS = high salt, 
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Table 5-1. Rat SKIN histochemical analysis. 
 
Variables WKY NS WKY HS Change% 
Fisher LSD 










Water content (%WW) 60.62 ± 4.17 62.44 ± 3.29 3.00 ns 0.101 56.29 ± 2.18 59.43 ± 2.91 5.58 ** 0.007 ns ** **** 
Water content (mg/mgDW) 1.565 ± 0.261 1.683 ± 0.253 7.54 ns 0.108 1.293 ± 0.116 1.476 ± 0.186 14.15 * 0.016 ns ** **** 
Na⁺ content (mmol/gDW) 0.151 ± 0.033 0.156 ± 0.027 3.32 ns 0.588 0.113 ± 0.018 0.137 ± 0.026 20.69 * 0.021 ns * **** 
Na⁺ concentration (mmol/l) 95.6 ± 8.0 92.5 ± 7.2 -3.30 ns 0.262 86.7 ± 7.8 92.0 ± 9.3 6.11 0.08 0.082 * ns * 
K⁺ content (mmol/gDW) 0.083 ± 0.023 0.088 ± 0.012 6.36 ns 0.346 0.075 ± 0.010 0.082 ± 0.016 10.11 ns 0.200 ns ns 0.08 
K⁺ concentration (mmol/l) 52.7 ± 8.7 53.0 ± 7.3 0.55 ns 0.922 57.5 ± 7.5 55.9 ± 9.8 -2.77 ns 0.612 ns ns 0.08 





Water content (%WW) 59.42 ± 4.11 63.28 ± 3.97 6.50 * 0.033 55.88 ± 2.57 58.16 ± 2.27 4.08 ns 0.241 ns * ** 
Water content (mg/mgDW) 1.458 ± 0.240 1.754 ± 0.329 20.30 * 0.029 1.270 ± 0.132 1.394 ± 0.123 9.76 ns 0.344 ns * ** 
Na⁺ content (mmol/gDW) 0.137 ± 0.027 0.161 ± 0.040 17.91 ns 0.096 0.101 ± 0.018 0.120 ± 0.018 18.43 ns 0.276 ns ns ** 
Na⁺ concentration (mmol/l) 91.9 ± 7.3 91.2 ± 6.4 5.26 ns 0.846 79.9 ± 6.5 85.4 ± 9.0 0.38 ns 0.221 ns ns ** 
K⁺ content (mmol/gDW) 0.077 ± 0.018 0.090 ± 0.012 17.56 ns 0.112 0.076 ± 0.012 0.083 ± 0.021 9.36 ns 0.443 ns ns ns 
K⁺ concentration (mmol/l) 51.9 ± 9.5 52.4 ± 9.9 1.08 ns 0.919 60.00 ± 11.7 58.9 ± 12.6 -1.83 ns 0.863 ns ns 0.09 






Water content (%WW) 61.70 ± 4.15 61.77 ± 2.65 0.11 ns 0.956 56.54 ± 2.01 60.31 ± 3.09 6.67 ** 0.009 ns ns ** 
Water content (mg/mgDW) 1.636 ± 0.272 1.626 ± 0.170 -0.61 ns 0.916 1.306 ± 0.111 1.534 ± 0.206 17.46 * 0.014 ns ns ** 
Na⁺ content (mmol/gDW) 0.165 ± 0.033 0.151 ± 0.011 3.32 ns 0.211 0.121 ± 0.013 0.149 ± 0.024 20.69 * 0.013 ** ns ** 
Na⁺ concentration (mmol/l) 99.4 ± 7.1 93.5 ± 8.0 -5.89 ns 0.081 91.0 ± 5.2 96.7 ± 6.5 6.27 0.09 0.088 * ns ns 
K⁺ content (mmol/gDW) 0.090 ± 0.027 0.087 ± 0.013 -2.87 ns 0.743 0.074 ± 0.009 0.082 ± 0.013 10.71 ns 0.313 ns ns 0.07 
K⁺ concentration (mmol/l) 53.5 ± 8.4 53.4 ± 4.9 -0.19 ns 0.973 55.9 ± 3.4 53.8 ± 7.4 -3.78 ns 0.488 ns ns ns 
Na⁺ + K⁺ concentration (mmol/l) 152.9 ± 12.7 147.0 ± 7.8 -3.86 ns 0.176 146.8 ± 7.6 150.4 ± 7.8 2.45 ns 0.409 ns ns ns 
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Table 5-2. Rat LIVER histochemical analysis. 
 
Variables WKY NS WKY HS Change% 
Fisher LSD 










Water content (%WW) 69.44 ± 0.68 69.47 ± 0.93 0.04 ns 0.911 68.43 ± 0.99 69.42 ± 1.09 1.45 ** 0.003 * * * 
Water content (mg/mgDW) 2.274 ± 0.072 2.278 ± 0.100 0.18 ns 0.917 2.170 ± 0.097 2.275 ± 0.119 4.84 ** 0.003 * * * 
Na⁺ content (mmol/gDW) 0.077 ± 0.007 0.075 ± 0.007 -1.89 ns 0.553 0.067 ± 0.006 0.074 ± 0.008 10.28 ** 0.006 * ns ** 
Na⁺ concentration (mmol/l) 33.7 ± 2.7 33.1 ± 2.8 -2.02 ns 0.437 31.0 ± 1.9 32.3 ± 2.6 4.10 ns 0.156 ns ns ** 
K⁺ content (mmol/gDW) 0.275 ± 0.015 0.272 ± 0.017 -0.87 ns 0.679 0.272 ± 0.018 0.275 ± 0.017 0.99 ns 0.631 ns ns ns 
K⁺ concentration (mmol/l) 120.9 ± 7.3 118.8 ± 9.2 -1.74 ns 0.468 125.6 ± 8.1 120.8 ± 9.1 -3.82 ns 0.104 ns 0.10 ns 





Water content (%WW) 68.94 ± 0.57 69.19 ± 1.06 0.36 ns 0.618 67.96 ± 1.00 69.39 ± 1.29 2.10 * 0.013 ns * ns 
Water content (mg/mgDW) 2.221 ± 0.058 2.249 ± 0.115 1.26 ns 0.609 2.123 ± 0.095 2.273 ± 0.144 7.07 * 0.014 ns * ns 
Na⁺ content (mmol/gDW) 0.073 ± 0.006 0.072 ± 0.005 -1.55 ns 0.740 0.064 ± 0.004 0.076 ± 0.010 19.84 ** 0.002 * * ns 
Na⁺ concentration (mmol/l) 32.9 ± 2.8 32.1 ± 2.7 -2.64 ns 0.543 30.2 ± 2.1 32.8 ± 3.4 8.71 ns 0.104 0.10 ns ns 
K⁺ content (mmol/gDW) 0.272 ± 0.007 0.266 ± 0.007 -2.50 ns 0.346 0.267 ± 0.016 0.271 ± 0.015 1.76 ns 0.531 ns ns ns 
K⁺ concentration (mmol/l) 122.7 ± 4.4 118.3 ± 8.6 -3.59 ns 0.251 125.6 ± 6.4 118.6 ± 10.0 -5.57 ns 0.095 ns * ns 






Water content (%WW) 69.88 ± 0.42 69.72 ± 0.77 -0.23 ns 0.683 68.76 ± 0.89 69.44 ± 0.99 0.99 0.07 0.067 ns ns * 
Water content (mg/mgDW) 2.321 ± 0.048 2.303 ± 0.084 -0.78 ns 0.661 2.303 ± 0.088 2.277 ± 0.108 -1.13 0.06 0.061 ns ns * 
Na⁺ content (mmol/gDW) 0.080 ± 0.007 0.078 ± 0.008 -2.15 ns 0.578 0.069 ± 0.005 0.073 ± 0.005 4.45 ns 0.295 ns ns *** 
Na⁺ concentration (mmol/l) 34.5 ± 2.6 33.9 ± 2.7 -1.48 ns 0.632 31.5 ± 1.7 31.9 ± 1.9 1.24 ns 0.704 ns ns ** 
K⁺ content (mmol/gDW) 0.277 ± 0.020 0.278 ± 0.016 0.54 ns 0.860 0.276 ± 0.018 0.278 ± 0.019 0.65 ns 0.830 ns ns ns 
K⁺ concentration (mmol/l) 119.3 ± 9.1 119.2 ± 9.1 -0.08 ns 0.994 125.6 ± 9.4 122.4 ± 8.7 -2.55 ns 0.447 ns ns ns 
Na⁺ + K⁺ concentration (mmol/l) 153.7 ± 7.6 154.5 ± 6.9 0.52 ns 0.828 157.0 ± 10.0 154.2 ± 8.8 -1.78 ns 0.460 ns ns ns 
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Table 5-3. Rat LUNG histochemical analysis. 
 
Variables WKY NS WKY HS Change% 
Fisher LSD 










Water content (%WW) 79.75 ± 0.72 79.95 ± 0.40 0.25 ns 0.599 80.48 ± 1.50 81.66 ± 1.50 1.47 ** 0.004 0.08 * **** 
Water content (mg/mgDW) 3.944 ± 0.128 3.992 ± 0.098 -0.56 ns 0.674 4.156 ± 0.437 4.486 ± 0.462 7.94 ** 0.005 0.08 * **** 
Na⁺ content (mmol/gDW) 0.28 ± 0.024 0.281 ± 0.026 0.29 ns 0.962 0.325 ± 0.055 0.373 ± 0.072 14.84 ** 0.006 * * **** 
Na⁺ concentration (mmol/l) 71.1 ± 4.7 70.5 ± 5.5 -0.83 ns 0.802 78.8 ± 8.1 82.1 ± 8.2 4.19 ns 0.163 ns ns *** 
K⁺ content (mmol/gDW) 0.32 ± 0.023 0.321 ± 0.018 0.34 ns 0.878 0.308 ± 0.022 0.304 ± 0.022 -1.20 ns 0.613 ns ns ** 
K⁺ concentration (mmol/l) 80.8 ± 5.3 80.6 ± 4.7 -0.19 ns 0.953 75.3 ± 8.7 69.0 ± 9.7 -8.34 * 0.017 0.10 ns **** 





Water content (%WW) 79.43 ± 0.49 80.14 ± 0.26 0.89 ns 0.106 80.21 ± 0.90 81.25 ± 1.34 1.30 * 0.032 ns ** ** 
Water content (mg/mgDW) 3.864 ± 0.114 4.038 ± 0.066 4.50 ns 0.152 4.067 ± 0.236 4.356 ± 0.386 7.11 * 0.031 ns * ** 
Na⁺ content (mmol/gDW) 0.282 ± 0.017 0.292 ± 0.026 3.55 ns 0.660 0.323 ± 0.039 0.372 ± 0.073 15.09 * 0.046 ns 0.08 *** 
Na⁺ concentration (mmol/l) 73.0 ± 3.2 72.3 ± 5.7 -0.90 ns 0.832 81.6 ± 5.0 83.7 ± 8.5 2.67 ns 0.509 ns ns *** 
K⁺ content (mmol/gDW) 0.332 ± 0.025 0.321 ± 0.021 -3.37 ns 0.379 0.308 ± 0.026 0.312 ± 0.024 1.43 ns 0.726 ns ns 0.06 
K⁺ concentration (mmol/l) 83.7 ± 2.9 79.6 ± 5.8 -4.86 ns 0.284 77.0 ± 6.0 72.3 ± 10.2 -6.14 ns 0.219 ns ns * 






Water content (%WW) 80.04 ± 0.80 79.80 ± 0.44 -0.30 ns 0.698 80.65 ± 1.79 81.98 ± 1.61 1.65 * 0.028 0.06 ** ** 
Water content (mg/mgDW) 4.016 ± 0.208 3.955 ± 0.107 -1.52 ns 0.737 4.210 ± 0.528 4.590 ± 0.509 9.03 * 0.036 0.08 ns ** 
Na⁺ content (mmol/gDW) 0.279 ± 0.031 0.274 ± 0.023 -1.90 ns 0.832 0.326 ± 0.066 0.374 ± 0.076 14.65 0.06 0.058 ns ns *** 
Na⁺ concentration (mmol/l) 69.4 ± 5.3 69.3 ± 5.2 -0.26 ns 0.957 77.1 ± 9.4 80.1 ± 8.1 4.73 ns 0.270 ns ns *** 
K⁺ content (mmol/gDW) 0.309 ± 0.014 0.321 ± 0.016 3.91 ns 0.153 0.308 ± 0.021 0.298 ± 0.020 -3.28 ns 0.217 0.06 ns * 
K⁺ concentration (mmol/l) 78.5 ± 5.8 81.3 ± 5.8 3.59 ns 0.429 74.2 ± 10.2 66.3 ± 8.9 -10.59 * 0.028 * ns *** 
Na⁺ + K⁺ concentration (mmol/l) 147.9 ± 8.5 150.6 ± 5.1 1.83 ns 0.469 151.3 ± 11.2 147.1 ± 4.7 -2.78 ns 0.237 ns ns ns 
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Table 5-4. Rat SKELETAL MUSCLE histochemical analysis. 
 
Variables WKY NS WKY HS Change% 
Fisher LSD 










Water content (%WW) 75.57 ± 0.62 75.36 ± 0.77 -0.28 ns 0.349 75.19 ± 0.58 75.14 ± 0.57 -0.07 ns 0.801 ns ns 0.06 
Water content (mg/mgDW) 3.096 ± 0.101 3.062 ± 0.124 -1.10 ns 0.355 3.033 ± 0.093 3.024 ± 0.010 -0.30 ns 0.802 ns ns 0.06 
Na⁺ content (mmol/gDW) 0.073 ± 0.017 0.079 ± 0.018 8.22 ns 0.365 0.078 ± 0.014 0.097 ± 0.021 23.59 ** 0.004 ns ** * 
Na⁺ concentration (mmol/l) 24.0 ± 6.1 26.4 ± 6.5 9.92 ns 0.306 27.2 ± 5.5 32.5 ± 7.5 19.51 * 0.017 ns * ** 
K⁺ content (mmol/gDW) 0.411 ± 0.044 0.402 ± 0.037 -2.24 0.09 0.094 0.397 ± 0.029 0.383 ± 0.035 -3.35 ns 0.171 ns * *** 
K⁺ concentration (mmol/l) 134.0 ± 9.7 131.5 ± 9.2 -1.87 ns 0.421 130.8 ± 8.6 128.1 ± 8.4 -2.06 ns 0.366 ns ns ns 





Water content (%WW) 75.59 ± 0.48 75.70 ± 0.57 0.15 ns 0.684 75.31 ± 0.48 75.09 ± 0.48 -0.29 ns 0.402 ns ns * 
Water content (mg/mgDW) 3.099 ± 0.081 3.117 ± 0.010 0.58 ns 0.668 3.052 ± 0.077 3.016 ± 0.078 -1.18 ns 0.410 ns ns * 
Na⁺ content (mmol/gDW) 0.065 ± 0.013 0.069 ± 0.007 6.23 ns 0.409 0.064 ± 0.004 0.075 ± 0.010 17.95 * 0.025 ns * ns 
Na⁺ concentration (mmol/l) 20.9 ± 4.5 22.2 ± 2.1 5.98 ns 0.550 23.3 ± 5.3 25.0 ± 2.9 7.03 ns 0.414 ns ns 0.07 
K⁺ content (mmol/gDW) 0.433 ± 0.014 0.430 ± 0.020 -0.60 ns 0.819 0.405 ± 0.032 0.409 ± 0.017 0.96 ns 0.720 ns ns ** 
K⁺ concentration (mmol/l) 139.8 ± 4.4 138.8 ± 4.2 -0.72 ns 0.728 135.2 ± 7.0 135.5 ± 5.8 0.22 ns 0.918 ns ns 0.06 






Water content (%WW) 75.55 ± 0.80 75.09 ± 0.84 -0.61 ns 0.219 75.10 ± 0.66 75.18 ± 0.67 0.11 ns 0.830 ns ns ns 
Water content (mg/mgDW) 3.094 ± 0.128 3.018 ± 0.131 -2.46 ns 0.213 3.019 ± 0.106 3.031 ± 0.114 0.40 ns 0.826 ns ns ns 
Na⁺ content (mmol/gDW) 0.084 ± 0.016 0.088 ± 0.020 4.81 ns 0.542 0.089 ± 0.007 0.114 ± 0.008 28.85 *** 0.000 * ** ** 
Na⁺ concentration (mmol/l) 27.6 ± 6.1 29.3 ± 7.0 6.50 ns 0.479 30.3 ± 3.4 38.6 ± 3.0 27.17 *** 0.001 0.06 ** ** 
K⁺ content (mmol/gDW) 0.389 ± 0.054 0.382 ± 0.032 -1.83 ns 0.689 0.390 ± 0.026 0.363 ± 0.033 -6.78 ns 0.129 ns ns ns 
K⁺ concentration (mmol/l) 128.3 ± 10.3 126.4 ± 8.4 -1.48 ns 0.624 127.3 ± 8.3 122.2 ± 4.3 -4.01 ns 0.160 ns ns ns 
Na⁺ + K⁺ concentration (mmol/l) 156.3 ± 6.7 155.7 ± 4.5 -0.38 ns 0.817 157.6 ± 5.9 160.7 ± 5.1 1.97 ns 0.218 ns ns 0.09 
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Table 5-5. Rat LEFT VENTRICULAR MYOCARDIUM histochemical analysis. 
 
Variables WKY NS WKY HS Change% 
Fisher LSD 










Water content (%WW) 75.18 ± 0.49 75.55 ± 0.746 0.49 ns 0.057 75.65 ± 0.41 75.62 ± 0.50 -0.04 ns 0.888 ns ns * 
Water content (mg/mgDW) 3.030 ± 0.078 3.093 ± 0.125 2.08 ns 0.051 3.108 ± 0.071 3.104 ± 0.086 -0.13 ns 0.884 ns ns 0.05 
Na⁺ content (mmol/gDW) 0.125 ± 0.015 0.127 ± 0.016 1.59 ns 0.662 0.127 ± 0.013 0.127 ± 0.009 -0.16 ns 0.971 ns ns ns 
Na⁺ concentration (mmol/l) 41.3 ± 4.4 41.1 ± 4.1 -0.56 ns 0.859 40.8 ± 3.7 40.8 ± 2.8 0.05 ns 0.988 ns ns ns 
K⁺ content (mmol/gDW) 0.326 ± 0.016 0.332 ± 0.016 1.99 ns 0.173 0.326 ± 0.012 0.322 ± 0.010 -1.07 ns 0.462 ns ns ns 
K⁺ concentration (mmol/l) 108.5 ± 6.5 107.6 ± 6.2 -0.83 ns 0.626 104.8 ± 4.7 104.0 ± 3.4 -0.76 ns 0.650 ns ns ** 





Water content (%WW) 75.3 ± 0.39 75.61 ± 0.81 0.41 ns 0.287 75.75 ± 0.30 75.73 ± 0.57 -0.03 ns 0.959 ns ns ns 
Water content (mg/mgDW) 3.050 ± 0.062 3.104 ± 0.134 1.77 ns 0.262 3.126 ± 0.053 3.123 ± 0.098 -0.10 ns 0.955 ns ns ns 
Na⁺ content (mmol/gDW) 0.120 ± 0.012 0.129 ± 0.020 7.24 ns 0.199 0.123 ± 0.008 0.123 ± 0.007 0.33 ns 0.960 ns ns ns 
Na⁺ concentration (mmol/l) 39.4 ± 3.6 41.4 ± 5.5 5.26 ns 0.276 39.3 ± 2.2 39.4 ± 2.1 0.38 ns 0.942 ns ns ns 
K⁺ content (mmol/gDW) 0.333 ± 0.011 0.331 ± 0.015 -0.21 ns 0.909 0.328 ± 0.009 0.326 ± 0.007 -0.37 ns 0.839 ns ns ns 
K⁺ concentration (mmol/l) 109.1 ± 5.6 107.2 ± 8.2 -1.74 ns 0.491 104.9 ± 3.8 104.5 ± 1.6 -0.38 ns 0.900 ns ns 0.09 






Water content (%WW) 75.07 ± 0.56 75.50 ± 0.73 0.57 ns 0.114 75.58 ± 0.48 75.54 ± 0.47 -0.05 ns 0.891 ns ns ns 
Water content (mg/mgDW) 3.01 ± 0.09 3.084 ± 0.124 2.39 ns 0.112 3.096 ± 0.082 3.090 ± 0.079 -0.19 ns 0.889 ns ns ns 
Na⁺ content (mmol/gDW) 0.130 ± 0.017 0.126 ± 0.013 -2.92 ns 0.555 0.130 ± 0.015 0.129 ± 0.010 -0.39 ns 0.931 ns ns ns 
Na⁺ concentration (mmol/l) 43.1 ± 4.4 40.8 ± 2.7 -5.20 ns 0.190 41.9 ± 4.3 41.8 ± 2.9 -0.17 ns 0.967 ns ns ns 
K⁺ content (mmol/gDW) 0.320 ± 0.019 0.333 ± 0.017 3.97 ns 0.084 0.325 ± 0.014 0.320 ± 0.010 -1.54 ns 0.479 ns ns ns 
K⁺ concentration (mmol/l) 107.9 ± 7.5 107.9 ± 4.5 0.00 ns 0.997 104.8 ± 5.5 103.6 ± 4.3 -1.15 ns 0.645 ns ns * 
Na⁺ + K⁺ concentration (mmol/l) 151.0 ± 4.3 148.8 ± 4.6 -1.46 ns 0.275 146.6 ± 5.1 145.4 ± 3.6 -0.82 ns 0.544 ns ns * 
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Lower water and Na+ between control (NS) strains in skin and liver reflect differences in 
fat content (Figure 5-5) that limit the volume of distribution (and total content, accordingly) 
of both. 
 
Figure 5-5. Fat content in skin and liver. 
Panel A: skin fat content. Significant strain differences in skin fat content (approximately 3-5% of WW), 
regardless of treatment, are in keeping with the difference in water (and Na+ content) observed between 
NS WKY and SHRSP (Figure 5-3). Panel B: trends are similar for liver, although not significant; due to 
smaller content and relative difference (as for water content, Figure 5-3) in liver compared to skin, this 
likely suggests a type II statistical error, rather than a lack of strain difference. Bars: medians ± 95%CI. 
Most importantly, K+ concentration ([K+]) showed opposite trends to [Na+] (Tables 5-1 
to 5-5). In physiological conditions, the sum of [K+] and [Na+] in both ECV and ICV is 
similar, although with opposite predominance of Na+ and K+, respectively (Figure 4-1); 
a mixture of ECV and ICV in any proportion would still result in a solution of 
approximately 140-160 Na++K+ mmol/L. In all tissues, [Na++K+] consistently fell 
within this range, with no differences between strains or NS/HS allocation (Figure 5-4); 
overall, along with the concomitant increase observed for tissue water, this points to 
tissue oedema.  
In fact, water paralleled Na+ content with identical regression slopes across all groups 
(Figure 5-6), except for skeletal muscle where the water-independent “K+-to-Na+” (i.e. 
ICV-to-ECV) predominance  shift is likely due to some degree of HS-induced 
sarcopenia, as suggested by studies extensively discussed in chapter 1 and 3 (Kitada et 
al., 2017).  
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Figure 5-6. Regression lines for tissue Na+ and water content in different tissues.  
No difference in slope or intercept was detected across experimental groups in either organ, so that one 
curve adequately fitted all points. For skeletal muscle, no regression line was drawn, as no significant 
correlation was found within either group beforehand: the dissociation between Na excess and water in 
skeletal muscle likely reflects an oedema-independent shift in ECV/ICV ratio due to salt-induced 
catabolic muscle loss (Kitada et al., 2017). 
Notably, the results obtained for tissue Na+ across organs under experimental 
conditions fit extremely well with the theoretical prediction model discussed in the 
previous section. 
 
Figure 5-7. Predicted and experimental results. 
Panel A: X = experimental results from control NS WKY rats in different tissues (means from Tables 5-1 
to 5-5), superimposed on the general prediction model based on ECV% (Chapter 4); red circles = 
predicted tissue [Na+], yellow squares = predicted tissue [K+]. [Na+] and [K+] results effectively 
differentiate organs physiologically sitting at different points of the ECV% axis. Panel B: percentage 
change of Na+ content (red bars) and water content (white bars) in tissues showing oedema accumulation 
upon HS in SHRSP rats (from Tables 5-1 to 5-5); panel C: same percentage change, normalised for 
water change, showing a proportionally larger increase in Na+ compared to water content when tissue 
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The reported water-independent tissue Na+ accumulation, although not confirmed in this 
study as such, was previously suggested to induce VEGF-c mediated signaling via 
TonEBP/NFAT5 (Machnik et al., 2009, Wiig et al., 2013). TonEBP/NFAT5 is traditionally 
associated with the response to osmotic stress (Miyakawa et al., 1999, Choi et al., 2020), but 
recently reported to respond also to biomechanical stimuli in vascular smooth muscle cells 
(Scherer et al., 2014). Despite no evidence of hypertonicity, an increase in TonEBP/NFAT5 
expression in skin, lungs and (borderline significant) liver was indeed observed in SHRSP-
HS (Figure 5-8).  
 
Figure 5-8. Tissue-specific TonEBP expression upon salt loading. 
Increased TonEBP gene expression followed Na+ and water accumulation despite no hypertonicity. Data 
are presented as Delta Ct, median ± 95%CI for all rats; n = 16-18 animals/group 
5.3.3 Ageing model 
The hypertensive and target-organ damage phenotype in SHRSP is not only salt- but 
also age-sensitive. This is the case also for many human cardiovascular diseases and for 
salt-sensitivity itself, which becomes more prevalent or exacerbates with ageing. 
Therefore, in a second set of experiments with normal-salt-fed rats, ageing rather than 
salt-loading was used as a “second-hit” and left ventricular myocardium was analysed 
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Figure 5-9. Rat phenotypes in the ageing experiment. 
Differences in systolic blood pressure, body weight and myocardial remodelling (Heart weight/body 
weight) in the 4 groups of animals. These data, collected by Dr Adam Harvey at the time of rat culling 
and before the start of my PhD, were available in n ≥ 3/group from the experimental animals used for the 
herein presented myocardium chemical analysis. For all panels, 2-way ANOVA results are reported at 
bottom.  
5.3.3.1 Chemical Analysis and TonEBP 
  
Figure 5-10. Myocardial Na+ excess and TonEBP expression in hypertensive ageing. 
Myocardial Na+ content (and concentration) increased in 52 weeks vs 20 weeks old SHRSP, paralleled 
by water and mirrored by K+, so that tissue [Na+ + K+] was constant across groups (not shown); this is 
suggestive of myocardial oedema. Increased TonEBP gene expression followed oedema accumulation. 
Bars show mean ± 95%CI, or median ± 95%CI for TonEBP gene expression; n=6-10/group.  
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At variance with young salt-loaded SHRSP rats, the myocardium of 52-week-old 
animals showed an increase in water, as well and Na+ content and [Na+], with 
commensurate mirror-like decrease in [K+] which resulted in a similar [Na++K+] across 
groups. Again, TonEBP/NFAT5 myocardial gene expression was increased despite lack of 
hypertonicity. 
5.3.3.2 Sulphated Glycosaminoglycans (sGAG) Quantification 
In keeping with the observed remodelling, myocardial sGAG increased with aging in 
both strains, but was higher in SHRSP animals compared to WKY. A qualitative 
comparison of Alcian Blue-stained and Picrosirius-stained sections suggested 
comparable distribution of sGAG and collagen deposition. 
 
Figure 5-11. Myocardial glycosaminoglycans in hypertensive ageing. 
Sulphated glycosaminoglycans (sGAG) content in mid-myocardium and sub-epicardium, estimated by 
Alcian Blue staining and normalised by WKY young rats; right inserts: representative Alcian Blue+ areas 
in mid-myocardium and sub-epicardium  corresponding to dotted lines (i.e. 1x, 8x, 64x and 256x young 
WKY rats, as reference; black arrows: Alcian Blue staining; dotted lines inside inserts: epicardial 
border). Left ventricular sGAGs increased with ageing but was higher in SHRSP compared to WKY; 
whether this extracellular matrix remodelling facilitates myocardial oedema, is a consequence of it or 
both, in a putative vicious circle, remains unknown. Bars show median ± 95%CI. 

































































































































































Chapter 5 – Tissue Na+ accumulation: preclinical data 
 105 
5.3.4 Impact of salt on arterial function 
Contrarily to the expectations regarding the impact of Na+ excess on peripheral 
resistance, HS treatment in-vivo did not result in hypercontractile responses. The 
magnitude of response to KCl was rather reduced upon repeated stimuli (Figure 5-12).   
 
Figure 5-12. Impact of in vivo Na+ excess on agonist-independent contractile function.  
Contractile response to KCl, by strain and experimental treatment; WKY-NS: n = 15 and HS n = 18, 
SHRSP-NS: n = 14 and HS n= 17; two-way ANOVA results at bottom and predefined or post hoc (inter-
strain) comparisons on top. Left: the response to the first KCl stimulation was higher in SHRSP than 
WKY but was unaffected by in vivo HS treatment. Right: the response to a second stimulation, 
expressed as percentage of first peak response, was reduced in SHRSP, particularly upon HS. 
Contractile responses to U46619 (a thromboxane-receptor agonist), showing higher 
peaks and over-sensitivity to the agonist (i.e. lower effective concentration to produce 
50% of the maximal response; EC50) in SHRSP compared to WKY, were unaffected by 
treatment of rats with salt. At variance, salt treatment reduced the vasorelaxant effect of 
nitric oxide (NO), directly released by the NO-donor nitroprusside (SNP), in SHRSP 
(Figure 5-13, top and Table 5-6). No significant differences were observed for 
endothelium-dependent responses (not shown). 
To test whether an HT environment could induce vascular changes consistent with 
those observed in HS-treated rats and/or likely to sustain high blood pressure, arterioles 
from NS rats were also preincubated in an isotonic or hypertonic (HT; +15 mmol/L 
NaCl) solution. Akin to HS in vivo, HT ex vivo incubation did not affect contractile 





















































post hoc, p < 0.005
p = 0.08
Strain: ***; HS: ns: Interaction: ns Strain: **; HS: ns: Interaction: 0.07
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responses; however, it induced an opposite shift toward an earlier NO-induced loss of 
pre-constriction tone in both WKY and SHRSP (Figure 5-13, bottom and Table 5-6). 
Similar effects were observed for endothelium-dependent (Ach-induced) relaxation, 
although with overall higher statistical p values and heterogeneity in significance (but 
not trends) between sexes (Table 5-6).  
 
Figure 5-13. Impact of in-vivo and ex-vivo Na+ excess on arterial function.  
Contraction and relaxation dose–response curves to U46619 (thromboxane A2 receptor agonist; n =11–
17/group) and SNP (endothelium-independent nitric oxide donor; n =9–16/group), respectively; mean ± 
SEM. Differences in maximal responses and half maximal effective/inhibitory concentrations (EC50 and 
IC50, respectively) across groups are shown by brackets; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 
0.0001. Top, effect of 1% NaCl in drinking water (HS): HS did not worsen the hypercontractile 
phenotype observed in SHRSP rats but reduced their sensitivity to NO-mediated relaxation; no 
significant effect was observed in WKY rats. Bottom, effect of ex vivo 5 h incubation in a hypertonic 
(+15 mmol/l NaCl, HT) vs. physiological solution on vessels from NS rats: ex vivo hypertonic Na+ 
excess did not affect contractile responses, but induced oversensitivity to NO in both strains, opposite to 
in vivo HS; none of these ex vivo effects would justify an increase in peripheral vascular resistance. 
Please see Table 5-6 for all comparisons. 
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In-vivo High Na+ (HS diet)
Ex-vivo Hypertonic Na+ (+15 mmol L-1; HT)
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Table 5-6. Impact of in-vivo and ex-vivo Na+ excess on arterial function. 
   in-vivo protocol 
       1% NaCl (HS) 








(75.31 to 83.35) 
16 
92.68****  
(88.63 to 96.91) 
16 
72.81  
(68.74 to 77.19) 
17 
93.15  
(87.81 to 99.02) 
  LogEC50 -7.238  (-7.312 to -7.163) 
-7.361*  
(-7.428 to -7.292) 
-7.317  
(-7.405 to -7.226) 
-7.274  
(-7.367 to -7.178) 
Ach max rel 
16 
1.964 
(-0.585 to 4.463) 
14 
4.842 
(1.077 to 8.471) 
17 
4.101 
(0.8967 to 7.222) 
17 
5.213 
(2.342 to 8.013) 
 LogIC50 -7.712 (-7.769 to -7.654) 
-7.892** 
(-7.991 to -7.791) 
-7.718 
(-7.795 to -7.642) 
-7.855 
(-7.926 to -7.783) 
SNP max rel 
13 
7.57  
(2.68 to 12.11) 
12 
5.12  
(1.19 to 8.85) 
16 
13.24  
(7.73 to 18.25) 
16 
10.21#  
(6.99 to 13.29) 
  LogIC50 -7.868  (-8.003 to -7.725) 
-8.052*  
(-8.164 to -7.937) 
-7.776  
(-7.926 to -7.614) 
-7.656####  





U4 max rel 
8 
72.23  
(67.18 to 77.66) 
6 
84.93***  
(80.53 to 89.55) 
8 
67.09  
(62.53 to 71.92) 
7 
89.95  
(80.66 to 101.30) 
  LogEC50 -7.295  (-7.399 to -7.186) 
-7.641****  
(-7.722 to -7.562) 
-7.258  
(-7.359 to -7.159) 
-7.283###  
(-7.463 to -7.082) 






(-0.955 to 12.2) 
8 
6.207  
(0.738 to 11.36) 
7 
3.469  
(-0.518 to 7.347) 
  LogIC50 -7.871  (-7.917 to -7.826) 
-7.837  
(-8.02 to -7.648) 
-7.72*  
(-7.855 to -7.579) 
-7.956 
(-8.05 to -7.858) 
SNP max rel 
8 
6.88  
(-0.47 to 13.37) 
5 
5.86  
(-1.39 to 12.40) 
7 
18.24  
(7.20 to 26.91) 
6 
8.52  
(4.23 to 12.60) 
  LogIC50 -7.861  (-8.057 to -7.646) 
-7.894  
(-8.09 to -7.686) 
-7.709  
(-7.989 to -7.366) 
-7.550##  






U4 max rel 
8 
86.21  
(80.65 to 92.37) 
10 
96.38**  
(92.45 to 100.40) 
8 
77.16*  
(71.08 to 84.05) 
10 
95.20  
(88.88 to 102.20) 
  LogEC50 -7.190  (-7.287 to -7.090) 
-7.212  
(-7.270 to -7.156) 
-7.370*  
(-7.501 to -7.228) 
-7.269  
(-7.371 to -7.163) 
Ach max rel 
8 
2.136  






(-1.682 to 5.843) 
10 
6.729  
(2.767 to 10.54) 
  LogIC50 -7.524  (-7.614 to -7.432) 
-7.932***  
(-8.043 to -7.816) 
-7.71**  
(-7.796 to -7.625) 
-7.788  
(-7.885 to -7.69) 
SNP max rel 
5 
8.53  
(2.07 to 14.47) 
7 
4.47  
(3.23 to 8.68) 
9 
9.29  
(3.08 to 14.95) 
10 
11.36#  
(6.86 to 15.56) 
  LogIC50 -7.875  (-8.051 to -7.690) 
-8.162**  
(-8.290 to -8.031) 
-7.821  
(-7.982 to -7.647) 
-7.729####  
(-7.853 to -7.602) 
  
Chapter 5 – Tissue Na+ accumulation: preclinical data 
 108 
   ex-vivo incubation (5h) 
   Physiological Salt Solution (PSS) PSS + 15 NaCl mM 







(79.08 to 86.97) 
11  
75.06 
(68.37 to 83.12) 
13  
77.86 
(74.44 to 81.55) 
12  
80.64 
(75.33 to 86.58) 
 LogEC50 -7.727 (-7.815 to -7.636) 
-7.615 
(-7.792 to -7.418) 
-7.701 
(-7.786 to -7.611) 
-7.568 
(-7.691 to -7.439) 
Ach max rel 
13  
1.376 
(-2.653 to 5.238) 
12  
14.93**** 
(9.604 to 19.94) 
13  
1.281 
(-2.897 to 5.291) 
12  
7.63## 
(2.92 to 12.10) 
 LogIC50 -7.776 (-7.877 to -7.674) 
-7.529** 
(-7.664 to -7.390) 
-7.843 
(-7.946 to -7.738) 
-7.621 
(-7.689 to -7.554) 
SNP max rel 
11  
5.95 
(0.67 to 10.84) 
9  
6.33 
(0.92 to 11.19) 
11  
4.55 
(-0.60 to 9.39) 
9  
7.63 
(2.92 to 12.10) 
 LogIC50 -8.004 (-8.152 to -7.848) 
-7.334**** 
(-7.467 to -7.194) 
-8.299** 
(-8.449 to -8.142) 
-7.891#### 








(79.33 to 88.69) 
6  
76.69 
(69.43 to 85.10) 
8  
78.04 
(74.23 to 82.15) 
6  
79.26 
(73.24 to 86.04) 
 LogEC50 -7.741 (-7.845 to -7.633) 
-7.740 
(-7.925 to -7.538) 
-7.859 
(-7.959 to -7.755) 
-7.642 
(-7.787 to -7.489) 
Ach max rel 
8  
1.336 
(-2.3 to 4.872) 
6  
10.74* 
(3.047 to 17.77) 
8  
1.933 
(-2.738 to 6.432) 
6  
2.322# 
(-1.264 to 5.851) 
 LogIC50 -7.701 (-7.785 to -7.617) 
-7.665 
(-7.843 to -7.472) 
-7.883* 
(-7.997 to -7.767) 
-7.627 
(-7.699 to -7.558) 
SNP max rel 
6  
7.06 
(-1.50 to 14.37) 
5  
5.45 
(-2.75 to 12.59) 
6  
6.96 
(-1.12 to 14.12) 
5  
10.86 
(4.43 to 16.77) 
 LogIC50 -7.883 (-8.119 to -7.623) 
-7.387** 
(-7.580 to -7.178) 
-8.520*** 
(-8.758 to -8.253) 
-7.622 









(74.41 to 89.28) 
5  
73.55 
(61.71 to 94.17) 
5  
76.76 
(72.20 to 81.86) 
6  
82.04 
(73.18 to 93.15) 
 LogEC50 -7.705 (-7.868 to -7.532) 
-7.437 
(-7.765 to -6.959) 
-7.479 
(-7.582 to -7.365) 
-7.497 
(-7.698 to -7.268) 
Ach max rel 
5  
0.4749 
(-8.929 to 8.602) 
6  
19.59*** 
(12.73 to 25.98) 
5  
-0.1907 
(-8.968 to 7.688) 
6  
11.24# 
(6.017 to 16.21) 
 LogIC50 -7.957 (-8.224 to -7.672) 
-7.386*** 
(-7.56 to -7.208) 
-7.767 
(-7.974 to -7.545) 
-7.609# 
(-7.728 to -7.488) 
SNP max rel 
5  
3.39 
(-2.83 to 9.23) 
4  
7.18 
(0.22 to 13.10) 
5  
2.758 
(-2.920 to 8.174) 
4  
3.44 
(-0.19 to 6.98) 
 LogIC50 -8.124 (-8.282 to -7.957) 
-7.260**** 
(-7.425 to -7.080) 
-8.101 
(-8.248 to -7.947) 
-8.191#### 
(-8.283 to -8.099) 
U4 = U46619, thromboxane A2 receptor agonist; Ach = acetylcholine; SNP = sodium nitroprusside, 
nitric oxide NO) donor. Max con and rel = maximal contraction (% of response to 62.5 mM KCl) and 
relaxation (% of pre-constriction with U46619 concentration producing 75±5% of maximal contractile 
response), respectively. LogEC50/IC50 = Log of half maximal effective/inhibitory concentrations, 
respectively. Data are presented as non-linear least-square regression estimates (95%CI). Numbers of 
viable vessels (n) available for analysis are listed in the upper left corner of each group/experimental 
condition.  
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5.4 Discussion 
In keeping with the theoretical model (Chapter 4), experimental results from this new 
body composition study suggest that tissue Na+ excess upon high Na+ intake is a 
systemic, rather than skin-specific, phenomenon. This phenomenon reflects 
architectural changes, i.e. a shift in the extracellular-to-intracellular compartments, due 
to a reduction of the intracellular or accumulation of water-paralleled, isotonic Na+ in 
the extracellular space. The same changes were shown for hypertensive ageing, which 
could pragmatically be regarded as a condition of “cumulatively-high” Na+ intake. No 
evidence of tissue Na+ hypertonicity was found. Based on the vascular function 
experiments and consistently with the above, I also show that a hypertonic Na+ 
accumulation is unlikely to justify the observed development of experimental 
hypertension.  
If Na+ were to water-independently accumulate in tissues and to exert a biologically 
relevant modulation of local immune cells by boosting their inflammatory potential 
(Kleinewietfeld et al., 2013, Jantsch et al., 2015, Zhang et al., 2015, Barbaro et al., 
2017, Van Beusecum et al., 2019), one would expect that also other surrounding cells 
or structures would similarly be affected. Moreover, an increase in arterial resistance 
would be responsible for the salt-sensitive hypertension induced by blockade of the 
interstitial-Na+/TonEBP/VEGFc cascade (Machnik et al., 2009, Wiig et al., 2013), if 
the phenomenon were volume-independent (Laragh, 2001). Overall, these 
considerations indicate blood vessels as putative targets of a Na+-hypertonic 
interstitium mediated biological effects. Since supraphysiologic Na+ concentrations in 
the culture medium had already been shown to induce early changes in protein turnover 
and cellular hypertrophy of vascular smooth muscle cells (Gu et al., 1998), I focused on 
the function of intact resistance arteries, with the expectation of changes consistent 
with increased arterial resistance. As it is unquestionably hard to conceptually reconcile 
a dual osmotically-active and -inactive nature of interstitial Na+ excess, driving 
TonEBP-mediated signalling while simultaneously eluding commensurate water 
accrual, I also hypothesised that a hypertonic interstitium would facilitate fluid 
extravasation at an even more peripheral, capillary level: this specific hypothesis was 
investigated in vivo in humans, as discussed in Chapter 7. 
The changes that I observed in rat resistance arteries upon exposure to a Na+-
hypertonic bath solution were neither in keeping with those observed after in-vivo salt 
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loading, nor reminiscent of classic hypertensive vascular phenotypes. Contractile 
responses were unaffected and sensitivity to NO-mediated loss of tone was increased 
by hypertonicity: both speak against an increase in arterial resistance and are overall 
more reminiscent of conditions where neuromuscular tissues are exposed to Na+ 
concentrations which are “toxic” to the cell membrane electrochemical equilibrium and 
result in loss-of-function (e.g. lethargy or muscle weakness), like diabetes insipidus. In-
vivo salt treatment similarly had no effect on the contractile response to U46619, but 
reduced the contraction to repeated stimuli and the relaxation to NO. Therefore, a 
volume-dependent nature of the induced hypertension, possibly including parallel Na+-
and-water accumulation in the arterial wall (as for other tissues, vide infra), appears 
more plausible. Swelling of the vascular wall could well determine increased peripheral 
resistance and vascular stiffness (to both contraction and relaxation): this idea dates 
back to the 1950s (Tobian and Binion, 1952), was supported by subsequent evidence 
(Tobian et al., 1961, Sullivan et al., 1987, Laffer et al., 2016) extending also to heart 
failure (Zelis et al., 1970), but lacks firm chemical demonstration. 
This sort of chemical evidence is the one I aimed for in the rat body composition study, 
which unfortunately could not include vessels due to the confounding chemical impact 
of washing blood out of the lumen to conduct tissue analysis.  
Salt-loaded SHRSP rats showed an increase in skin, lung and liver Na+, which was 
paralleled by an increase also in tissue water. As previously discussed (section 4.4), 
their different proportional magnitude does not necessarily indicate any hypertonic or 
‘uneven’ accumulation and may simply reflect different sensitivities of Na+ and water 
changes to oedema detection (Rossitto et al., 2018). In fact, the regression slope for 
each tissue Na+ and water contents was the same across the experimental groups. 
Similarly, the total cationic sum of [Na++K+] never exceeded physiological ‘isotonic’ 
values and was identical across groups. Overall, the unaffected [Na++K+] and the 
mirror trends for [Na+] and [K+] point to a shift in ECV/ICV ratio rather than any 
hypertonic phenomenon. Along with the concomitant increase in tissue water, this 
suggests the development of systemic tissue oedema in the salt-sensitive SHRSP rats 
upon salt-loading. Laffer et al previously concluded that also in salt-sensitive 
normotensive volunteers a salt-loading protocol resulted in body weight gain 
“commensurate to iso-osmolar water retention”, at variance with their salt-resistant 
controls (Laffer et al., 2016).  
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Notably, skeletal muscle and myocardium showed results at odds with the other tissues. 
I contend that the increase of Na+ without a parallel increase of water in skeletal muscle 
upon salt-loading can be explained by an ECV/ICV shift secondary to some degree of 
salt-induced sarcopenia (Kitada et al., 2017), even if no muscular oedema is in place. 
Of note, even NS treated SHRSPs, with their genetically-determined secondary 
aldosteronism and salt-retentive predisposition, were lighter than WKY, despite higher 
skin fat content: this may indicate a relative deficit of fat-free mass.  
Myocardium showed no signs of Na+ or water accumulation upon salt-loading, but 
myocardial water-paralleled accumulation of Na+ (i.e. oedema) became apparent with 
hypertensive ageing. The increase in negatively charged sulfated glycosaminoglycan in 
the matrix per se is clearly not an argument for water-independent Na+ binding, in light 
of their equal capacity to bind also water (hygroscopic properties, crucial to the 
physiology and mechanics of cartilage). Previous gravimetric studies in hypertensive 
and normotensive dogs led to similar conclusions (Laine, 1988, Laine and Allen, 1991). 
Notably, even small amount of myocardial oedema were shown to induce systolic and 
diastolic dysfunction (Dongaonkar et al., 2010), thus highlighting the translational 
relevance of the finding. Resistance of skeletal or cardiac muscle to accumulation of 
fluids in young animals likely reflects low interstitial physical compliance (Wiig and 
Reed, 1985) when compared to other tissues and/or sufficient drainage provided by the 
lymphatic system (Chapter 7).   
Even disregarding strain, age or salt loading, different organs from control animals 
showed marked heterogeneity in their Na+ and K+ contents, which nicely fitted the 
proposed theoretical model when the structural characteristics (i.e. ECV%) of each 
tissue were taken into account. The predictive power of the model for solid and 
homogeneous tissues appears confirmed not only by experimental data from my 
experiments, but also from others (skeletal muscle Na+ in Titze et al., 2005; K+ not 
provided). Reports for skin [Na+] are - admittedly - more heterogeneous, with values 
ranging from 90 to 125 mmol/l. I suggest this is due to: 1) the dual composition of skin, 
by epidermis and dermis, with respective ECV% close to the opposite extremes; 
sampling thickness and protocols have therefore a considerable impact on total Na+ (or 
K+) content (please see also chapter 6); 2) skin being the only site where a 
supraphysiological [Na+ + K+] was reported (Machnik et al., 2009, Wiig et al., 2013, 
Jantsch et al., 2015), thus indicating an accumulation at least in part independent of 
water.  
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However, these previous reports of hypertonicity were limited to rodents and, 
intriguingly, such hypertonicity (ranging between 177 and 195 mmol/l) was found also 
when animals were on low-salt diets (Titze et al., 2005, Machnik et al., 2009, Wiig et 
al., 2013). Skin interstitial fluid and lymph, at variance, were shown to have an isotonic 
Na+ content by multiple approaches even upon salt-loading (Nikpey et al., 2017).  
It is certainly not straightforward to reconcile apparently diverging results, but I 
contend that the experimental protocols and evaporation of tissue water (or moisture, as 
referred to by others; Lowry and Hastings, 1942) may play a role. I personally observed 
the magnitude and velocity of water evaporation during my experiments whenever 
handling of samples on the ultraprecision scale wasn’t sufficiently fast. In particular, 
when I plotted WW and all the consequent histochemical derived calculations as a 
function of the time the sample was left on the scale, I realised that just a couple of 
minutes of tissue handling would shift baselines from physiological isotonic values to 
hypertonic (Figure 5-14). 
 
Figure 5-14. Impact of prolonged tissue handling and evaporation on histochemical analysis. 
Data from a representative skin sample. Evaporation of water from tissues reduces the estimates of wet 
weight (WW) to a considerable extent in few minutes, while dry weight remains (by definition) stable. 
This dramatically and quickly impacts the estimates of water content, those of Na+ or K+ or total (Na+ + 
K+) concentrations and conclusions regarding iso or hypertonicity of the tissue, accordingly.  
Experiments where entire mouse or rat carcasses were totally deskinned to conduct the 
chemical analyses (Titze et al., 2005, Machnik et al., 2009, Wiig et al., 2013) could 
well be affected by the time needed for the surgical procedure, compared to my 
approach of small, quickly collected and immediately frozen tissue samples (see 
methods, 5.2). This contention is obviously no firm guarantee of the validity of my 
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conclusions, particularly regarding human tissues. Therefore, after the rat body 
composition study, I designed the S2ALT study (Chapter 6) to conduct similar 
histochemical analyses on the skin of patients with hypertension, one of the first 
clinical conditions where a hypertonic accumulation of Na+ had been suggested. 
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6 TISSUE SODIUM ACCUMULATION: HYPERTENSIVE PATIENTS 
6.1 Background and study aims 
Since the very first reports, the phenomenon of a water-independent skin Na+ 
accumulation has been linked to the pathogenesis of arterial hypertension.  
Chemical analysis of skin first suggested local accumulation of Na+ in excess of water 
in rodent models of salt-sensitive hypertension, induced by infusion of the 
mineralocorticoid 11-deoxycorticosterone acetate (DOCA) + 1% saline to drink (Titze 
et al., 2005). Subsequent studies identified a complex signalling cascade which locally 
regulated Na+ via lymphatic network plasticity as the ultimate effector; whenever such 
regulation was impaired and the animals were salt-loaded, the resulting phenotype was 
salt-sensitive hypertension with skin Na+ excess (Machnik et al., 2009, Wiig et al., 
2013). Therefore, when 23Na-MRI of human calves revealed a much higher Na+ signal 
in hypertensive patients (particularly if old, with uncontrolled BP or with a typical salt-
sensitive form as primary aldosteronism) compared to controls (Kopp et al., 2012, 
Kopp et al., 2013), it came as no surprise and appeared well in keeping with preclinical 
experimental data. 
At variance with the proposed theoretical framework of a hypertonic skin-specific Na+ 
accumulation, the rat body composition study discussed in chapter 5 led to conclude 
that tissue Na+ excess was rather a systemic phenomenon, reflecting relative or 
absolute extracellular volume expansion. Nevertheless, some peculiar aspects of skin, 
the specificity of the original description and the lack of robust histochemical data from 
human skin samples to complement the reported 23Na-MRI signal justified additional 
investigations on this specific tissue. 
Skin, and particularly the relatively acellular dermis rich in negatively charged 
glycosaminoglycans, would be the ideal site for active storage of Na+ (Bhave and 
Neilson, 2011). Moreover, functional and structural similarities between skin and 
kidneys had been observed (Hofmeister et al., 2015): both serve as ‘barrier organs’ to 
preserve the “milieu intérieur” (C. Bernard) and the hairpin-like lymphatic and blood 
capillary sub-epidermal structures could function as the counter-current system typical 
of kidney physiology to maintain osmotic gradients. Therefore, at least theoretically, 
skin could be an exception to our isotonic findings – as kidney physiologically is! – by 
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virtue of these mechanisms that would maintain the originally proposed hypertonic Na+ 
gradients.  
If that was the case and in light of the ‘barrier’ concept above, when approaching skin 
specific studies I also wondered how much of a putatively hypertonic Na+ excess could 
result from the accumulation of Na+ itself or, rather, to a relative deficit of water lost at 
the barrier. In line with this contention, the finalistic dominance of body water- over 
Na+- homeostasis had recently been reappraised (Kitada et al., 2017), as extensively 
discussed in chapters 1 and 3. 
On these premises, the S2ALT study was primarily designed to define the isotonic or 
hypertonic nature of skin Na+ accumulation in a hypertensive population and, 
secondarily, to identify clinical correlates to this phenomenon, including surface skin-
specific mechanisms of Na+/water exchange (e.g. sweating and transepidermal water 
loss, TEWL). A parallel study on young healthy volunteers (SOWAS) provided 
histochemical insights also on the skin of human normotensive subjects.  
6.2 Study-specific methods 
6.2.1 Study protocols 
6.2.1.1 S2ALT: Skin Sodium Accumulation and water baLance in hyperTension 
The protocol for the cross-sectional S2ALT (Skin Sodium Accumulation and water 
baLance in hyperTension) study was approved by the West of Scotland Research 
Ethics Committee 3 (ref. 18/WS/0238) and Greater Glasgow and Clyde NHS Research 
and Development (ref. GN18CA634); Appendix 1. The study was conducted in 
compliance with the Declaration of Helsinki.  
Adult, non-pregnant patients were recruited from the Blood Pressure clinic, Queen 
Elizabeth University Hospital, Glasgow between March and July 2019. A participant 
information leaflet (Appendix 2) was sent to all patients scheduled for a clinic 
appointment ≥ 7-10 days before they attended, along with the usual reminder. On the 
day of their appointment (9:00 AM to 4:30 PM), non-pregnant patients willing to take 
part gave written, informed consented and had anthropometric (body height and 
weight) and routine office blood pressure (BP) measures taken as per current guidelines 
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(Williams et al., 2018); pulse pressure (PP) was calculated as systolic BP – diastolic 
BP. Relevant comorbidities and ongoing medications were recorded. On the same 
occasion a short dietary questionnaire was administered to estimate sodium intake, 
transepidermal water loss (TEWL) was measured and a pilocarpine-induced sweat 
sample, a skin biopsy, serum and EDTA-plasma (for Na+, Urea, Creatinine and s-
VEGFc [measured by Quantikine ELISA assay, R&D systems] and for NT-proBNP, 
respectively) and a random spot urine sample (for microalbuminuria) were collected.  
6.2.1.2 SOWAS: SOdium and WAter Skin balance  
A cross-sectional study on healthy volunteers (SOWAS: SOdium and WAter Skin 
Balance) recruited among MVLS students was approved by the University of Glasgow, 
MVLS College Ethics Committee (ref. 200170153) and conducted between July and 
December 2018.  
One of the study aims was to provide sex-specific skin chemical reference values from 
a young healthy population. The second study aim, i.e. to investigate ex-vivo the 
modulation of osmolytes/water-specific human skin channels by hypertonic Na+ 
conditions and aldosterone (which is a classic fluid balance regulator and its excess is 
known to induce skin Na+ accumulation; Titze et al., 2005, Kopp et al., 2012) did not 
undergo completion due to technical issues briefly examined below and will not be 
further discussed. 
Student volunteers were recruited through advertisement in the University areas and 
media, with a 30£ voucher as a compensation for their time and potential travel 
expenses. Participants (50% females) attended the Research Centre for a preliminary 
visit (study discussion, consent and review of exclusion criteria, i.e. office BP > 140/90 
mmHg, obesity, or previous diagnosis of diabetes, thyroid, renal or coagulation 
disease) and a main visit. This included measurement of BP, body weight and non-
invasive body composition (BC-418MA, Tanita UK Ltd), and collection of blood 
samples, overnight-collected 24h urine, one additional spot urine sample, and 2 skin 
biopsies. For female participants, the main visit was arranged in the early follicular 
phase of their menstrual cycle, just after period termination; in 4 cases, due to personal 
logistics or continuous progesterone treatment (skin implants or vaginal coil) the main 
visit coincided with a luteal or luteal-like phase. Salinity of the 24h urine sample was 
checked by colorimetric strips (Salinity View, Health Mate®) to confirm normal salt 
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intake and eligibility, accordingly. Biopsies were performed on adjacent sites in the 
gluteal external upper quadrant, as described below. 
One skin sample was cut in halves and immediately frozen for chemical (chapter 7) 
analyses. The second sample was used for whole-tissue culture (Maubec et al., 2015) 
and randomly assigned to different incubation conditions (standard culture medium, 
culture medium enriched in NaCl [+30 mmol/l], standard culture medium + 10-7 M 
aldosterone, culture medium enriched in NaCl [+30 mmol/l] + 10-7 M aldosterone). An 
interim analysis revealed marked histological changes in tissue architecture upon 
culture, e.g. epidermal layer detachments with apparent neo-epidermogenesis, 
independent of the specific culture condition. Because of this major confounder, this 
experimental arm of the study was stopped. 
6.2.2 Skin punch biopsy and chemical analysis 
The protocols for the skin punch biopsy and water and Na+/K+ tissue content analysis 
have already been described in Chapter 2 and are only briefly recollected here.  
Approximately 40 minutes after application of a Na+-free topical anaesthetic cream, the 
arm (S2ALT) or gluteal (SOWAS) surgical site was cleaned with alcohol swabs to 
ensure sterile conditions. The epidermis and superficial dermis were pierced by a sterile 
punch (3-4 mm blade diameter; Kai Medical), the biopsy removed with a sterile blade 
and haemostasis obtained with sterile gauze. The excised sample was immediately put 
into a pre-cooled Eppendorf tube, frozen in dry ice and stored at -80°C until tissue 
chemical analysis. The biopsy site was closed with steri-strips (3M) and wound care 
information sheet and plasters were provided to the participant. 
At the time of the analysis, frozen skin samples were transversally cut into a superficial 
layer, including the epidermis and the immediately adjacent superficial dermis (ESD), 
and deeper dermis (DD; Figure 6-1).  
Samples were weighed on a 5 decimal (0.00001 g) scale to determine Wet Weight 
(WW). After complete desiccation of samples to a stable dry weight (DW), water 
content was estimated as (WW-DW)/DW, or as percentage (WW-DW) ´ 100/WW. 
Dried samples underwent complete digestion in HNO3 and the resulting solutions were 
used for Na+ and K+ quantification by flame photometry (Sherwood scientific, model 
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410C), with calibration standards as reference. All samples were analysed in a batch. 
Na+ and K+ concentrations in the analysed solutions were used to back-calculate their 
total content in the digested samples and were normalised by DW for Na+ and K+ tissue 
content (mmol/gDW), or by tissue water for Na+ and K+ tissue concentration (mmol/l).  
 
Figure 6-1. Human skin samples and anatomical strategy of analysis. 
Representative skin sections from a male (left) and a female (right) subject (picrosirius-red staining); 
dashed line = representative of the cutting plane for separation of ESD and DD in all study samples; 
black-circled areas in DD = subcutaneous fat, typically more abundant in female subjects. 
6.2.3 Sodium intake questionnaire (S2ALT study) 
A short, validated questionnaire (Charlton et al., 2008) was administered to patients 
while waiting for their scheduled visit (Appendix 3). It included 42 food items with six 
possible consumption frequency responses: never; 1–3 times per week; 4–6 times per 
week; once a day; twice a day; and 3+ times a day. Predefined absolute amounts of 
sodium per serving size per specific item, according to MRC Food Composition Tables  
(Langenhoven et al., 1991) were multiplied by the consumption frequency factor that 
500 μm
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each individual reported, and summed up to a total weekly Na+ intake for each subject, 
later divided by 7 to estimate daily intake. For simplicity, the absolute amounts of Na 
per serving for each food category were divided by 50 mg Na+ units and rounded to the 
nearest integer (Charlton et al., 2008).  The frequency factor in the weekly calculation 
was taken as the value midway between the upper frequency value of one category and 
the lower of the next (i.e. 0, 2, 5, 7, 14, 21).  
Missing questionnaire data were scrutinised by Little’s ‘missing completely at random’ 
(MCAR) test. For subjects with more than half of the responses missing calculations of 
weekly scores was considered unreliable and excluded. For subjects with £ 10% 
missing responses median substitution was used for imputation and calculation of 
weekly scores. 
6.2.4 Transepidermal water loss (S2ALT study) 
Before blood collection and skin biopsy and following a ³ 20-minute period of 
acclimatisation in a temperature-controlled environment (20 - 21°C) and ³ 5 minutes of 
quiet sitting, transepidermal water loss (TEWL; Fluhr et al., 2005) was assessed from 
the flexor portion of the forearm with a Tewameter® TM300 probe (Courage & 
Khazaka GmbH, Cologne, Germany). The probe estimates TEWL through 2 pairs of 
temperature and humidity sensors and Fick’s diffusion law. Readings were 
automatically stopped and recorded by an MPA 580 system and dedicated software 
when a ≤ 0.1 standard deviation was reached.  
6.2.5 Pilocarpine-induced sweat test (S2ALT study) 
Immediately before the clinic visit, upon consent and exclusion of an implanted 
pacemaker/cardioverter-defibrillator, a small area of skin on one arm of the study 
participants was cleaned with distilled water and dried. Two pilocarpine (a 
parasympathomimetic alkaloid) pads (Pilogel® Iontophoretic Discs, ELITech Group) 
were attached with straps. In order to get the pilocarpine into the skin to induce 
sweating, the area was stimulated by a small current (1.5 mA) for five minutes 
(iontophoresis; Webster Sweat Inducer Model 3700, ELITech Group). After removal of 
the pilocarpine pads, a dedicated plastic coil (Macroduct® no-dye collectors, ELITech 
Group) was attached on the stimulated arm with straps for collection of sweat over the 
next 30-40 minutes, including the time while the clinic visit took place. 
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The sweat collected in the coil was then transferred to 200 ul sterile microtubes, frozen 
in dry ice and stored at -80°C until chemical analysis. At the time of the analysis 
samples were thawed to measure the volume with a calibrated micropipette and 
appropriately diluted to determine Na+ and K+ concentrations (mmol/l) by flame 
photometry, as described in chapter 2 for HNO3-digested tissues. Total Na+ or K+ sweat 
content was calculated as concentration ´ volume.  
6.2.6 Statistics 
Statistical analysis was performed using Prism (GraphPad Software) and SPSS (IBM). 
Categorical variables are presented as absolute numbers and percentages and compared 
by χ² test. Student t-test for normally distributed variables (presented as mean±SD or, 
graphically, as mean [95%CI]) or Mann-Whitney test for non-normally distributed 
variables (presented as median [interquartile range] or, graphically, as median 
[95%CI]) were used for comparisons. Outliers were automatically identified by ROUT 
method (Q = 1%) and excluded from analysis but reported on the relative figures.  
Correlations were ascertained by Pearson test, upon appropriate transformation of 
skewed variables to attain normal distribution, or Spearman if normality was not 
attained. Univariable and multivariable (including age, sex, BMI and estimated Na 
intake) linear regression models were estimated and results were presented as 
standardised B coefficients (95%CI).  
The α level was set at 0.05 and all statistical tests were 2-tailed (*p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001). 
6.3 Results 
Out of 90 study participants, 76 agreed to undergo a skin biopsy as part of the study 
procedures. Their characteristics and sex-specific differences are summarised in Table 
6-1. 
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Table 6-1. Characteristics of S2ALT patients. 
Variables ALL (n=76) FEMALES p MALES 
Females 36 (47.4%) -  - 
Age (years) 58 ± 15 56 ± 16 0.359 59 ± 13 
BMI (kg/m2) 30.3 (27.5-36.3) 31.6 (26.5-38.3) 0.212 29.7 (27.8-33.9) 
Office SBP (mmHg) 148 ± 21 148 ± 26 0.869 149 ± 15 
Office DBP (mmHg) 89 ± 12 87 ± 13 0.278 90 ± 11 
Office HR (beats per minute) 74 (65-87) 77 (66-89) 0.82 73 (64-84) 
Uncontrolled HTN 56 (73.7%) 21 (60.0%) 0.006 35 (87.5%) 
Number of anti-HTN 
medications 
2 (0-4) 2 (1-3) 0.011 3 (1-3) 
0 8 (10.5%) 6 (16.7%) 
0.056 
2 (5%) 
1 17 (22.4%) 9 (25%) 8 (20%) 
2 15 (19.7%) 10 (27.8%) 5 (12.5%) 
3 22 (28.9%) 6 (16.7%) 16 (40%) 
³ 4 14 (18.4%) 5 (13.9%) 9 (22.5%) 
ACEi/ARB 60 (78.9%) 25 (69.4%) 0.054 35 (87.5%) 
CCB 41 (53.9%) 15 (41.7%) 0.042 26 (65%) 
Diuretic 33 (43.4%) 12 (33.3%) 0.092 21 (52.5%) 
BB 18 (23.7%) 7 (19.4%) 0.41 11 (27.5%) 
MRA 9 (11.8%) 2 (5%) 0.108 7 (17.5%) 
AB 12 (15.8%) 6 (5.6%) 0.842 6 (15%) 
Obesity 41 (53.9%) 22 (61.1%) 0.235 19 (47.5%) 
Diabetes mellitus 10 (13.3%) 3 (8.6%) 0.256 7 (17.5%) 
Dyslipidaemia 43 (58.1%) 17 (50%) 0.192 26 (65%) 
Chronic kidney disease 8 (10.5%) 3 (8.3%) 0.555 5 (12.5%) 
Na+ intake (g/d) 2.79 (2.24-3.76) 2.64 (2.39-3.44) 0.323 3.09 (2.16-4.56) 
s-Na+ 140 (139-142) 140 (139-142) 0.565 140 (139-141) 
s-Urea (mmol/l) 5.3 (4.5-6.5) 4.8 (3.9-5.9) 0.005 5.6 (4.9-7.3) 
s-Creatinine (umol/l) 73 (63-86) 65 (55-73) <0.001 84 (72-96) 
u-ACR (mg/gCr) 6.7 (2.6-16.8) 6 (3.4-11.7) 0.848 6.7 (2.3-24.7) 
NT-pro-BNP (pg/ml) 71.8 (43.1-184.1) 79 (46-142) 0.577 68 (34-253) 
Qualitative data presented as n (%). Quantitative data presented as mean ± SD or median (interquartile 
range), as appropriate. BMI = Body Mass Index. SBP = systolic blood pressure. DBP = diastolic blood 
pressure. HR = heart rate. HTN = hypertension. Uncontrolled HTN = SBP ³ 140 and/or DBP ³ 90 
mmHg. ACEi/ARB = ACE inhibitors or Angiotensin receptor blockers. CCB = calcium channel 
blockers. BB = beta blockers. MRA = mineralocorticoid antagonists. AB = alpha blockers; Na+ intake = 
estimated sodium intake (questionnaire); s- = serum. u-ACR = urinary albumin to creatinine ratio 
(random urine sample). 
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6.3.1 Histochemical analysis 
As the theoretical model would predict (chapter 4), [Na+] and [K+] were lower and 
higher in the more cellular ESD compared to mostly acellular DD, respectively (Figure 
6-2). In virtually no patients, and thereby in none of any prespecified clinical 
subgroups, did [Na++K+] exceed the physiological value of 155 mmol/L in either layer 
(Figure 6-2), thus ruling out any hypertonic accumulation. 
         
Figure 6-2 Na+ and K+ concentrations and water content by skin layer 
Left: bars show mean ± 95%CI, with individual points (overlay); Na+ and K+ concentrations and water 
content in the Epidermis/Superficial dermis (ESD) and Deep Dermis (DD) layers, reflecting different 
architecture and cellularity. Right: skin Na+ + K+ concentration in ESD and DD; red X = automatically 
detected outliers (ROUT, Q=1%); in virtually no patient, including n = 3 cases with primary 
aldosteronism, did [Na+ + K+] exceed physiological values (grey). 
In both ESD and DD, water content was positively and negatively correlated with [Na+] 
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In DD, water, Na+ and K+ contents, but not concentrations, were all positively and 
highly correlated. This likely reflects the volume of distribution of watery fluids, either 
cellular or extracellular, as opposed to fat. As discussed for rat tissues (Figure 5-5), 
whenever a tissue volume is occupied by fat the space for cells or extracellular fluid 
(and water and the accompanying cations, accordingly) is reduced: therefore water 
content in the fat-rich DD is lower than ESD (Figure 6-2). Similarly, male DD 
contained more water, Na+ and K+ than female dermis, which is known to be richer in 
subcutaneous fat, with no such differences observed in ESD (Table 6-2).  
Almost identical sex differences were observed in gluteal biopsies from young healthy 
volunteers (SOWAS, Table 6-3). Fluid-retentive (White et al., 2011) progestinic states 
were characterized by higher water and Na+ content, but unchanged [Na++K+] (Figure 6-4). 
 
Figure 6-4. Histochemical sex-differences in the skin of young healthy volunteers and impact of fat.  
Mean ± 95%CI; blue (M) = males, light pink (F(F)) = females in follicular phase, dark pink (F(P)) = 
females in progestinic phase/state. No differences were observed between M and F(F) in ESD. In DD, 
water, Na+ and K+ content, but not concentration, were lower in F(F). F(P) overall had higher skin water 
and Na+ content than F(F).  
In SOWAS, where body composition (bioimpedance) data were available, the 
histochemical impact of fat was further supported by the inverse correlation between 
gluteal dermal Na+ content and percentage fat mass in the leg (r = -0.54, p = 0.005); 
similar correlations were observed with directly-measured bioimpedance values (W; 
leg: r = -0.40, p = 0.047; whole-body: r = -0.62, p < 0.001) and for dermal water 
content (with leg fat %: r = -0.62, p = 0.001; with leg W: r = -0.42, p = 0.04; with 
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Table 6-2. Skin histochemical differences between hypertensive males and females. 


























Water content (mg/mgDW) 2.57 ± 0.32 0.864 2.58 ± 0.29 2.50 ± 0.21 0.244 2.62 ± 0.33 
Water content (%WW) 71.62 ± 2.35 0.708 71.83 ± 2.36 71.32 ± 1.64 0.337 72.13 ± 2.68 
Na+ content (mmol/gDW) 0.290 ± 0.049 0.821 0.290 ± 0.044 0.264 ± 0.026 0.005 0.302 ± 0.047 
Na+ concentration (mmol/l) 113.5 ± 8.3 0.371 111.7 ± 8.9 105.8 ± 6.4 0.002 115.1 ± 8.4 
K+ content (mmol/gDW) 0.076 ± 0.013 0.602 0.078 ± 0.009 0.082 ± 0.009 0.032 0.075 ± 0.009 
K+ concentration (mmol/l) 29.9 ± 5.5 0.694 30.4 ± 4.2 32.9 ± 3.9 0.005 28.9 ± 3.7 










Water content (mg/mgDW) 1.68 ± 0.41 0.007 1.40 ± 0.42 1.24 ± 0.26 0.159 1.46 ± 0.46 
Water content (%WW) 61.67 ± 6.82 0.009 57.26 ± 7.02 54.69 ± 5.53 0.207 58.12 ± 7.45 
Na+ content (mmol/gDW) 0.208 ± 0.057 <0.001 0.158 ± 0.054 0.136 ± 0.042 0.144 0.166 ± 0.056 
Na+ concentration (mmol/l) 122.7 ± 8.9 0.004 114.0 ± 13.4 111.8 ± 9.5 0.735 114.3 ± 15.1 
K+ content (mmol/gDW) 0.029 ± 0.008 0.007 0.024 ± 0.006 0.022 ± 0.007 0.446 0.024 ± 0.006 
K+ concentration (mmol/l) 17.2 ± 3.8 0.795 17.4 ± 3.5 17.9 ± 2.6 0.449 17.1 ± 3.9 
Na+/K+ ratio 7.48 ± 1.78 0.061 6.69 ± 1.65 6.15 ± 1.24 0.226 6.95 ± 1.84 
Data presented as mean ± SD and compared by Student t-test. Menop = menopause. Missing data because of technical issues or unavailable sample ≤ 8/total  
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Table 6-3. Characteristics of young healthy volunteers. 
Variables ALL MALES  
(n= 18) 
p FEMALES (F)  
(n = 11) 
p FEMALES (P)  
(n = 4) 
Females 15 (45.5%) -   -   - 
Age (years) 25 ± 4 25 ± 3 0.769 25 ± 6 0.498 28 ± 5 
Office SBP (mmHg) 115 ± 11 118 ± 12 0.096 111 ± 8 0.882 115 ± 8 
Office DBP (mmHg) 65 ± 9 63 ± 10 0.501 66 ± 9 0.518 69 ± 8 
Office HR (beats per minute) 67 ± 8 66 ± 10 0.318 69 ± 8 0.918 69 ± 4 
BMI (kg/m2) 22.7 ± 2.8 23.0 ± 2.7 0.945 23.1 ± 3.0 0.109 20.4 ± 1.0 
Body Weight (Kg) 68.3 ± 13.3 74.5 ± 13.0 0.012 62.1 ± 10.2 0.352 57.0 ± 3.9 
Impedance (whole body, Ω) 630 ± 77 590 ± 68 0.0001 676 ± 33 0.891 682 ± 133 
Total body water (estimated; %) 58.7 ± 6.0 62.4 ± 3.3 <0.0001 53.0 ± 5.2 0.131 58.0 ± 5.9 
Total body fat (estimated; %) 19.7 ± 8.3 14.7 ± 4.5 <0.0001 27.7 ± 7.1 0.13 20.7 ± 8.1 
Leg fat (estimated; %) 20.8 ± 9.9 13.2 ± 4.4 <0.0001 32.0 ± 3.9 0.098 27.2 ± 5.9 
Trunk fat (estimated; %) 17.7 ± 7.1 15.3 ± 5.5 0.008 22.2 ± 6.8 0.255 16.7 ± 10.3 
p-Na+ (mmol/l) 141 (140-141) 141 (140-142) 0.218 140 (140-141) 0.376 140 (139-142) 
p-Urea (mmol/l) 4.7 ± 1.4 4.9 ± 1.7 0.336 4.5 ± 0.8 0.555 4.2 ± 1.0 
p-Creatinine (umol/l) 76 ± 12 80 ± 11 0.111 72 ± 13 0.348 72 ± 13 
24h-urinary volume (ml) 1875 ± 900 1800 ± 775 0.7 1950 ± 1150 0.879 2050 ± 775 
24h-u Na excretion (g/d) 2.23 (1.77-3.27) 2.09 (1.47-3.52) 0.555 2.37 (1.07-3.27) 0.373 2.12 (1.89-2.48) 
Qualitative data presented as n (%). Quantitative data presented as mean ± SD or median (interquartile range), as appropriate. (F) = females in follicular phase; (P) = females 
in progestinic phase/state. BMI = Body Mass Index. SBP = systolic blood pressure. DBP = diastolic blood pressure. HR = heart rate. 
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6.3.2 Clinical correlates in hypertensive patients 
In the hypertensive S2ALT population, age (range 21-86 years) was independently 
associated with an increase in ESD water and [Na
+
], and a decrease in [K
+
] in both 
layers; this likely indicates excess fluid (oedema) accumulation in the context of 
reduced tissue cellularity, traditionally accepted as a hallmark of skin aging (Figure 6-5). 
 
Figure 6-5 Histochemical parameters and ageing 
Association of ESD water, [Na+] and [K+] with age, reflecting the shift in ECV/ICV ratio; red X = 
automatically detected outlier; bottom: representative pictures of age-related reduction in skin cellularity; 
immuno-fluorescence, DAPI-staining; scale bars = 200 μm. 
Salt intake, estimated by dietary questionnaires (Little’s Missing Completely At 
Random test, p = 0.593; five subjects with > 50% missing responses excluded; 22 
additional subjects with £ 10% missing responses and 10/22 only 1), predicted 




 or their ratio), independently of age, sex and 
BMI.  




Office diastolic BP was inversely associated with ESD water content (ρ = -0.250; p = 
0.03) and a surrogate of vascular stiffness, pulse pressure (PP), was positively 
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 ratio in both layers; in ESD, the ratio was higher in patients 
with uncontrolled BP, independent of other covariates. No significant interaction with 
medications was observed.  
NT-proBNP levels, positively associated with age (ρ = 0.526; p < 0.001), estimated 
Na
+
 intake (ρ = 0.260; p = 0.03) and systolic BP (ρ = 0.288; p = 0.01) and negatively 
with diastolic BP (ρ = -0.277; p = 0.02), mirrored all measures of skin oedema 
accumulation. 
Contrarily to the predefined hypothesis that local regulatory mechanisms could make 
skin an exception to the isotonic nature of systemic tissue Na
+
 excess/accumulation via 
a relative deficit of water, transepidermal water loss showed no correlations with 
histochemical skin data (Figure 6-6). 
 
Figure 6-6 Histochemical parameters and other relevant clinical correlates 
Relationships between skin histochemical parameters, age, BMI, Na intake and pulse pressure (PP), 
plasma NT-proBNP and transepidermal water loss (TEWL), by skin layer. Data are presented as 
standardised B regression coefficients (95%CI); for skin histochemical parameters, coefficients for all 
patients are visualised in black, for males in blue, for females in pink. PP and NT-proBNP positive 
associations with ESD water accumulation were mostly driven by females; the association with Na+/K+ 
ratio was overall generalised to both layers and sexes. No significant associations were observed with 
TEWL, making relative local water deficit an unlikely explanation for an even putative Na+ hypertonic 
excess.   
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6.3.3 Skin-specific mechanisms of Na+/water exchange 
Both age and [Na
+
] in ESD, as a measure of skin ECV, were positively correlated with 
sweat [Na
+
] (Spearman ρ: = 0.367, p = 0.001 and ρ: = 0.345, p < 0.01, respectively; 
Figure 6-7). The association between ESD and sweat [Na
+
] was independent of sex, 
BMI and use of RAS system blockers (ACEi/ARBs; padjusted=0.031); the latter was the 




In particular, patients who were on ACEi or ARBs had higher sweat [Na
+
] compared to 
those who were not (32.8 [26.0-45.8] vs 25.8 [18.4-39.5] mmol/l, p = 0.038); the same 
was true when the analysis was limited to those on ACEi or ARBs only (n=13; 39.2 
[31.6-51.2] mmol/l) vs no antihypertensive medications (n=9; 25.7 [18.4-37.7] mmol/l; 
p = 0.049 for comparison). Sweat [Na
+
] inversely correlated with sweat [K
+
] (ρ: = -
0.230, p = 0.041). 
 
Figure 6-7. Sweat Na+ concentration in relation to ESD Na+ concentration and age. 
ESD [Na+], as a measure of skin ECV, and age were positively correlated with sweat [Na+]. X = 
automatically identified outliers (ROUT = 1%). 
Office diastolic, but not systolic, BP inversely correlated with sweat [Na
+
] (Spearman ρ 
=-0.309, p=0.006), independent of age and the other potential confounders 
(padjusted=0.02). Although no difference was found for sweat [Na+], total sweat volume 
and excreted Na
+
 were lower in patients with uncontrolled office BP (defined as BP > 
140/90 mmHg; p<0.01 for both; padjusted<0.005). 
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Figure 6-8. Sweat and blood pressure. 
Left: Sweat [Na+] was inversely and independently associated with diastolic BP. BP control was 
associated with higher total sweat [Na+] and total sweat volume (data presented as median [95%CI]).  
Sweat volume also positively correlated with TEWL and serum-VEGFc (p<0.05 for both). 
6.4 Discussion 
The S2ALT study, designed to define the nature of skin Na+ excess in hypertensive 
patients, failed to identify any hypertonic Na
+
 accumulation. Despite some anatomical 
and functional aspects of the skin that could make it similar to the kidney (Hofmeister 
et al., 2015) and therefore support the theoretical plausibility of Na
+
 storage 
mechanisms different from all other organs, a direct histochemical analysis of these 
human skin biopsies revealed no exception to what has already been observed in the rat 
body composition study.  
In fact, maintenance of the Na
+
 gradients in the renal medulla requires “elaborate 
arrangements of renal tubules in combination with specific enrichment of active 
sodium transporters (Na/K-ATPase, Na-K-Cl cotransporters, Na-Cl cotransporters, 
etc), in addition to enormous flow in tubules and blood vessels. (…) Given the lack of 
conclusive evidence for structural or functional features required for the maintenance 


























ρ: -0.309; p < 0.01 
standardised B sig 
Diastolic BP -.278 .020
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of local hypertonicity in the skin,” (Hyug Moo Kwon, personal communication) an 
isotonic accumulation, as suggested by Figure 6-2 and as observed also in all other 
organs in rats (Chapter 5), clearly appears more plausible.  
There are very few other studies on direct chemical analysis of human skin to put these 
findings into context.  
Fischereder et al. measured Na
+
 and GAG content in skin and (epigastric) arterial 
samples taken from renal transplant living donors and end-stage kidney recipients, free 
from clinically detectable oedema (Fischereder et al., 2017). Although non significantly 
different between groups, skin Na
+
 (mmol/gDW) and arterial tissue Na
+
 showed a 
positive correlation; additionally, both correlated with the respective tissue GAG 
content. While the simple cocnlusion, in keeping with Titze’s theoretical framework, 
was that interstitial Na
+
 storage is regulated by GAGs in humans, associations do not 





 concentration: based on the histochemical approach discussed in chapters 
4-5, excess extracellular space (including GAGs and possibly oedema) is well in 
keeping with higher Na
+
 content regardless of hypertonic accumulations. What is 
intriguing, and supports my view of a systemic phenomenon (chapter 5), is the 
correlation between the systemic vasculature and skin Na
+
.  
Another study, with a double-blind cross-over design, was conducted on healthy 
participants randomized to placebo (70 mmol sodium/d) or oral slow sodium (200 
mmol/d; Selvarajah et al., 2017). Skin Na
+




, was 8% 
higher following the slow sodium phase and positively correlated with BP and 
peripheral vascular resistance (PVR). The authors very carefully assessed any possible 
contaminations, including in the subcutaneous anaesthetic, prior to the biopsies. 
However, they acknowledged that “smaller” (which, in the context of standardised 
punch approaches, should read as “more superficial”) “samples recorded greater 
proportional water contents” and interpreted the phenomenon as a “technical 
limitation”. This led them to favour Na+:K+ ratios over Na+ concentration values; 
therefore, the same aforementioned limitations in the interpretation of findings apply. 
In fact, the reported biopsy-depth related differences do not appear a technical 
limitation but rather consistent with S2ALT findings, the role of a subcutaneous fat 
typically more represented in deeper layers and the need for a critical histochemical 
interpretation of data (Figures 6-1,2).  
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Chachaj et al performed a cross-sectional analysis of skin biopsies from patients 
undergoing elective abdominal surgery, stratified according to hypertension status: 
while hypertensive patients did not show significantly higher skin Na
+
 content than 
normotensives, skin Na
+
 and water were closely correlated (r = 0.57; p < 0.001; 
Chachaj et al., 2018) 
One last report that is worth mentioning comes from the field of human heart failure 
(Nijst et al., 2018). The topic of heart failure (HF), prototypic of overt - as opposed to 
subclinical -congestion, will be extensively discussed in the next chapter. However, 
some experimental aspects are briefly summarised here. A punch biopsy of the lower 
leg (a classic site of dependent oedema in HF patients) was obtained in patients with 
HF and reduced ejection fraction (HFrEF) and healthy subjects. The authors found a 
higher interstitial glycosaminoglycan content, which strongly associated with tissue 
water content and peripheral oedema, in patients with HFrEF compared to controls. 
The specific approach to sample handling and processing (defatting protocol) 
unfortunately prevented concomitant Na
+
 assessment on the biopsies, but – once again 
– their results appeared in keeping with the hygroscopic (and not only Na
+
-binding) 
properties of GAGs, with Fischereder’s data and, overall, with my widely-applicable 
conclusions (chapter 5).  
On a parallel note, S2ALT results not only did provide direct evidence of an isotonic 
phenomenon, but also linked it to relevant clinical correlates.  
The most robust association was with ageing, a salt-sensitive condition (Elijovich et al., 
2016) with typically good response of blood pressure to diuretic therapy, accordingly.  
S2ALT data suggest that this salt-sensitivity goes hand-in-hand with subclinical 
congestion. NTproBNP, a product of cardiac tissue in response to volume overload and 
a well-established predictor of cardiovascular events in people with or without baseline 
cardiovascular disease (Wang et al., 2004, Everett et al., 2015, Natriuretic Peptides 
Studies et al., 2016, Paget et al., 2011, Welsh et al., 2014), was closely associated with 
age, estimated salt intake and histochemical evidence of excess skin water and Na
+
. 
The investigation of skin-specific mechanisms of water and Na
+
 exchange (i.e. sweat 
and TEWL) revealed interesting associations with measures of tissue Na
+
 status and 
suggests them as parts of a systemic homeostatic regulation. Similar to NTproBNP, 
sweat [Na
+
] was positively correlated with age and skin [Na
+
], thus reflecting a 
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possible attempt to eliminate excess total body Na
+
; in keeping with this contention, the 
higher the concentration of excreted Na
+
, the lower the diastolic BP. With all the limits 
of independent studies comparisons, hypertensive patients enrolled in S2ALT had a 
lower sweat [Na
+
] than normotensive controls recruited in a previous study (Quintero-
Atencio et al., 1966: 30.6 [25.5-42.3] mmol/l vs 34.8 [29.0-51.9] mmol/l, p = 0.038); 
patients with severe, uncontrolled, possibly malignant (by current definitions) 
hypertension in that same study had an even lower sweat Na
+
 concentration (23.3 
[16.8-31.3] mmol/l). In relation to putative modulators of this response, an inverse 
association with [K
+
] and an interaction with the use of renin-angiotensin-aldosterone 
system blockers were also identified.  
Although TEWL was not significantly correlated with histochemical skin data, which 
further excludes a barrier water loss disproportionate to Na
+
 loss in the maintenance of 
a putative hypertonic interstitium, it was positively associated with sweat volume and 
circulating VEGFc. Modulation of both sweat generation and trans-epidermal 
evaporation requires a rich and competent dermal microcirculation, which is regulated - 
among many other factors - by VEGFc via VEGFR2 and VEGFR3 (Simons et al., 
2016).  
The exact role of this interplay remains to be elucidated. However, with the 
acknowledged limitations of 1) a cross-sectional study design which prevents 
conclusions on causality and role of confounders, 2) the use of pilocarpine-stimulated 
sweating rather than a whole-body washdown or similar approaches (Lemon et al., 
1986, Shirreffs and Maughan, 1997) and 3) the lack of information on sweat 
rate/composition or TEWL during exercise, this preliminary body of evidence suggests 
that neurohormonal axes and peripheral (micro)vascular function could directly 
modulate sweat and TEWL. These, in turn, could play an active role in the regulation 
of total body Na
+
 and water in hypertension. Of note, these mechanisms are potentially 
actionable (Laukkanen et al., 2018).  
In summary, and regardless of local mechanisms of regulation, S2ALT data call for 
reconsideration of excess tissue Na
+
 in light of a pragmatic histochemical approach: 
while it cannot - and was not designed to - unconditionally exclude an hypertonic Na
+
 
accumulation in any tissue milieu or any clinical/experimental condition, it firmly 
supports preclinical evidence already presented in chapters 4-5 and raises due caution 
in the interpretation of tissue Na
+
 data. Bhave and Neilson in their “hypothetical 
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framework” made the contention that “real” excess (water-independent) Na
+
 storage 
would occur only with very-high sodium diet (>300 mEq/d), thus concluding that “only 
about 5% of essential hypertension in American patients may involve alterations in 
(tissue) Na+ storage” (Bhave and Neilson, 2011). 
Either their projection was excessively conservative, or the epidemics of high Na
+
 
signal later observed by 
23
Na-MRI in aging, uncontrolled and/or secondary 
hypertension, diabetes, CKD, heart failure and systemic sclerosis is (at least in a 
considerable part) a different phenomenon, i.e. subclinical oedema. Numquam est 
ponenda pluralitas sine necessitate (Duns, 1497).  
I now interpret many of the aforementioned ‘at–risk’ patients as part of a “congestion 
continuum”, which can directly impact on the function of vessels and other organs and 
can ultimately lead to the overt syndrome currently identified as “heart failure”. The 
latter is the specific topic of discussion of the next chapter. 
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7 INTERSTITIUM AND MICROVASCULAR FUNCTION 
7.1 Background and study aims 
Heart failure (HF) is a leading cause of morbidity and mortality (Benjamin et al., 
2018). Current trends of increased heart failure hospitalizations are mostly driven by 
heart failure with preserved ejection fraction (HFpEF), carrying a 1-year prognosis 
almost as poor as in patients with reduced ejection fraction (HFrEF; Chang et al., 2018, 
Campbell et al., 2012, Borlaug et al., 2006). 
HFpEF is a clinical syndrome closely associated with multiple cardiovascular 
comorbidities and risk factors, such as hypertension, obesity, coronary artery disease, 
diabetes mellitus, atrial fibrillation and chronic kidney disease (Pfeffer et al., 2019). 
The notion that these comorbidities are not just associated with HFpEF but may be 
directly involved in its pathogenesis via comorbidity-associated inflammation and 
coronary microvascular dysfunction (Paulus and Tschope, 2013) has gained support 
from a large body of post-mortem, non-invasive and invasive evidence (Shah et al., 
2018, D'Amario et al., 2019, Mohammed et al., 2015). In addition to the coronary 
vascular bed, peripheral vessels also appear dysfunctional (D'Amario et al., 2019). In 
particular, impaired systemic vasodilator reserve and low skeletal muscle capillary 
density, as well as low peripheral O2 extraction paralleling microvascular rarefaction, 
were reported as determinants of exercise intolerance in patients with HFpEF (Borlaug 
et al., 2006, Haykowsky et al., 2011, Kitzman et al., 2014, Dhakal et al., 2015). Such 
findings challenged the paradigm of a purely cardiac disorder in favor of a more 
systemic phenomenon (Kitzman et al., 2015). However, whether and how a 
dysfunctional microcirculation could directly impact congestion, “the core of the HF 
syndrome” (Pfeffer et al., 2019), has not yet been investigated. 
In the previous chapters, the concepts of tissue Na
+
 accumulation and Na
+
- driven 
lymphatic network expansion (Machnik et al., 2009) have been extensively discussed. 
Notably, tissue Na
+
 excess was found in most of the conditions/risk factors associated 
with the clinical HFpEF syndrome (i.e. older age, hypertension, diabetes, chronic 
kidney disease; Kopp et al., 2013, Karg et al., 2018, Schneider et al., 2017). At the time 
the herein presented study was conceived, results from the model (Chapter 4), rat body 
composition study (Chapter 5) or S2ALT study (Chapter 6) were not available and the 
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putative hypertonic nature of tissue Na
+
 excess in HFpEF, as well as its functional 
relevance to fluid homeostasis, had not been demonstrated.  
Therefore, the Heart fAilure with Preserved ejection fraction: Plethysmography for 
Interstitial Function and skin biopsY (HAPPIFY) study was designed to investigate 
capillary-interstitium fluid exchange and to test the hypothesis that an osmotic effect 
secondary to high interstitial Na
+
 levels could impact microvessels and result in excess 
fluid extravasation and oedema in patients with HFpEF.  
Secondary analyses included the assessment of arterial function in patients with HFpEF 
by “classic” methods, i.e. measures of arterial stiffness and flow-mediated dilatation, 
and by ex-vivo functional evaluation of subcutaneous resistance arteries by wire 
myography, in comparison to healthy subjects of similar age and sex; additionally, the 
subcutaneous microvasculature – including lymphatics - was anatomically and 
molecularly compared between groups.  
7.2 Study- specific methods  
7.2.1 Protocol and subjects 
The HAPPIFY study conforms to the Declaration of Helsinki and the protocol 
(Appendix 4) was approved by the West of Scotland Research Ethics Committee 3 (ref. 
17/WS/0091) and Greater Glasgow and Clyde (GG&C) NHS Research and 
Development (ref. GN17CA152).  
Subjects with HFpEF identified from outpatient HF clinics in Glasgow, UK, and 
healthy volunteers with no history of cardiovascular or renal disease, hypertension or 
diabetes, recruited by public advertisement (Appendices 5-6), were invited to an 
eligibility visit where inclusion and exclusion criteria were reviewed. HFpEF diagnosis 
was per the 2016 European Society of Cardiology guideline definition: (i) signs and/or 
symptoms of HF clinically stable for > 1 month, (ii) elevated BNP > 35 pg/ml, (iii) an 
ejection fraction ≥ 50% and (iv) evidence of structural heart disease (left atrial 
enlargement and/or left ventricular hypertrophy) or diastolic dysfunction.(Ponikowski 
et al., 2016) Patients with history of recent (<3 months) cerebrovascular event, 
myocardial infarction or coronary revascularisation; significant valve disease; unstable 
coronary artery disease; hypertrophic/infiltrative cardiomyopathy or constrictive 
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pericarditis; chronic kidney disease > stage 3 were not considered for participation. 
General exclusion criteria also entailed history of idiopathic oedema/capillary leak 
syndrome, myxedema, lymphatic obstruction; evidence of systemic inflammation at the 
time of study visit; active malignancy or any major hypercoagulable state or history of 
venous thrombosis/embolism on no ongoing anticoagulation; incapacity. Study 
procedure-specific exclusion criteria are listed below in the pertinent subsections.  
The eligibility and main visits were conducted in the morning, in a temperature-
controlled room, asking participants to refrain from caffeine and smoking, to fast for >8 
h (eligibility) or >4h from a light breakfast if prolonged fasting for the whole night and 
morning was deemed unfeasible/unsafe (main) and to avoid vasoactive (ACE 
inhibitors/ARBs, beta blockers, calcium channel blockers, nitrates) or diuretic 
medications on the morning of the visit.  
The study procedures included history/physical examination; full blood count, BNP, 
HbA1c and renal, liver and thyroid function; urinary albumin-to creatinine ratio 
(morning spot sample); simultaneous bilateral brachial and calf blood pressure 
measurement; two-dimensional echocardiography; flow-mediated dilatation; pulse 
wave velocity/analysis; venous occlusion strain gauge plethysmography and a gluteal 
skin punch biopsy.  
Participants without specific contraindication (e.g. ongoing anticoagulation) were 
offered to participate in an optional sub-study (Appendix 4) involving surgical 
collection of extra skin and subcutaneous fat tissue around the site of the punch biopsy 
for dissection of resistance arteries and/or molecular biology. 
7.2.2 Blood pressure measurement 
Participants underwent 3 consecutive bilateral simultaneous measurements of brachial 
artery blood pressure (BP) values with a calibrated oscillometric monitor after 5 





readings. Similar measurements were later performed on the calves, up to 3 times if 
tolerated. Mean blood pressure (MBP) was calculated as (0.33 × Systolic BP) + (0.67 × 
Diastolic BP); a difference > 3 mmHg in limb MBP between sides was accounted for in 
the calculation of arterial resistance to flow with plethysmography (see below).  
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Normotension as inclusion criterion for healthy controls was defined upon evidence of 
office BP < 140/90 mmHg, or confirmation by 24h ambulatory blood pressure 
monitoring for those who showed office BP values above such threshold, without any 
antihypertensive medication. 
7.2.3 Echocardiography 
Two-dimensional echocardiography with Doppler and tissue Doppler imaging was 
performed by a single operator during the eligibility visit, using a Siemens ACUSON 
SC2000 system. Cardiac structure and function were blindly quantified off-line at the 
end of the study, as recommended by the American Society of Echocardiography / 
European Association of Cardiovascular Imaging (Lang et al., 2015, Nagueh et al., 2016). 
7.2.4 Traditional non-invasive assessment of arterial function  
7.2.4.1 Brachial artery Flow Mediated Dilatation (FMD) 
FMD measurements were performed according to guidelines (Thijssen et al., 2011), 
during the eligibility visit, with a semi-automated device, as extensively detailed in 
Chapter 2 (2.3.2.3). Scans judged as non-diagnostic at the time of the eligibility visit (if 
intima-intima was not stably visible throughout the reading, in case of gross arm 
misplacements and/or overt failures of the probe position adjusting software) were 
repeated at the beginning of the main visit under the same conditions. All the images 
and automated outputs were manually reviewed and analysed with UNEX software off-
line at the end of the study. Outputs from any scan previously judged as non-diagnostic 
but rescued by off-line analysis were averaged with results from the second scan, if 
available. The analysis was conducted blind to the group allocation of scans. 
7.2.4.2 Pulse Wave Analysis (PWA) and Velocity (PWV) 
Pressure waveform analysis (PWA) and pulse wave velocity (PWV) measurement were 
performed during the main visit with a SphygmoCor XCEL System, in a supine 
position after 5 minutes of rest. Rationale for and details on use of PWA and PWV for 
vascular phenotyping have been discussed in Chapter 2.  
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For PWA, multiple sequential artery pressure waveforms were acquired from a 
dedicated brachial cuff and averaged into an ensemble, used by the software to derive 
and synthesize the central aortic pressure waveform parameters.  
For PWV, the carotid-femoral (cf) distance was calculated by the SphygmoCor 
software by subtraction method from the sternal notch to the top edge of the femoral 
(thigh) cuff and from the patient’s carotid measurement site to the sternal notch. Once 
the system detected a carotid pulse signal of valid quality from the tonometer, a 
femoral cuff was inflated and the cfPWV measurement started automatically. All 
measurements were taken consecutively in duplicate, whenever possible, and averaged. 
Inaccurate measurements, according to the automated quality control, were discarded. 
7.2.5 Plethysmography and microvascular fluid dynamics 
Rationale and approach for use of strain gauge plethysmography (EC6, Hokanson) to 
measure forearm and calf arterial blood flow (Φ), peripheral venous pressure (PV, as a 
surrogate for central venous pressure - CVP) and net fluid extravasation toward the 
interstitium at increasing venous occluding pressures have been extensively described 
in section 2.3.3 (Gamble et al., 1993, Wilkinson and Webb, 2001, Gamble, 2002, 
Stewart, 2003, Bauer et al., 2004). 
Briefly, patients were positioned almost supine. Measurements were performed in the 
non-dominant arm and ipsilateral calf, unless local contraindications/exclusion criteria 
(e.g. previous surgery or stroke, venous varices) applied. Limbs were maintained at the 
height of the right atrium. Inflatable cuffs for venous occlusion were placed proximal to 
the strain gauges. PV was determined by gradually increasing the occlusion pressure, 
sustained until any limb volume change was detected. Arterial blood flow was 
determined from the rate of change in limb volume after consecutive cycles of sudden 
venous occlusion to 45 mmHg, as described (Wilkinson and Webb, 2001). Arterial 
resistance to flow was calculated as (mean BP – PV)/blood flow (Stewart, 2003). To 
assess microvascular filtration parameters, we used cumulative 8 mmHg occluding 
pressure steps, lasting 3.5 minutes each and starting at the first multiple exceeding PV, 
up to a maximum of 56 mmHg or less if diastolic BP was lower. The time courses 
(slopes) of limb volume change (in ml/100ml of tissue) at each pressure step, after 
exclusion of the initial curvilinear phase corresponding to venous filling, was 
calculated off-line (LabChart) as the averaged first derivative from portions of tracing 
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devoid of motion artifacts, and corresponds to interstitial fluid accumulation. These 
slopes were plotted against Pcuff to determine the relationship between interstitial fluid 
accumulation and experimental increases in hydraulic pressure.  
Least-square fitting of at least 3 valid pressure points was used to identify these linear 
associations for each limb/participant, in order to determine the slope (microvascular 
filtration coefficient, Kf) and the intercept with the pressure axis (i.e. Pi; Figure 2-6), 
blindly to group allocation. Limbs with less than 3 points free of motion artefacts for 
regression fitting (Gamble et al., 1993, Mohanakumar et al., 2019) or with predefined 
limb-specific exclusion criteria were excluded from analysis.  
7.2.6 Surgical skin samples 
All participants (except for 1 patient, due ineffective topical anesthesia) underwent a 4-
mm skin punch biopsy on a gluteal external upper quadrant, after topical anesthesia 
with Na
+
-free lidocaine cream (LMX4, Ferndale) as described in Chapter 2.  
Surgical-specific exclusion criteria were allergy to lidocaine or chlorhexidine 
gluconate; chronic diffuse skin condition without uninvolved areas suitable for biopsy; 
history of keloid scar formation; known diagnosis of hepatitis B or C or HIV or decline 
to undergo a skin/gluteal biopsy. The excised skin sample was cut on the bench into 
two hemicylinders, each including both epidermis and dermis: one was fixed in 
paraformaldehyde 2% for 8-10h at room temperature, washed in phosphate-buffered 
saline (PBS) and stored in 70% ethanol at 4°C until paraffin inclusion for subsequent 
histological analyses; the second was immediately put into a pre-cooled Eppendorf 
tube, frozen in dry ice and stored at -80°C until tissue chemical analysis. 
Participants who were eligible and consenting also to an ex vivo sub-study, 
subsequently underwent a skin and subcutaneous fat biopsy (measuring approximately 
2.5 × 1 × 1.5 cm) on the same gluteal site, upon anaesthesia with subcutaneously-
injected lidocaine 2%. Predefined additional exclusion criteria for this procedure 
included ongoing treatment with warfarin or other anticoagulant medication or severe 
obstructive iliac artery disease. A small portion of the excised dermis and epidermis 
was immediately frozen in dry ice and stored at -80°C for molecular biology (n = 7 
HFpEF and 10 HC); the remaining available tissue was used to dissect small resistance 
arteries for ex vivo functional testing.  
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7.2.7 Ex vivo assessment of vascular function 
The protocol for the functional assessment of resistance arteries has been reported in 
Chapter 2, section 2.3.1. Briefly, small arteries were freshly dissected from fat/dermis, 
stored at 4°C in physiological saline solution overnight and, on the following day, cut 
into 2-mm ring segments, which were mounted on isometric wire myographs. Vessels 
with an internal diameter ³ 500 µm were excluded. (Mulvany and Aalkjaer, 1990, 
Heagerty et al., 1993) After normalization and assessment of viability by the addition 
of KCl (62.5mmol/L), endothelium-dependent and -independent relaxation was 




 M) or the nitric oxide 




 M), respectively, following pre-
constriction with the thromboxane agonist U46619 dose that produced 75% of the 
maximal contractile response.  
7.2.8 Skin histochemical analysis 




 tissue content analysis has already been described in 
Chapter 2 and is only briefly recollected here. Frozen skin samples were 
macroscopically transversally cut into a superficial layer (including the epidermis and 
the immediately adjacent superficial dermis; ESD) and a deeper dermis layer (DD) in a 
cold room, to prevent evaporation of moisture. Tissue water content was estimated by a 
gravimetric approach as wet weight (WW) – dry weight (DW), obtained after 
desiccation at 65°C for > 40 hours and assessed on a 5 decimal (0.00001 g) scale 




 were measured in the HNO3-digested samples 
by flame photometry (Sherwood scientific, 410C) and expressed as absolute content 
(mmol/gDW) or concentration (mmol/l, after normalization by tissue water). Flame 
photometry analysis was conducted blind to group allocation of samples.  
7.2.9 Skin microvascular immunofluorescence and image analysis 
Paraffin embedded skin sections (5-μm-thick) including both epidermis and dermis 
were mounted on Superfrost Plus Adhesion slides (Fisher Scientific UK Ltd), 
deparaffinized in xylene and rehydrated through baths of ethanol solutions (100% to 
50%) to dH2O. Sections from all participants were further processed in a single batch 
to maximize homogeneity of handling and staining. Antigen retrieval was performed by 
overnight incubation in Unitrieve (Innovex Biosciences) at 42°C; this approach was 
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preferred over high-temperature/pH-based approaches upon evidence of better 
preservation of dermal architecture in the SKILLS study (see section 2.2.3.1). After 
blocking in 15% donkey serum (D9663, Sigma) + Tween20 0.05% in TBS for 1h at 
room temperature, sections were incubated overnight at 4°C with a goat anti-human 
Lyve-1 antibody (AF2089, R&D systems) at a concentration of 3 μg/ml in TBS/15% 
serum; matched isotype goat IgGs (Vector laboratories) were used as negative controls. 
On the following day, sections were washed and incubated with Alexa-fluor-488-
conjugated donkey anti-goat IgG secondary antibody (2 μg/ml; Invitrogen) for 1h at 
room temperature and counterstained with Ulex europaeus agglutinin I (UEA-I) lectin 
conjugated to Rhodamine (RL-1062, Vector Laboratories), specifically binding 
glycoproteins and glycolipids on human endothelial cells (Holthofer et al., 1982), at a 
final concentration of 10 μg/ml in 1xTBS for 30 mins at RT. After treatment with 
Sudan Black 0.1% to minimize autofluorescence, slides were stained with DAPI (100 
μg/ml; Life technologies), mounted in ProLong Gold anti-fade mounting media 
overnight at room temperature and then stored at 4°C in the dark. 
Tiled images of the entire epidermal line and the sub-papillary dermis (≥ 2 mm of 
minimal imaged thickness), where the blood and lymphatic network are consistently 
located (Figure 7-1), were acquired at 20× magnification using an inverted 
epifluorescence microscope (Axio Observer Z1, Zeiss) and a dedicated software (Zen 
Blue Program, Zeiss). Laser excitation and acquisition settings were maintained 
constant across all slides. Automated image analysis for the quantification of 
microvessels was performed with ImageJ, blind to group allocation of samples. The 
600-μm-thick dermal area starting from the epidermis-dermis junction and spanning the 
entire length of the biopsy, with the exception of portions affected by gross 
mounting/staining artefacts, was manually identified and selected (Figure 7-1). After 
splitting RBG channels, a standardized threshold algorithm was used for vessel 




 area (as % of total selected 
dermal area); the stain intensity threshold was set to exclude nonspecific staining, 
including the faint and inconsistent lectin
+
 staining of lymphatic endothelium (Figure 
7-1). On thresholded images, microvascular density (n/tissue mm
2
) and size (μm
2
) were 
measured with the operator-independent ‘analyze particles’ command, without 
circularity constraints due to variability in the orientation of dermal microvessels. 
Dermal fat quantification was performed with ImageJ, after staining of additional 
sections from the same samples with Picrosirius Red for 1h. Adypocytes-occupied area 
was manually identified and expressed as % of total area for comparisons.  
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Figure 7-1. Immunofluorescence imaging analysis. 
Panel A: Representative tiled image of the entire epidermal line (nuclei in blue; DAPI) and dermis. 
Dense blood (lectin+, red) and lymphatic (lyve-1+, green) vascular networks were located close to skin 
annexes and in the subpapillary dermis. Panel B: the 600-μm-thick dermal area starting from the 
epidermis-dermis junction was selected as the region of interest (ROI, in yellow). The red (panel C, E, 
G) and green (panel D, F, H) channels were split to characterize blood and lymphatic vascular network 
anatomy, respectively, by standardized thresholding (E and F) and ‘analyse particles’ (G and H, count 
and %area of total ROI). Insert (*) at bottom: the stain intensity threshold for lectin was set to exclude 
the low and inconsistent lectin+ staining of lymphatic endothelium; scale bars = 100 μm.  
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7.2.10 Skin gene expression analysis 
Total RNA was extracted from the frozen skin samples from gluteal surgical biopsies 
(sub-study; n=17, 7 HFpEF and 10 HC) using QIAzol lysis reagent and RNAesy mini-
column kit (Qiagen) according to the manufacturer’s instructions. cDNA was generated 
from total RNA using the High-Capacity cDNA Reverse Transcription Kits (Applied 
Biosystems). After preamplification (TaqMan® PreAmp technology, Applied 
Biosystems) of target cDNA, a custom-made TaqMan® Array Card was used to 
perform quantitative gene expression of markers or growth/transcription factors 
specific to blood and/or lymphatic vessels, including: VEGF-A (Hs00900055_m1), 
VEGF-B (Hs00173634_m1), VEGFR1 (or FLT1; Hs01052961_m1), VEGFR2 (or 
KDR; Hs00911700_m1), VE-cadherin (Hs00901465_m1), Lyve-1 (Hs00272659_m1), 
Podoplanin (Hs00366766_m1), Prox-1 (Hs00896293_m1), VEGF-C 
(Hs01099203_m1), VEGFR3 (Hs01047677_m1). Real-time PCR was run with samples 
in duplicate in a QuantStudio™ 12K Flex System. Gene expression levels were 
compared and presented as ΔCt values, with β-actin (Hs99999903_m1) as 
housekeeping gene based on evidence of CT consistency between study groups. 
7.2.11 Statistical analysis 
No previous data on Kf were available in HFpEF or similar aged populations for formal 
power calculation. Based on the heterogeneity of HFpEF and data from different 
diseases (type 1 diabetes, POTS) (Jaap et al., 1993, Stewart, 2003) we estimated that a 
sample size of n = 20/group allowed sufficient power to detect the predicted difference 
in the coefficient of filtration (increase) and in isovolumetric pressures (decrease) 
between patients with HFpEF and age/sex-matched controls, as well as differences in 
skin Na
+
 based on pilot data in young healthy subjects (Chapter 6). After conclusion of 
the Ethics-approved duration of the study and recruitment of 16/20 subjects per group, 
an interim analysis was conducted. The results, herein presented, showed a trend for the 
coefficient of filtration opposite to what predicted and highly significant differences in 
isovolumetric pressure. Accordingly, recruitment was stopped for futility in relation to 
the primary hypothesis and no study extension was requested.  
Statistical analysis was performed using Prism (version 8, GraphPad Software) and 
SPSS (version 25, IBM). Categorical variables are presented as absolute numbers and 
percentages and compared by χ2 test. Continuous variables were tested for normality of 
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distribution by graphical plot and Kolmogorov-Smirnov test; they are presented as 
mean ± SD (or SEM when stated) or median (interquartile range), as appropriate. 
Parametric (t-student) or non-parametric (Wilcoxon) unpaired unadjusted tests were 
used for comparison of primary (microvascular) and secondary endpoints between 
groups, accordingly. The combined effect of time and group on shear rate during FMD 
was tested by two-way ANOVA; time-clusters for differences between curves were 
defined based on ³ 3 significant differences at consecutive timepoints based on 
multiple-t-test.  
Least square fit was used for both non-linear regression (ex vivo vascular function; 
log(agonist) vs. response, no slope constraint) and linear regression (Na
+
/water content 
in skin biopsies; interstitial fluid accumulation and calculations of Kf and Pi). 
Comparisons of curves for vascular function and skin Na
+
/water regression slopes was 
performed by the extra sum-of-squares F test. Correlations were assessed by Spearman 
test.  
The α level was set at 0.05 and all statistical tests were 2-tailed. 
7.3 Results 
7.3.1 Subject characterstics 
Between August 2017 and December 2018, 16 eligible subjects with HFpEF and 16 
healthy controls (HC) were recruited.  
Clinical characteristics of the two study groups are provided in Table 7-1.  
Patients with HFpEF and HC were similar for age and sex distributions. Patients with 
HFpEF showed typical characteristics, with high prevalence of hypertension, obesity, 
paroxysmal or permanent atrial fibrillation, left ventricular hypertrophy and signs of 
atrial remodelling and/or diastolic dysfunction (Table 7-2), diabetes and chronic kidney 
disease. Compared to HC, they had higher BNP, albuminuria and plasma urea, lower 
eGFR and haematocrit, but similar plasma albumin. 
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Table 7-1. HAPPIFY: group characteristics. 
Variables HC (n=16) 
HFpEF 
(n=16) p 
Females 11 (69%) 10 (63%) 0.710 
Age (years) 68 ± 5 72 ± 6 0.060 
BMI (kg/m2) 25.1 ± 2.9 33.9 ± 4.4 <0.001 
Overweight / Obese 8 (50%) / 1 (6%) 4 (25%) / 12 (75%) <0.001 
BSA (m2) 1.78 ± 0.21 2.00 ± 0.28 0.021 
SBP (mmHg) 130 ± 14 146 ± 21 0.017 
DBP (mmHg) 73 ± 8 71 ± 14 0.659 
HR (beats per minute) 60 ± 7 65 ± 16 0.256 
Left atrial volume index (ml/m2) 23.3 ± 6.1 46.8 ± 12.8 <0.001 
Left ventricular mass index (g/m2) 84.3 ± 17.9 127.8 ± 26.6 <0.001 
Left ventricular ejection fraction (%) 63.2 ± 3.5 60.8 ± 6.7 0.222 
E/e’ 8.0 ± 1.6 10.8 ± 2.9 0.001 
Comorbidities:    
Hypertension  - 15 (94%) <0.001 
Coronary artery disease - 3 (20%) 0.060 
Atrial Fibrillation - 11 (69%) <0.001 
Diabetes mellitus - 7 (44%) 0.003 
Chronic kidney disease  - 7 (44%) 0.003 
Smoking (current/prior)  0 (0%) / 2 (13%) 3 (19%) / 7 (44%) 0.011 
Medications    
ACEi/ARB - 14 (88%) <0.001 
BB - 14 (88%) <0.001 
CCB - 3 (19%) 0.069 
Diuretic (loop/thiazide) - 15 (94%) / 1 (6%) <0.001 
MRA - 1 (6%) 0.310 
Long-acting nitrates - 2 (13%) 0.144 
Statin - 8 (50%) 0.001 
Digoxin - 5 (31%) 0.015 
Aspirin - 4 (25%) 0.033 
Anticoagulation - 7 (44%) 0.003 
Na+ 140 (139-142) 140 (136-142) 0.361 
K+ 4.5 (4.2-4.7) 4.2 (4.0-4.7) 0.224 
Urea (mmol/l) 5.5 (4.7-6.0) 6.4 (5.9-9.8) 0.007 
Creatinine (umol/l) 71 (59-84) 79 (67-90) 0.138 
eGFR (CKD-EPI; mL/min/1.73 m2) 81.7 ± 11.0 70.9 ± 17.0 0.042 
Urinary ACR (mg/gCr) 4.8 (3.2-6.1) 33.9 (10.7-87.4) 0.001 
Haemoglobin (g/l) 145 ± 8.8 133 ± 17 0.022 
Haematocrit (%) 44.1 ± 2.5 40.5 ± 4.7 0.013 
Albumin 39.3 ± 3.1 37.8 ± 2.7 0.155 
BNP (pg/ml) 24 (16-32) 170 (93-320) <0.001 
Data as n (%) for qualitative variables and mean ± SD or median (interquartile range) for normally 
distributed or skewed quantitative variables, respectively. BMI = Body Mass Index. BSA = Body 
Surface Area (Mosteller). SBP and DBP = office systolic and diastolic blood pressure. E/e’ = average of 
septal and lateral velocity ratio. HR = heart rate. Chronic kidney disease defined as eGFR <60 
mL/min/1.73 m2.  ACEi/ARB = ACE inhibitors or Angiotensin receptor blockers. CCB = calcium 
channel blockers. BB = beta blockers. MRA = mineralocorticoid receptor antagonists.  
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Table 7-2. HAPPIFY: echocardiographic characteristics. 
Variables HC (n=16) 
HFpEF 
(n=16) p 
Diastolic septal wall thickness (cm) 1.0 ± 0.2 1.3 ± 0.2 <0.001 
Diastolic posterior wall thickness (cm) 1.0 ± 0.1 1.3 ± 0.2 <0.001 
LV mass index (g/m2) 84.3 ± 17.9 127.8 ± 26.6 <0.001 
LV end-diastolic volume index (ml/m2) 41.3 ± 10.0 44.2 ± 6.9 0.367 
LV end-systolic volume index (ml/m2) 15.2 ± 4.1 17.0 ± 4.3 0.140 
LV ejection fraction (%) 63.2 ± 3.5 60.8 ± 6.7 0.222 
LA volume index (ml/m2) 23.3 ± 6.1 46.8 ± 12.8 <0.001 
E velocity (cm/s) 68.1 ± 14.7 89.8 ± 25.6 0.006 
A velocity (cm/s; SR only) 78.3 ± 15.1 76.8 ± 29.8 0.865 
E/A ratio (SR only) 0.9 ± 0.2 1.2 ± 0.5 0.198 
LV e’ velocity – average (cm/s) 8.6 ± 1.9 8.7 ± 1.6 0.900 
LV e’ velocity – average (cm/s; SR only) 8.6 ± 1.9 7.3 ± 0.7 0.022 
LV a’ velocity – average (cm/s; SR only) 11.8 ± 2.0 8.7 ± 2.9 0.009 
LV s’ velocity – average (cm/s) 8.1 ± 1.2 7.4 ± 1.2 0.142 
LV E/e’ ratio – average  8.0 ± 1.6 10.8 ± 2.9 0.001 
LV E/e’ ratio – average (SR only) 8.0 ± 1.6 11.3 ± 3.2 0.025 
TV regurgitation velocity (m/s) 2.1 ± 0.1 2.6 ± 0.5 0.005 
Data presented as n (%) or mean ± SD. LV = left ventricle. LA = left atrium. SR = sinus rhythm at the 
time of exam (n=8). LV tissue Doppler values are avg of septal and lateral values. TV = tricuspid valve.  
7.3.2 Arterial function:  
7.3.2.1 Traditional in-vivo assessment   
PWA revealed no difference in augmentation pressure or augmentation index between 
study groups, likely due to the age range investigated and the tendency of these 
parameters to reach a plateau above the age of 50, at variance with pulse wave velocity 
(McEniery et al., 2005). In fact, cfPWV was higher in HFpEF compared to HC (Table 
7-3; in 3 study subjects no valid measurements could be obtained: 2 HFpEF, 1 control). 
Patients with HFpEF also showed an impairment in brachial flow-mediated dilatation, a 
measure of endothelial dysfunction, but defective vasorelaxation was accompanied by a 
reduced stimulus to such response, i.e. post-ischemic shear rate (Pyke and 
Tschakovsky, 2005): reactive hyperaemia relative to baseline was overall lower (2-way 
ANOVA, p < 0.001) and had a different profile with early divergence and delayed 
time-to-peak compared to HC (Table 7-3 and Figure 7-2).  
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Table 7-3. HAPPIFY: macrovascular function. 
Variables HC (n=16) 
HFpEF 
(n=16) p 
Pressure Waveform Analysis     
Brachial SBP (mmHg) 129 ± 14 151 ± 28 0.010 
Brachial DBP (mmHg) 75 ± 6 78 ± 14 0.382 
Central Aortic SBP (mmHg) 120 ± 12 137 ± 25 0.022 
Central Aortic DBP (mmHg) 76 ± 6 80 ± 15 0.385 
Central Aortic PP (mmHg) 44 ± 10 58 ± 22 0.037 
HR (beats per minute) 61 ± 6 67 ± 12 0.171 
Augmentation Pressure (mmHg) 16 ± 6 19 ± 9 0.258 
Augmentation index @75 (%) 29.3 ± 9.5 28.2 ± 9.1 0.727 
Carotid-femoral Pulse Wave Velocity (m/s) 6.8 ± 1.1 8.6 ± 1.3 0.001 
Brachial artery Flow-Mediated Dilatation     
Rest internal diameter (mm) 3.78 ± 0.50 3.94 ± 0.67 0.438 
Maximal internal diameter (mm) 3.99 ± 0.53 4.13 ± 0.70 0.538 
FMD (mm) 0.21 ± 0.06 0.15 ± 0.08 0.033 
FMD (% rest) 5.6 ± 1.5 3.9 ± 2.1 0.014 
Peak shear rate (× rest) 6.7 ± 1.7 4.6 ± 1.6 0.002 
Time-to-peak shear rate (sec) 7.6 ± 2.8 10.9 ± 5.4 0.041 
Data presented as mean ± SD. SBP and DBP = systolic and diastolic blood pressure; PP = pulse pressure. 
HR = heart rate. Augmentation index @75 = HR-corrected augmentation index, assuming HR= 75 bpm.  
 
Figure 7-2. Peripheral arterial function assessed in vivo. 
Left panel: endothelium-dependent brachial artery flow-mediated dilatation (FMD, expressed as 
percentage change from baseline) was reduced in patients with HFpEF (red) compared to healthy 
controls (HC, B/W). Right panel: shear rate imposed on the endothelial surface of the vascular wall 
during the post-ischemia hyperaemic flow response (i.e. reactive hyperaemia relative to baseline) was 
also reduced HFpEF compared to HC. Vertical and horizontal black capped lines identify differences in 
magnitude of and time to peak shear rate, respectively, between groups. Inset: influence of time, group 
and interaction on hyperaemic response curve profile (2-way ANOVA). All figure data are presented as 
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7.3.2.2 Direct ex-vivo assessment   
In keeping with post-ischemic reactive hyperaemia, subcutaneous resistance arteries of 
patients with HFpEF showed a reduced ex-vivo endothelium-mediated response to 
Ach, as evident from a right-shift in the relaxation curves compared to HC (Log IC50 
(M) = -7.045 [95% CI: -7.072 to -7.021] vs -7.565 [-7.603 to -7.527], p < 0.001; sub-
study, n = 6 subjects/group; Figure 7-3), particularly impacting the concentration range 
of the curve that is physiologically critical to flow autoregulation (grey area in Figure). 
Also maximal endothelial-independent relaxation to the NO donor SNP was reduced in 
HFpEF (22.0 [18.8 to 24.9]% vs 3.9 [-2.6 to 9.2]% of U46619-induced pre-
constriction, p < 0.001), although the response was similar to HC for most of the 
autoregulation physiological range (Figure 7-3). Originally planned comparisons with 
vessels incubated in hypertonic Na
+
, as done for rats (Figure 5-13), were limited by the 
number of viable dissected vessels. 
 
Figure 7-3. Peripheral arterial function assessed ex vivo. 
Left panel: endothelium-dependent relaxation to a cumulative concentration curve of acetylcholine 
(Ach), expressed as percentage of U46619-induced pre-constriction. Subcutaneous resistance arteries of 
patients with HFpEF showed reduced vasodilation, shown by the right-shift in the HFpEF curve 
compared to HC: concentrations of Ach required for autoregulation of peripheral blood flow were ~5 
times higher in HFpEF than controls. Right panel: endothelium-independent relaxation to a cumulative 
concentration curve of sodium nitroprusside (SNP), expressed as percentage of pre-constriction, 
revealing a lower maximal relaxation to SNP in HFpEF. Grey areas highlight the steepest portions of the 
curves (and relative Ach or SNP concentration ranges, accordingly), critical for fine-tuned peripheral 
modulation of arterial resistance and flow autoregulation. Horizontal and vertical and black capped lines 
identify differences in IC50 and maximal relaxation, respectively, between groups. All data are shown as 
mean ± SEM; n = 6/group. Vessels from four additional subjects were excluded due to lack of viable 
vessels [n=2 HC], unsuitable vessel size [n=1 HC] or spontaneous vasomotor activity generating early 
loss of vascular tone after pre-constriction, at doses of Ach or SNP unable to physiological induce 
relaxation in either group and automatically identified as outliers (Log EC50 Ach: -9.00; ROUT method, 
Q = 1%), possibly due to vessel damage in the mounting process [n=1 HFpEF]. * p<0.05 
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7.3.3 Skin salt  
Water content (%WW - or mg/mgDW, not shown), Na+ concentration (mmol/L of 
water) and total Na
+
 content (mmol/gDW) in the epidermis/superficial dermis (ESD) 
were similar between HFpEF and HC (Figure 7-4, A). In the deeper dermis (DD), 
water and Na
+
 content were lower in HFpEF than HC (Figure 7-4, B) in keeping with 
the distribution of BMI and dermal fat (Figure 7-4, C).  
 
Figure 7-4. Chemical analysis of the skin. 
Panels A and B: water content, Na+ content, Na+ concentration and (Na+ + K+) concentration in the outer 
(epidermis and superficial dermis, ESD) and the inner (deep dermis, DD) layers of the skin biopsies. 
Panel C: representative skin sections from a control and a HFpEF subject (picrosirius red staining); 
dashed line: cutting plane for separation of ESD and DD; black-circled areas represent dermal fat, 
quantified in the sections as % of biopsy area and more abundant in patients with HFpEF than controls. 
All data presented as mean ± SD; * p<0.05, **p<0.01. Panel D: association between Na+ and water 
content, including both ESD and DD values; the slope of the regression line was similar between study 
groups. 
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As previously discussed (chapters 5 and 6 for both rats and hypertensive subjects), fat 
limits the volume of distribution of both water and electrolytes in the tissue, while 







concentrations, i.e. upon content normalization for water, were similar between groups, 
as in ESD. Both water and Na
+
 content in the dermis were inversely associated with 
dermal fat content, semi-quantitatively assessed by fat-occupied % of biopsy area in 
histology sections (Spearman r = -0.415, p = 0.020 and r = -0.431, p = 0.016, 
respectively). No differences were found in the slope of the associations at extra sum-




 concentration consistently fell within 
a physiological range (140-155 mmol/l) in both layers. Likewise, the slope of the 
regression line for skin water and Na
+
 content did not differ by group (p=0.810; Figure 
7-4, D) or tissue layer (ESD vs DD, p=0.922; not shown).  
These histochemical data were further contrasted with those from the SOWAS study 
(please see section 6.2.1.2 and Table 7-4 below), where gluteal skin biopsies, sample 
processing and analysis where conducted with identical approach in young healthy 
subjects (Y-HC).  
Table 7-4. Characteristics of young healthy subjects, for contrast. 
 SOWAS  HAPPIFY 





Females 11 (64.7%) 11 (68.8%) 10 (62.5%) 
Age (years) 25 ± 5 68 ± 5 72 ± 6 
BMI (kg/m2) 23.8 ± 2.9 25.1 ± 2.9 33.9 ± 4.4 
BSA 1.80 ± 0.25 1.78 ± 0.21 2.00 ± 0.28 
SBP (mmHg) 112 ± 9 130 ± 14 146 ± 21 
DBP (mmHg) 64 ± 8 73 ± 8 71 ± 14 
HR (beats per minute) 67 ± 10 60 ± 7 65 ± 16 
Na+ (mmol/l) 140 (140-141) 140 (139-142) 140 (136-142) 
K+ (mmol/l) 4.2 (4.1-4.5) 4.5 (4.2-4.7) 4.2 (4.0-4.7) 
Urea (mmol/l) 4.8 ± 1.2 5.5 (4.7-6.0) 6.4 (5.9-9.8) 
Creatinine (umol/l) 75 ± 13 71 (59-84) 79 (67-90) 
eGFR (CKD-EPI; mL/min/1.73 m2) 106 ± 16 81.7 ± 11.0 70.9 ± 17.0 
urinary ACR (mg/gCr) 4.7 (2.2-10.5) 4.8 (3.2-6.1) 33.9 (10.7-87.4) 
Data presented and abbreviations as per Table 7-1. Due to excess male participants in the original 
SOWAS cohort (n=18) compared to HAPPIFY, for this comparison sex-matching was achieved by 
random selection of 6/18 males (via randomly generated sequences). The 11 females were in the early 
follicular phase of their menstrual cycle, just after period termination. 
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While formal statistical comparison across different studies does not seem appropriate, 
Y-HC had a lower BMI, lower SBP and higher DBP, and higher estimated GFR 
compared to both HAPPIFY groups. Histochemical comparisons (Table 7-5) revealed:  
1. an increase in water and Na+ content (in ESD) and Na+ concentration (in both 
ESD and DD), as well as the decrease in K
+
 content and concentration (in both 
ESD and DD), in the old compared to young subjects; this is consistent with 
histological changes associated with ageing already described in chapter 6 
(section 6.3.2)  
2. a decrease in DD water and Na+ content across groups, consistent with BMI 
distribution (Table 7-4) as a surrogate for subcutaneous fat; 
3. the similar total cationic (Na++K+) concentration across groups. 
Table 7-5. Skin chemical analysis, contrasted with young healthy subjects. 







Epidermis / Superficial Dermis (ESD) 
Water content (%WW) 70.6 ± 1.3 72.0 ± 1.0 71.3 ± 1.4 
Na⁺ content (μmol/gDW) 264 ± 18 304 ± 21 296 ± 33 
Na⁺ concentration (mmol/l) 109.9 ± 4.9 118.1 ± 6.2  118.6 ± 7.4 
K⁺ content (μmol/gDW) 99 ± 12 90 ± 12 75 ± 10  
K⁺ concentration (mmol/l) 41.0 ± 4.6 34.7 ± 4.3 30.3 ± 4.0 
Na⁺ + K⁺ concentration (mmol/l) 150.9 ± 6.4 152.7 ± 7.0 150.0 ± 6.2 
Deep Dermis (DD) 
Water content (%WW) 65.6 ± 3.8 61.7 ± 4.6 56.0 ± 5.8  
Na⁺ content (μmol/gDW) 228 ± 39 206 ± 43 162 ± 47  
Na⁺ concentration (mmol/l) 117.4 ± 7.2 125.1 ± 8.3 125.2 ± 10.9 
K⁺ content (μmol/gDW) 49 ± 13 34 ± 8 22 ± 3 
K⁺ concentration (mmol/l) 24.9 ± 4.2 20.4 ± 2.9 17.2 ± 2.9 
Na⁺ + K⁺ concentration (mmol/l) 142.4 ± 7.3 145.5 ± 9.5  142.1 ± 11.3 
Data presented as mean ± SD. WW = wet weight; DW = dry weight. 
In summary, the concentration of Na
+
 in the skin of patients with HFpEF was high 
when contrasted to a previously reported cohort of young healthy subjects, but was 
accompanied also by higher water content and both were not different from skin values 
of healthy controls of similar age distribution. Overall, no evidence of any hypertonic, 
water-independent accumulation of Na
+
 was found in the skin of patients with HFpEF.  
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7.3.4 Rarefaction of skin microvessels and gene expression 
7.3.4.1 Blood microvessels 
Patients with HFpEF had dermal rarefaction of blood microvessels compared to HC (p 
= 0.003; Figure 7-5), independent of age (Spearman correlation with number of vessels: 
r= -0.141, p = 0.449).  
No significant difference was observed in the size of skin vessels or in the gene 
expression of vascular endothelial growth factors A and B (VEGF-A, VEGF-B) and 
their blood-vessel specific receptors (VEGFR1 and VEGFR2); the expression of VE-
cadherin, present in both blood and lymphatic vessels, was not different either (Figure 7-6). 
7.3.4.2 Lymphatic microvessels 
Lymphatic vessels were similarly reduced in number (p = 0.012) but were larger (p = 
0.007) in HFpEF compared to HC (Figure 7-5). Neither number nor average vascular 
size showed significant associations with age (r = -0.009, p = 0.963 and r = 0.307, p = 
0.099).  
 
Figure 7-5. Skin microvascular anatomy. 
Skin microvascular anatomy assessed as density (number of vessels/mm2 tissue), average cross-sectional 
area of the vessels (avg size; µm2) and total stain+ area (expressed as percentage of the dermal area) of 
the vessels identified in the section. Blood vessels (BV; Panel A) showed a reduction in number and total 
area+; lymphatic vessels (LV; Panel B) were reduced in number but on average larger in size in patients 
with HFpEF compared to HC. Panel C: representative sections, showing blood vessels (lectin+, red) and 
lymphatic vessels (lyve-1+, green); arrowheads: small terminal lymphatic vessels, reduced in HFpEF 
compared to HC; larger vessels appeared unaffected; scale bar at bottom right = 200 μm. All data are 
presented as mean ± SD; *p<0.05, **p<0.01. 
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In patients with HFpEF, skin prospero homeobox protein 1 (Prox-1, a LEC-specific 
transcription factor driving development and dynamic maintenance of lymphatic 
vessels and valves (Srinivasan and Oliver, 2011, Cha et al., 2018)) and lymphatic 
vessel endothelial hyaluronan receptor 1 (Lyve-1, a marker of lymphatic endothelial 
cells expressed since the most initial vessels), but not Podoplanin (a glycoprotein 
generally expressed in the endothelium of lymphatic vessels above a certain diameter 
(Henri et al., 2016)), were reduced compared to HC. Vascular endothelial growth factor 
C (VEGF-C) showed a similar trend (p = 0.06), but the expression of its lymphatic-
specific receptor VEGFR3 did not differ between groups (Figure 7-6).  
 
Figure 7-6. Skin microvascular gene expression. 
Panel of gene expressions, presented as ΔCt (the higher the value, the lower the gene expression; β-actin 
as housekeeping gene); coloured bars on top to indicate blood (red), lymphatic (green) or mixed vascular 
specificity; x = automatically detected outlier (ROUT = 1%, GraphPad Prism). All data are presented as 
mean ± SD; *p<0.05, ***p<0.001. 
In summary, both structural and molecular skin lymphatic alterations were detected in 
patients with HFpEF.  
7.3.5 Microvascular fluid dynamics 
Patients with HFpEF had forearm and calf mean blood pressure, rest limb blood flow 
(normalized for ml of tissue) and arterial resistance similar to HC; at variance, their rest 
peripheral venous pressure (PV) was higher, although not to values suggestive of overt 
decompensation (Table 7-6). 
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Table 7-6. Microvascular dynamics. 
Variables HC (n=16) 
HFpEF 
(n=16) p 
FOREARM    
Mean arterial pressure  
(mmHg) 92 ± 7 94 ± 12 0.529 
Blood flow  
(ml×100ml of tissue-1×min-1) 1.9 ± 0.8 1.9 ± 0.9 0.992 
Arterial peripheral resistance  
(mmHg/ml×100ml tissue-1×min-1) 50.1 ± 14.5 56.3 ± 29.5 0.459 
Venous pressure  
(mmHg) 5 (4-6) 8 (7-10) <0.001 
Filtration coefficient, Kf  
(µl×100ml of tissue-1×min-1×mmHg-1) 5.66 (4.69-8.38) 5.16 (3.86-5.43) 0.234 
Isovolumetric Pressure, Pi  
(mmHg) 25 ± 5 17 ± 4 <0.001 
CALF    
Mean arterial pressure 
(mmHg) 94 ± 8 96 ± 14 0.555 
Blood flow 
(ml×100ml of tissue-1×min-1) 3.3 ± 1.6 3.6 ± 1.4 0.573 
Arterial peripheral resistance  
(mmHg/ml×100ml tissue-1×min-1) 33.1 ± 15.4 29.3 ± 11.8 0.459 
Venous pressure  
(mmHg) 5 (4-5) 7 (7-9) <0.001 
Filtration coefficient, Kf  
(µl×100ml of tissue-1×min-1×mmHg-1) 4.66 (3.70-6.15) 3.30 (2.33-3.88) 0.008 
Isovolumetric Pressure, Pi  
(mmHg) 22 ± 4 16 ± 4 0.003 
Data presented as mean ± SD or median (interquartile range) and compared with t-test or Mann-Whitney 
U test, as appropriate. 
Because of motion artefacts, 3 forearm (n=1 HFpEF, n=2 HC) and 4 calf (n=3 HFpEF, 
n=1 HC) tracings were excluded from the analysis of microfiltration; one additional 
calf tracing from a patient with HFpEF was excluded as per procedure-specific 
exclusion criteria (overt bilateral venous insufficiency).  





), induced with progressively higher PV by stepped inflations of proximal cuffs, 
was not increased in patients with HFpEF above HC as initially predicted.  
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In fact, the slope of the regression line between interstitial fluid accumulation and cuff 
pressure was lower in HFpEF compared to HC in the calf (microvascular filtration 
coefficient, Kf = 3.30 (2.33-3.88) vs 4.66 (3.70-6.15) µl × 100ml of tissue-1 × min-1 × 
mmHg
-1
, p = 0.008); a similar non-significant trend was observed in the forearm (5.16 
(3.86-5.43) vs 5.66 (4.69-8.38) µl × 100ml of tissue-1 × min-1 × mmHg-1; Table 7-6 and 
Figure 7-7). However, patients with HFpEF also showed a reduced isovolumetric 
pressure (Pi; calf: 16 ± 4 vs 22 ± 4 mmHg, p = 0.003; forearm: 17 ± 4 vs 25 ± 5 mmHg, 
p < 0.001): in the HAPPIFY in vivo experimental setting, this reflects the critical 
pressure up to which lymphatic drainage can fully compensate for the continuous 
extravasation of fluid at even low PV and no net interstitial fluid accumulation occurs 
(i.e. the intercepts of the lines with x axis, Figure 7-7).  
 
Figure 7-7. Microvascular fluid dynamics. 
Net accumulation of interstitial fluid at different hydraulic pressures (P), at which cuffs were inflated to 
oppose venous drainage in the forearm (left panel) and the calf (right panel). Each regression line 
corresponds to a participant. The slope of the lines is the microvascular coefficient of filtration (Kf; 
please see table 7-6). Red lines (HFpEF) intersect the x axis at lower pressures compared to black lines 
(HC; scale magnification below): the intersect indicates the threshold above which interstitial fluid 
accumulation starts to develop (isovolumetric pressure, Pi). Data presented as mean ± SD; **p<0.01, 
***p<0.001. 
In summary, the clearance of interstitial fluid fails early to meet demands imposed by 
the capillary extravasation induced by hydraulic (venous) pressure in HFpEF. 
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7.4 Discussion 
For the first time in the understanding of HFpEF, the HAPPIFY study extended the 
concept of microvascular dysfunction to the lymphatic system. As predictable in 
retrospect, based on the results of the previous studies in rat models and hypertensive 
patients (chapters 5 and 6, respectively), I failed to identify any tissue Na
+
 hypertonic 
excess to facilitate oedema or drive peripheral arterial dysfunction. However, I showed 
that the lymphatic vessels of patients with HFpEF exhibit structural and molecular 
alterations in the skin and cannot effectively compensate for fluid extravasation and 
interstitial accumulation by commensurate drainage. Along with direct ex-vivo 
evidence of primary dysfunctional small subcutaneous resistance arteries and 
rarefaction of skin blood vessels, as already described in myocardium (Mohammed et 
al., 2015) and in skeletal muscle (Kitzman et al., 2014, Kitzman et al., 2015), this 
functional and structural vascular impairment further supports the systemic nature of 
HFpEF syndrome (Kitzman et al., 2015).  
7.4.1 Rarefaction of microvessels 
Impaired vasodilatation is an established characteristic of patients with HFpEF and 
contributes to exercise disability (Borlaug et al., 2006). In the HAPPIFY study, this 
was confirmed not only by classical indirect approaches like brachial FMD and post-
ischemic reactive hyperaemia, but also by the first ex vivo analysis of vascular 
endothelium-dependent (via Ach) and -independent (via SNP) relaxation of systemic 
resistance arteries (Figures 7-2 and 7-3).  
In vivo, however, any hyperaemic flow response is critically affected also by the 
number of ultimate effectors, i.e. vessels, as demonstrated by experimental disruption 
of coronary microvasculature in pigs (Fearon et al., 2003). In patients with HFpEF, the 
reduced coronary microvascular density found in autopsy samples (Mohammed et al., 
2015) is likely to cause pathological heterogeneity and mismatch in blood 
supply/demand (Pries and Reglin, 2017), thus impairing myocardial O2 extraction and 
performance. Similarly, exercise capacity in HFpEF is further reduced by low 
peripheral O2 extraction and skeletal muscle capillary density (Haykowsky et al., 2011, 
Dhakal et al., 2015, Kitzman et al., 2014). 
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Here I showed that rarefaction of blood microvessels in HFpEF occurs also in the skin, 
by far the largest human organ and key in the regulation of body haemodynamics. On 
the other hand, and at variance with the above largely ‘arteriocentric’ paradigms, my 
findings prompt reconsideration of the role of microvasculature as a whole, to include 
functions other than vascular resistance homeostasis and structures other than arteries 
in HFpEF pathogenesis. 
7.4.2 Interstitium, microvasculature and congestion in HFpEF 
Congestion, i.e. oedema, is central to HF syndrome (Pfeffer et al., 2019) but to the best 
of my knowledge this study was the first to investigate the fine capillary-interstitium 
fluid homeostasis in HFpEF.  
As extensively discussed in the previous chapters, over the last decade excess Na
+
 has 
been reported in the skin and skeletal muscle of aged hypertensive patients (Kopp et al., 
2013), in diabetes (Karg et al., 2018) and CKD (Schneider et al., 2017). This 
phenomenon had been described in rodents as water-independent (Titze et al., 2003) 
and capable of stimulating a lymphangiogenic signalling pathway to increase the 
drainage of tissue Na
+
 itself (Machnik et al., 2009). Although a direct demonstration in 
HFpEF was missing, all the above are typical comorbidities of patients with the 
syndrome and I originally hypothesised that hypertonic Na
+
 accumulation could drag 
excess fluid out of vessels and thereby favour oedema.  
Whilst the concentration of Na
+
 in the skin of patients with HFpEF was high when 
contrasted to a cohort of young healthy subjects (SOWAS, it was accompanied also by 
higher water content and was not different from controls of similar age distribution, 
likely reflecting the lack of overt decompensation of HF and oedema in a non-
dependent site in our cohort of patients with HFpEF. The excess Na
+
 and water content 
in the skin of our participants compared to young healthy subjects is reminiscent of the 
age-dependent isotonic Na
+
 retention observed also in the S2ALT study in 
uncomplicated hypertensive patients (Chapter 6) and reflects the expansion of the 





between study groups rules out any hypertonic Na
+
 excess.  
Accordingly, and contrarily to my initial expectations, the rate of tissue fluid 
accumulation induced by increasing hydraulic pressures (i.e. the microvascular 
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filtration coefficient, Kf) was not higher in HFpEF compared to HC. In keeping with 
the dependence of Kf on the vascular surface available for fluid exchange and with the 
rarefaction of blood vessels observed in HFpEF, it actually was lower (Figure 7-8). It is 
possible that blood flow in HFpEF, similar to HC when normalised by limb volume 
(Table 7-6), was partially diverted from exchanging capillaries to functional shunting 
(Pries and Reglin, 2017); in other conditions characterized by increase in local blood 
flow, e.g. postural tachycardia syndrome, Kf was elevated (Stewart, 2003). 
At variance with ex vivo preparations, the in vivo plethysmographic approach 
accounted not only for the capillary fluid extravasation regulated by Starling-Landis 
balance, but also for the simultaneous fluid drainage out of the tissue. In fact, 
contemporary direct measurements of the hydraulic and oncotic interstitial forces 
revealed that under most conditions there is no sustained reabsorption of interstitial 
fluid at the venous end of the capillary beds, that transvascular flow is generally 
unidirectional (from the capillary lumen to the interstitium) and that drainage, up to 
8L/day, is provided by lymphatics (Levick and Michel, 2010; please see also chapter 
1). Under the assumption that the osmotic pressure of albumin (σΠ) was similar 
between study groups, based on similar plasma concentrations, the equilibrium 
hydraulic pressure above which net extravasation of fluids starts to overfill the 
interstitium (i.e. generate oedema) is mostly determined by lymphatic drainage. The 
results of the HAPPIFY study showed that this pressure (Pi) was lower in HFpEF 
compared to HC in both arms and legs. A lower Pi and a higher central venous pressure 
(CVP, as one can estimate by peripheral venous pressure values in Table 7-6) leaves 
HFpEF patients with a much lower range of pressures that can be compensated for by 
their lymphatics.  
In other words, they appear to have reduced ‘lymphatic reserve’ (Figure 7-8).  
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ß Figure 7-8. Microvascular fluid dynamics and reduced lymphatic reserve in HFpEF. 
In healthy subjects, the fluid filtering out of the capillary bed of the blood vasculature (BV) is evenly 
balanced by commensurate fluid drainage by lymphatic vessels (LV); as a result, the physiological 
amount of interstitial fluid (IF) is homeostatically preserved. In HFpEF, the net fluid extravasation tends 
to be lower because of the reduced vascular surface available for fluid exchange (i.e. capillary 
rarefaction) and the possible diversion of blood flow (Φ) toward arteriovenous (AV) shunts (Pries and 
Reglin, 2017); however, drainage by the impaired lymphatic system is inadequate to meet demands and 
facilitates accumulation of interstitial fluid at lower venous pressures. Both anatomical and functional 
defects (dashed green) could explain the reduced lymphatic reserve. 
7.4.3 The lymphatic system in HFpEF 
Lymphatic vessels are organized into a series of coordinated functional units, each 
called lymphangion, separated by intraluminal one-way valves and capable of 
spontaneous pumping activity, as discussed in Chapter 1. Their physiology has striking 
similarities with heart function, namely a systole-diastole cycle and a contractility 
modulated by pre- and after-load, conferring remarkable plasticity in response to 
increased requirements (Scallan et al., 2016). The complexity of contractile machinery, 
valvular function and electromechanical coordination suggests that also functional 
impairment, rather than the sole anatomical severance traditionally implicated in most 
secondary lymphatic disorders, could contribute to disease whenever an imbalance 
develops between microvascular filtration and lymphatic drainage.  
It has indeed been suggested that all “chronic oedema could be considered as 
synonymous with lymphedema” (Mortimer and Rockson, 2014), intended as relative 
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lymphatic failure or inadequate reserve. The functional results of the HAPPIFY study 
support this contention in HFpEF.  
The morphological changes observed in skin lymphatics, with rarefaction of terminal 
capillaries and larger residual vessels, as well as the reduced gene expression of factors 
important for lymphangiogenesis and valve/vascular integrity maintenance (Srinivasan 
and Oliver, 2011, Cha et al., 2018), offer only preliminary clues as to what sustains the 
functional defect observed in HFpEF. In particular, I cannot conclusively identify cause 
and effect. Based on the study results I can only speculate as to whether a constitutive 
defect or a limited functional reserve of the lymphatic system is a primary predisposing 
factor toward an overt clinical syndrome when additional insults occur (i.e. 
comorbidity-driven chronic inflammation and/or elevated CVP) or, vice-versa, a result 
of their long-term, potentially additive  detrimental effects (Escobedo and Oliver, 2017, 
Scallan et al., 2015). The latter, i.e a consequence of comorbidities and of target organ 
damage with diastolic dysfunction, would be in keeping with morphological changes 
and impaired maximal lymphatic pumping capacity reported in patients with a Fontan 
circulation, in whom chronically increased CVP would induce initial compensation of 
the afterload but long-term failure (Mohanakumar et al., 2019). Conversely, an 
underlying predisposing defect would remind of cases with secondary lymphedema, 
where systemic alterations in lymphatic drainage precede the clinical onset of 
lymphedema and affect also the contralateral limbs (Stanton et al., 2009, Burnand et al., 
2012). Detection of lymphatic impairment also in the upper limbs, where not even trace 
oedema was detectable in either group compared to the calves or ankles of some of our 
patients with HFpEF, suggests a systemic nature of the phenomenon, although 
involvement of other organ-specific microvascular beds remains to be investigated. 
Regardless of ‘which-comes-first’, reduced capacity of the lymphatic system to prevent 
or minimize development of oedema could mark the clinical and prognostic distinction 
between patients with uncomplicated comorbidity and those presenting as HFpEF 
(Campbell et al., 2012). Moreover, by targeting oedema and its 
dysfunctional/inflammatory implications, improving lymphatic function could improve 
quality of life, muscle performance and exercise tolerance, disrupt vicious 
inflammatory cycles and reduce the need or dose of diuretic treatment to maintain 
sustained decongestion. Of note, although routinely impractical in its surgical 
approach, successful external thoracic duct drainage in advanced heart failure has 
already shown therapeutic promise as a proof-of-concept (Witte et al., 1969). 
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7.4.4 Limitations 
In addition to the aforementioned lack of causality demonstration, which warrants 
additional dedicated studies, other limitations deserve to be mentioned.  
Healthy subjects were chosen as controls and comparison of HFpEF with comorbidity-
matched patients is missing; similarly, a comparison between HFpEF with and without 
obesity (Escobedo and Oliver, 2017) would further define the specificity of the 
findings. Of note, none of the drug classes in use in the study, including calcium 
channel blockers (Telinius et al., 2014), have been reported to adversely affect 
lymphatic function in vivo.  
For my conclusions I assumed similar osmotic pressures of albumin (σΠ), critical for 
isovolumetric pressure ex vivo (Levick and Michel, 2010), between groups; as the 
accurate measurement of leakiness of blood vessels to albumin, i.e. σ, is cumbersome 
and unfeasible in clinical settings, the assumption was based on similar plasma albumin 
concentrations. Notably, even if excess permeability of blood vessels in HFpEF were 
demonstrated, the relative compensation provided by lymphatics would still remain 
inadequate.  
Finally, I assessed multiple physiological parameters and I cannot unconditionally 
exclude the presence of type I error; similar sample size reasons prevented sub-
phenotyping of the HFpEF cohort. 
7.5 Conclusions 
In summary, this study disproves the original contention of an osmotically active 
interstitial Na
+
 as a possible determinant of oedema in patients with HFpEF: in keeping 
with results in a general hypertensive population (Chapter 6), no hypertonic 
accumulation of Na
+
 was identified.  
However, it provides the first description of morphological and functional changes in 
the lymphatic vasculature in HFpEF, resulting in reduced clearance of extravasated 
fluid. Along with demonstration of a reduced blood microvascular density in the skin, 
such findings draw attention to a globally and systemically defective microcirculation. 
This definition extends beyond the traditional arterial dysfunction and calls for better 
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understanding of the role of arteries, veins, lymphatics and their mutual crosstalk for 
tissue fluid homeostasis in the pathogenesis of this multifaceted, syndromic disease. 
In particular,  whether the initial lymphatic anatomical and functional expansion 
observed in rodents under conditions of salt overload (Wiig et al., 2013, Karlsen et al., 
2018) would ultimately fail when these conditions become chronic (e.g. in 
hypertension, diabetes and chronic kidney disease) or cumulative (in elderly comorbid 
patients) and result in overt HFpEF is an hypothesis deserving further investigation.
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8 DISCUSSION 
This thesis depicts a journey. It incorporates multiple studies, different in aims and 
methodology but underpinned by a common theme, which together advances novel 
concepts of sodium homeostasis in cardiovascular disease. While some of our findings 
dispute previous conclusions, other findings support the notion of salt-independent BP 
effects. The sequence of chapters does not necessarily mirror the chronological 
sequence of events (and results!) over the course of my PhD. However, it reasonably 
recapitulates how apparently independent pieces came together and shaped a 
comprehensive, although still largely open, story.  
My interest hasn’t been sparked by the current pathophysiological or population 
science salt barricades, i.e. ‘primacy of renal changes vs vascular resistance in the 
pathogenesis of salt-sensitive hypertension’ (Titze and Luft, 2017) and ‘need vs futility 
of lowering the thresholds for recommended salt intake’ (He et al., 2020, O'Donnell et 
al., 2020), respectively (please see Chapter 1), but rather by the novel reports of a water 
independent tissue sodium accumulation and, immediately after, of a sodium-driven 
shift in metabolism.  
The results of my investigations synthesise the contribution of kidneys, of vessels (in 
the broadest meaning of the term) and of the systemic interstitium in the 
pathophysiological phenomenon of “salt excess”, likely transverse to many 
cardiovascular risk factors and diseases.  
8.1 The energetic implications of salt excess 
This salt excess, as suggested by the SYCAMORE study (Chapter 3), appears to have 
energetic implications. I showed that kidneys could effectively dissociate Na
+
 and 
water handling upon high Na
+
 intake in real-life patients as in preclinical settings 
(Rakova et al., 2017, Kitada et al., 2017). However, they could do so in parallel with 
glomerular hyperfiltration, higher energy-expensive tubular workload and, ultimately, 
with a plasma metabolomic signature suggestive of a catabolic state. Catabolism 
affected mostly proteins, with either muscle mass loss or excess food consumption as 
putative sources. Both clearly impact body composition and the risk of cardiovascular 
disease (Bray et al., 2012, Lavie et al., 2012, Medina-Inojosa et al., 2018, Iliodromiti et 
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al., 2018, Anand et al., 2015, Brandhorst and Longo, 2019), in keeping with reports of 
an independent association between salt-intake and obesity (Ma et al., 2015).   
As acknowledged among limitations, the retrospective cross-sectional design of the 
study offered no control over caloric intake. This is relevant not only to some 
differences observed between SYCAMORE and the original study conducted in few 
healthy subjects (Rakova et al.,2017; please see Chapter 3), but also to the findings of a 
recent secondary analysis of the DASH (Dietary Approaches to Stop Hypertension)-
Sodium trial, where caloric intake was controlled but not fixed (Juraschek et al., 2020).  
The DASH (Dietary Approaches to Stop Hypertension)-Sodium trial was a randomised 
crossover study that primarily examined the blood pressure effects of 3 levels of 
sodium intake (low = 0.5 mg Na
+
/kcal; medium = 1.1 mg Na
+
/kcal, or high = 1.6 mg 
Na
+
/kcal) in a parallel-design including a typical Western diet (control diet) or a 
healthy diet (DASH Diet) in adults with systolic blood pressure (SBP) of 120-159 mm 
Hg and diastolic blood pressure (DBP) of 80-95 mm Hg. The protocol included 24-





urea and creatinine were measured in all samples (Sacks et al., 2001). Feeding was 
controlled and recorded, but not fixed and adjusted approximately weekly with the goal 
of maintaining constant weight.  
By approaching the hypothesis that high salt intake could induce catabolism and weight 
loss from an opposite perspective, Juraschek et al tested whether low salt intake would 
then lead to weight gain. More precisely, based on DASH-Sodium design, they tested 
whether energy intake decreased upon low salt diet to maintain stable weight. At 
variance, they observed that estimated energy intake decreased and weight increased 
from low to high sodium study phases (Figure 8-1 for the control diet arm). These 
findings provide reassurance against a putative weight gain effect of low salt intake but 
also certify the failure of the trial at adjusting the energy intake of participants to 
maintain a stable weight, thus preventing other metabolic conclusions in the absence of 
calorimetry measures.   
How to reconcile a decreased energy intake with weight gain upon high sodium diet? I 
accessed the study data from the National Heart, Lung, and Blood Institute BioLINCC 
repository (16
th
 March 2020; https://biolincc.nhlbi.nih.gov/studies/dashsodium/) for an 
independent secondary analysis (University of Glasgow MVLS College Ethics 




 March 2020) and I found evidence of an uneven sodium 
balance to justify the above (Figure 8-1). My assessment relied on reported dietary 
intake and urinary excretion and could not account for faecal and sweat losses, but 
identified excess Na
+
 retention upon high sodium diet; if one accepts parallel water 
retention (not formally assessed in DASH-Na), this would explain weight gain.  
  
Figure 8-1. Secondary analysis of the DASH-Sodium trial 
Left and middle panels: Changes in caloric intake and weight across levels of sodium intake within the 
control diet arm (highlighted comparisons are Holm-Sidak post-hoc tests of a mixed-model analysis, 
consistent with results by Juraschek et al); the study goal of maintaining stable weight failed, with weight 
gain upon high compared to low sodium intake despite lower caloric consumption. Panel D: net daily 
sodium balance (dietary intake – urinary excretion) at different levels of sodium intake (statistics as 
above); even balance (i.e. GAP = 0) dotted line for reference. Data presented as median (95%CI); * p < 
0.05, *** p < 0.001.  
The finding of uneven sodium balance also fosters additional considerations. 
First: whether the underlying body mass of DASH-Na participants was left unaffected 
in terms of fat vs fat-free composition (and basal metabolic rate/energy requirements, 
accordingly) remains unknown.  
Second: the magnitude and “plasticity upon intake” of the ‘insensible’ routes for water 
and sodium elimination (e.g. via respiration, sweat, TEWL, stools) remain similarly 
unknown. My contention, however, is that their contribution is not as trivial as often 
perceived. Preliminary evidence from the S2ALT study (chapter 6), consistent with 
reports from others (Collins, 1966, Braconnier et al., 2020), suggests that sweat and 
TEWL are important parts of systemic homeostatic mechanisms sensitive to total body 
sodium and, possibly, to microcirculatory function. Rats loaded with excess sodium 
exhibited accumulation of water and Na
+
 in the lungs (chapter 5), which are unlikely to 
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controls (Dr Sheon Mary, personal communication). All in all, I believe that the 
suggested “Randomized Clinical Trial in a Controlled Environment” to “end the salt 
wars” (Jones et al., 2018) should incorporate multiple measures (i.e. faecal, respiratory, 
renal, sweat, body composition including calorimetry, physical activity, water and 
caloric intake  - ideally without restrictions -, total body and local Na
+
, as a non-
exhaustive list) if the aim were to shed conclusive light on a complex pathophysiology 
and not just to draw a convenient line for recommended population intake. In light of a 
foreseeably gigantic effort, should we really bother? The answer likely depends on 
whether our view of “salt-sensitivity” will move away from a definition based on the 
sole ‘blood pressure’ biomarker and embrace a broader concept of Sensitivity (with 
capital S, in the next sections), linked to whole-body Na
+
 handling and tissue 
accumulation and possibly modulated by novel therapeutic approaches (please see 
sections 8.4)  
Third: if Figure 8-1 right panel is quantitatively (rather than qualitatively) analysed, 
what is the amount of Na
+
-paralleled water retention? If the positive balance of Na
+
 
upon high sodium intake were of ~35 mmol per day, this would isotonically correspond 
to approximately 250 ml of commensurate water, which is admittedly not plausible and 
not consistent with the degree of weight gain observed in DASH-Na trial (figure 8-1, 
middle panel). Increase in faecal and sweat losses upon high intake, as discussed above, 
could shift and/or tilt up the ‘even balance’ dotted line and make 35 mmol an 
overestimate, but to what extent? Even 1000 ml of water retention per month, simply 
due to dietary intake, would appear implausible in a lifespan perspective and are 
inconsistent with everyday clinical experience. This discrepancy actually reminds of 
the findings by Heer et al., which initially drove Titze’s investigations and led to the 
hypothesis of a water-independent hypertonic tissue Na
+
 accumulation.  
Was it right? 
8.2 The nature of salt excess 
8.2.1 An isotonic systemic phenomenon 
Multiple experimental approaches in the course of my PhD studies were actually 
designed assuming that a water-independent Na
+
 accumulation indeed occurred in 
tissues, certainly skin and possibly others, with still unknown implications for the 
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function of surrounding structures beyond what already reported for immune cells. 
These experiments also included the ex-vivo investigation of vascular function by wire 
myography in rats (chapter 6) and the in-vivo assessment of the microfiltration 
coefficient (Chapter 7), under the hypothesis that a hypertonic interstitium would 
facilitate capillary fluid extravasation. 
The very first findings of the rat body composition study, however, appeared at odds 
with the assumptions, as no Na
+
 hypertonicity was detected. Reappraisal of the 
methodological approach to tissue Na
+
 analysis, by means of a theoretical model 
(chapter 4), provided the opportunity for a shift in perspective.  
The simple model lacked some biophysical details (including capillary filtration 
dynamics and interstitial forces, interstitial matrix biophysical properties, triphasic 
modelling or exclusion phenomena, just to mention a few) extensively reviewed 
elsewhere (Aukland and Reed, 1993, Bhave and Neilson, 2011, Wiig and Swartz, 
2012) but made it clear that a whole-tissue chemical analysis is substantially affected 
by the admixture of different and differentially represented tissue components, or by 
the simple addition of an extra moiety of extracellular fluid, i.e. oedema. In other 
words, changes in whole-tissue Na
+
 concentration did not necessarily reflect 
hypertonicity.  
All subsequent chemical analyses conducted in rat tissues, skin of healthy subjects of 
young or older age, of hypertensive patients and of patients with HFpEF (chapters 5-7) 
revealed different Na
+
 concentrations but no Na
+
 hypertonic accumulation whatsoever. 
In fact, I re-interpreted the changes in tissue Na
+
 as changes in extracellular volume 
and, when accompanied by parallel water accumulation, as oedema.  
8.2.2 A new speculative theoretical framework 
How to reconcile a consistently isotonic phenomenon, as assessed by tissue chemical 
analysis, with the lack of total body water storage commensurate to Na
+
 storage 
observed by Heer et al. or by the DASH-Na trial? In addition to the above discussed 
limitations of previous human balance studies and to the different proportional changes 
of Na
+
 and water for the same amount of excess extracellular fluid (chapter 4), I 
speculate that “sieve” mechanisms could play a role, as herein discussed (Figure 8-2). 
Chapter 8 – Discussion 
 168 
The SYCAMORE study confirmed that kidneys can dissociate Na
+
 and water handling 
upon conditions of Na
+
 excess. It is likely that a similar dissociation applies to the other 
routes of “insensible” water and sodium elimination.  
I propose that, whenever the organism is challenged with a Na
+
 load exceeding the 
excretory capacity of Na
+
 and of osmotically coupled water, additional mechanisms 
kick in to guarantee maintenance of total body water (TBW) and tissue isotonicity. 
These mechanisms would entail the above routes of Na
+
-independent (free) water 
excretion and intracellular-to-extracellular water shifts, with the cellular membrane 
functionally acting as a sieve. As long as the intracellular space can “make room” for 
the extra Na
+
, the extra amount of water accompanying the unexcreted fraction of the 
Na
+
 load (or endogenously generated to prevent dehydration) can be eliminated (Figure 
8-2). This movement of the ECV/ICV sieve would induce some degree of cell 
shrinkage and “osmoadaptive responses in which intracellular electrolytes are 
gradually replaced by uncharged small organic osmolytes including sorbitol, betaine, 
myo-inositol, taurine and glycerophosphocholine” (Cheung and Ko, 2013).  
Replacement of K
+





] found in tissues. These responses are usually typical of 
hyperosmotic conditions and are driven by activation of TonEBP signalling (Choi et 
al., 2020). In the proposed theoretical framework, TonEBP activation would not be 
triggered by a hyperosmotic extracellular environment; rather, by the need to maintain 
it isosmotic, similar to a “clamp”. Increased hydraulic pressure in the extracellular 
space, by eliciting analogous mechanic stress, could also contribute to the TonEBP 
activation (Scherer et al., 2014).  
Under normal healthy conditions, cessation of the salt-load condition and upregulation 
of the Na
+
 excretion mechanisms would slowly switch down TonEBP signalling, revert 
the intracellular osmotic replacement phenomenon and bring the condition back to 
baseline. However, in case of persistent salt-loading or under salt-Sensitive conditions 
with decreased Na
+
/free water excretory capacity or “stiffening of the sieve” (possibly 
reflected by alterations in TonEBP signalling as a molecular correlate), the increase in 
ECV would no longer be compensated and an increase in TBW would ensue. The 
putative clinical result of this maladaptive response is subclinical or clinically overt 
oedema.  
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In addition, persistent total body Na
+
 excess and relative contraction of ICV, via 
changes in basal metabolic rate and a possible mismatch between energy intake and fat 
free mass, could facilitate fat deposition and further impact ECV/ICV distribution.  
 
Figure 8-2. The “sieve” hypothesis. 
Light blue: water; red: Na+; yellow: K+. ECV: extracellular volume, rich in Na+; ICV: intracellular 
volume, corresponding to approx. 2/3 of total body fluids, rich in K+. TBW: total body water. Middle and 
lower panels: theoretical response to a Na+ load under physiological and pathological conditions. Please 
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This complex framework is purely speculative at the time of writing. However, the 
concept of fluid shifts had been suggested also in the original report by Heer et al.: in 
healthy subjects high sodium intake did not induce total body water storage but induced 
a relative fluid shift from the interstitial into the intravascular space; notably, 
intravascular space is the gateway to free-water elimination, via glomerular filtration 
and tubular handling, as well as via perspiratio in the skin or lungs. In essential 
hypertension, abnormalities in the mechanism regulating the distribution of 
extracellular water are similarly not new (Tarazi et al., 1969). I herein expand on these 
concepts, by suggesting that also intracellular to extracellular water exchange could be 
impaired in hypertension and other salt-Sensitive conditions, by means of an altered 
sieve and TonEBP signalling. Surprisingly, this stress protein has been linked to 
autoimmune signals and inflammation, bacterial and viral infections, diabetes mellitus 
and diabetic nephropathy (Choi et al., 2020), but a mechanistic association with 
oedema (and oedema-related conditions) has never been sought.  
In summary, the sieve hypothesis moves the attention from the idea of a hypertonic 
extracellular Na
+
 to those of free-water excretion capacity and intracellular cellular 
plasticity/response in the pathogenesis of salt-related, or Sensitive, diseases. 
8.3 Neglected regulators of interstitial salt excess 
Identification of pre-clinical oedema in hypertension and, by pragmatic reappraisal of 
the literature, in all those cardiovascular conditions with reported evidence of high 
23
Na-MRI signal, suggests a ‘congestion continuum’ ultimately manifesting in the overt 
heart failure syndrome. Patients with systolic or diastolic ventricular disfunction are 
prone to congestion, i.e. heart failure, because of backward increases in hydraulic 
pressures. However, more and more over the last few years, the understanding and 
treatment of the disease has focused also on systemic, rather than purely 
myocardiocentric, dysfunctional mechanisms.  
In the specific context of HF with preserved systolic function (or ejection fraction, 
HFpEF), typically accompanied by the above salt-Sensitive conditions, I identified a 
reduced clearance of extravasated fluid by a dysfunctional lymphatic vasculature.  
Lymphatics are well-known regulators of interstitial fluid balance (Mortimer and 
Rockson, 2014, Herring & Paterson, 2018, Aspelund et al., 2016), but the 
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cardiovascular community has apparently long neglected their role in diseases other 
than the so called “lymphedema”. In the large majority of cases (i.e. the so-called 
“secondary” forms), lymphedema is diagnosed only upon severance (by surgery) or 
obstruction (by parasites, in low-income countries) of lymphatic vessels: if the 
suggested similarity between myocardium and lymphangion holds, limiting “lymphatic 
disease” to these conditions basically condense textbooks like Braunwald’s or Hurst’s 
to their chapters on cardiac tamponade. Studies like HAPPIFY are rather raising the 
attention to much broader functional aspects that closely parallels the topic of 
interstitial salt excess.  
In light of all the above conclusions on tissue Na
+
 nature and oedema, results by Wiig 
(Wiig et al., 2013) and Karlsen (Karlsen et al., 2018) on expanded lymphatic network 
and increased lymph flow in rodents upon salt-loading are not dissimilar from those 
derived in models of post-ischemic myocardial oedema (Henri et al., 2016). 
Anatomical and/or functional expansion of these master-regulators of interstitial 
homeostasis upon insults perturbing this homeostasis makes perfect finalistic sense. 
And it makes similar sense that when this expansion is experimentally blocked (Wiig et 
al., 2013) or inadequate, as suggested by HAPPIFY, local or systemic congestion 
occurs. Of note, this proposition is not necessarily specific to cardiovascular disease: 
rheumatologists have started to appreciate that dysfunctional lymphatics may well 
contribute to impaired resolution of local inflammation and associated oedema in 
conditions like rheumatoid arthritis (Bouta et al., 2018).  
If that is the case, better definition and identification of “dysfunctional lymphatics”, 
beyond the ‘tamponade’ conditions of classic lymphoedema, appear as a clearly unmet 
need. I propose this should take into account the complexity of those structures, 
including valvular, pace-making, systolic functions and their mutual coordination all 
along the entire lymphatic vascular tree.  
During the course of my PhD I was fortunate to receive training in ex-vivo assessment 
of these multiple lymphatic aspects (Prof Michael Davis, University of Missouri, 
Columbia, MO): in fact, systolic and valvular function can be assessed in response to 
modulation of lymphatic preload and afterload by means of pressure myography (Davis 
et al., 2012, Scallan et al., 2012, Castorena-Gonzalez et al., 2020); a representative 
picture for isolated flank murine lymphatics is shown in Figure 1-3, panel C. As part of 
the NHS Greater Glasgow & Clyde Biorepository (REC ref. 17/WS/0207), I also had 
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the opportunity to access surplus surgery tissue from coronary artery bypass grafting 
interventions (courtesy of Prof N. Al-Attar, Golden Jubilee National Hospital, 
Clydebank) and managed to isolate small lymph nodes from the perivascular fat 
discarded during the skeletonization of mammary arteries. These lymph nodes proved 
suitable anatomic markers to identify the otherwise transparent and almost invisible 
pre- and post-nodal lymphatic vessels, thus providing a proof of concept for feasibility 
of their isolation and ex-vivo testing (Figure 8-3).  
 
Figure 8-3. Human lymphnode with afferent and efferent lymphatic vessels. 
Front and back pictures of a representative mammary lymphnode dissected from the perivascular 
mammary fat of a patient undergoing CABG. The transparent vascular structures marked by arrowheads 
are afferent (pre-nodal) lymphatics. The efferent (post-nodal) vessel, together with the accompanying 
vein and artery, is marked by grey arrows.  
To pursue the above investigations on the role of lymphatic dysfunction in the 
pathogenesis of ‘traditional’ cardiovascular diseases, I plan to apply the myography 
methodology currently used in rodents also to human lymphatic vessels from suitable 
surgical groups.  
Parallel optimisation and validation of non-invasive but conceptually similar and 
currently evolving imaging approaches (Giacalone et al., 2020) will possibly expand 
the opportunities for vascular phenotyping of patients and facilitate targeted treatments 
in the future.  
1 mm
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8.4 Conclusions 
In conclusion, my studies offered a reappraisal of the tissue Na
+
 theory, disproved its 
water-independence in both experimental models and human subjects and suggested 
systemic isotonic Na
+
 excess as an important and likely prevalent determinant in the 
pathogenesis of hypertension and other cardiovascular diseases.  
I showed that excess Na
+
 per se may provide a fil rouge linking derangements in 
metabolism, renal and vascular function, even independent of blood pressure values, in 
the broad and often comorbid population of patients with cardiovascular disease.  
I also showed that accumulation of excess Na
+
 in tissues reflects expansion of the 
extracellular volumes and – depending on age, tissue biophysical specificities and 
probably many more local or systemic variables – tissue oedema. With very few 
exceptions, exemplified by seminal preclinical studies in the myocardium of dogs, 
where even extremely small amounts of tissue oedema were shown to induce systolic 
and diastolic dysfunction (Dongaonkar et al., 2010), the direct functional impact of this 
oedema on the function of the affected organs remains unknown. There is general 
evidence that it may directly contribute to extracellular matrix remodelling and 
interstitial fibrosis via activation of profibrogenic mechanisms in fibroblasts 
(Brakenhielm et al., 2020), thus promoting a vicious perpetuation of structural organ 
dysfunction; however, additional research is clearly needed. What is known is that, 
once overt clinical congestion (synonymous with systemic oedema) is established, it 
carries ominous prognostic significance (Campbell et al., 2012). Similarly, incomplete 
therapeutic decongestion in HF patients is associated with higher rates of both death 
and clinical relapses, suggesting an adverse biological role of oedema per se and 
persistence of maladaptive underlying mechanisms to maintain the condition (Boorsma 
et al., 2020, Lam et al., 2018). 
Treatment with diuretics is the current cornerstone of decongestive therapy in 
cardiovascular disease. By acting mainly via renal natriuresis and iso-osmotic urine 
excretion, diuretics facilitate resolution of interstitial oedema by reducing hydrostatic 
pressures in the capillary vessels and by shifting the local Starling equilibrium and 
fluids, accordingly. If the rate of urinary volume excretion exceeds the rate of fluid 
exchange at the capillary level, it is not uncommon clinical experience to observe 
intravascular fluid depletion with residual tissue congestion in diuretic-treated patients, 
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resulting in rebound adverse neurohormonal activation and worsening of renal 
function. Along with the issue of diuretic resistance, this exemplifies one of the many 
challenges posed by ‘traditional’ diuretics in treating congestion (Mullens et al., 2019, 
Wilcox et al., 2020, Boorsma et al., 2020, Felker et al., 2020).  
More recently, the portfolio of therapies to target the volume status of patients 
expanded to include new agents, i.e. SGLT2-inhibitors, which produce a 
natriuretic/diuretic-like effect without many of the disadvantages of other diuretics 
(Griffin et al., 2020). In addition to reduce tissue Na
+
 (Karg et al., 2018), these agents 
were shown to reduce HF hospitalizations (i.e. the rate of transition to overt/severe 
clinical congestion) in patients with type 2 diabetes mellitus (Zinman et al., 2015, Neal 
et al., 2017) and, more recently, to improve clinical outcomes in patients with HF and 
reduced ejection fraction, including those without diabetes mellitus (McMurray et al., 
2019). These findings come as no surprise, in light of the subclinical epidemic of Na
+
 
excess discussed in this thesis. While an in-depth discussion of these new drugs is well 
beyond my scopes here, I wonder if a broader use of these “clever diuretics” could 
offer even more benefit to the CVD population at large, when guided by the 
identification of patients with actual tissue evidence of Na
+
 excess.  
Of note, the diagnostic value of this tissue Na
+
 analysis may well extend beyond the 
sole cardiovascular field. Appreciation of the direct link between tissue Na
+
 signal and 
oedema and of its higher sensitivity to detect oedema compared with water, calls for 
the application of tissue Na
+
 analysis (by either 
23
Na-MRI or other approaches (De 
Marchi et al., 2017)) to the whole range of diseases where mechanical or inflammatory 
localized oedema is implicated, including rheumatological, immunological, oncological 
and neurological conditions. 
Wherever tissue Na
+
 excess is identified, a treatment directly targeting the interstitial 
space would clearly be the most appropriate. In this regard, the results of the HAPPIFY 
study, by demonstrating a reduced lymphatic function in a condition where congestion 
is “the core” (Pfeffer et al., 2019), open an entirely new line of research and potential 
therapeutics. Better understanding of the structural and molecular mechanisms 
responsible for reduced lymphatic reserve may facilitate the development of 
pharmacological interventions to improve interstitial fluid drainage in the whole 
spectrum of conditions herein identified as the ‘congestion continuum’.
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APPENDICES 
























































































































Appendix 6 - HAPPIFY participant information leaflet 
A very similar leaflet, with only slightly different wording in relation to NOT having 
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FC = fold change; p and pcorrected High-Na+ vs Low-Na+, pcorrected< 0.05 in bold and dark grey shaded. Ion: positive or negative mode peak acquisition. Evidence for LC/MS peaks: identified (matched 
by retention time and mass to a standard) or annotated (assigned putatively on the basis of mass) compounds   fragmentation (F), based on the Metabolite Standards Initiative guidelines 
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Appendix 8 – SYCAMORE: metabolomic peaks, higher in low-Na+ vs high-Na+. 
 
Uc/pc = urea cycle/protein catabolism. FC = fold change; p and pcorrected High-Na+ vs Low-Na+, pcorrected< 0.05 in bold and dark grey shaded. Ion: positive or negative mode peak acquisition. Evidence for 
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Appendix 9 – ImageJ MACRO for Alcian Blue+ area quantification. 
run("Image Sequence...", "open=E:\\mic\\XXX\\untitled000.tif sort"); 
run("Invert", "stack"); 
run("Color Threshold..."); 
// Color Thresholder 1.50i 























  selectWindow(""+i); 
  setThreshold(min[i], max[i]); 
  run("Convert to Mask"); 
  if (filter[i]=="stop")  run("Invert"); 
} 
imageCalculator("AND create", "0","1"); 
imageCalculator("AND create", "Result of 0","2"); 
for (i=0;i<3;i++){ 
  selectWindow(""+i); 
  close(); 
} 
selectWindow("Result of 0"); 
close(); 
selectWindow("Result of Result of 0"); 
rename(a); 
// Colour Thresholding------------- 
run("Close"); 
run("Make Binary", "method=Default background=Light calculate list"); 
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